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Abstract 
 
Investigation of terminal alkene formation by acyl-CoA dehydrogenases in the 
biosynthesis of complex natural products 
 
by 
 
Jacquelyn M Blake-Hedges 
 
Doctor of Philosophy in Chemistry 
 
University of California, Berkeley 
 
Professor Jay D. Keasling, Co-chair 
 
Professor Michelle C. Chang, Co-chair 
 
 
Polyketides are a class of natural products known for their chemical complexity and 
bioactive properties. They are biosynthesized by an assembly line-like system termed 
polyketide synthases (PKSs), in which each module consists of various enzymatic 
domains, each of which has a single catalytic function. The polyketide is extended by 
two carbons and selectively reduced by each module. These biosynthetic principles 
make PKSs attractive engineering targets, because a simple swap of one enzymatic 
domain could change the final polyketide structure and effect an improved or novel 
bioactivity. However, gaping holes in our understanding of polyketide biosynthesis still 
exist. In particular, the activities of polyketide-associated enzymes remain relatively 
under-characterized and are generally not the primary focus of engineering efforts. 
These enzymes, which include glycosyl transferases, cytochrome P450s, and many 
others, often are responsible for imparting bioactive functional groups into the 
polyketide backbone or after the assembly of the “naked” polyketide. Many of these 
non-canonical functional groups discovered within polyketides are therefore the most 
desirable engineering targets. In this dissertation, I describe my efforts to characterize a 
family of terminal alkene-forming enzymes which were originally identified in a 
polyketide biosynthetic cluster. I show that the enzymes are regioselective and that 
regioselectivity is controlled by a shift in the protein structure. Finally, I show that these 
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enzymes are widespread in not only polyketide biosynthetic gene clusters, but also in 
other natural product clusters in the genomes of diverse Actinomycetes.
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Chapter 1. Introduction and dissertation organization 
1.1. Polyketide biosynthesis as a source of undiscovered enzymology 
Polyketides are a class of natural products known for their chemical complexity 
and bioactive properties. They are biosynthesized by an assembly line-like system 
termed polyketide synthases (PKSs), in which each module consists of various 
enzymatic domains, each of which has a single catalytic function. The polyketide is 
extended by two carbons and selectively reduced by each module. These biosynthetic 
principles make PKSs attractive engineering targets, because a simple swap of one 
enzymatic domain could change the final polyketide structure and effect an improved 
or novel bioactivity.  
 However, gaping holes in our understanding of polyketide biosynthesis still 
exist. In particular, the activities of polyketide-associated enzymes remain relatively 
under-characterized and are generally not the primary focus of engineering efforts. 
These enzymes, which include glycosyl transferases, cytochrome P450s, and many 
others, often are responsible for imparting bioactive functional groups into the 
polyketide backbone or after the assembly of the “naked” polyketide. Many of these 
non-canonical functional groups discovered within polyketides are therefore the most 
desirable engineering targets. In this dissertation, I describe my efforts to characterize a 
family of terminal alkene-forming enzymes which were originally identified in a 
polyketide biosynthetic cluster. I show that the enzymes are regioselective and that 
regioselectivity is controlled by a shift in the protein structure. Finally, I show that these 
enzymes are widespread in not only polyketide biosynthetic gene clusters, but also in 
other natural product clusters in the genomes of diverse Actinomycetes. 
1.2. Dissertation organization 
 
In Chapter 2 I introduce polyketide synthases and describe the fundamental 
principles of polyketide biosynthesis. I focus on polyketide synthase engineering 
strategies, both at the protein and organism level. In the protein engineering section, 
engineering strategies for each polyketide synthase domain, for loading modules, and 
for intermodular linkers are discussed. In the host engineering section, I highlight several 
engineering strategies including precursor-directed biosynthesis, precursor pool 
engineering, expression of phosphopantetheinyl transferases, and transcriptional 
regulation/gene refactoring. Finally, I finish by describing how protein and host 
engineering methods can be combined to synergistically improve polyketide 
biosynthesis.   
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In Chapter 3 I describe the structural and biochemical characterization of a 
terminal alkene-forming acyl-CoA dehydrogenase, tcsD, that is implicated in the 
biosynthesis of the allylmalonyl-CoA extender unit from the biosynthesis of the 
immunosuppressant polyketide FK506. First, I disprove an earlier hypothesis that two 
enzymes from the allylmalonyl-CoA biosynthetic pathway can act interchangeably; 
instead, the pathway proceeds in a linear fashion. I then show that tcsD is regioselective 
for the γ,δ-position of acyl-ACP substrates and that it only acts on α,β-unsaturated 
substrates. By solving the crystal structure of the enzyme, I show that this 
regioselectivity is mediated by a lateral shift in the positioning of the FAD cofactor 
within the enzyme. Finally, I identify homologs of the enzyme and show that a 
phylogenetically distant homolog catalyzes the same reaction as tcsD and is also 
regioselective for the γ,δ-position of substrates. 
 
In Chapter 4 I have added supplementary information and discussion point 
related to chapter 3. This includes discussions regarding LC-MS/MS method 
development for monitoring enzymatic reactions on carrier protein-bound 
intermediates and the presence of an unknown metabolite that crystallized in the tcsD 
active site. In addition, I have included several figures that support the claims made in 
chapter 3. 
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Chapter 2. Engineered polyketides: synergy between host and protein engineering 
 
Including material from published work: Barajas, J.F.,* Blake-Hedges, J.M.,* Bailey, C.B.,* 
Curran, S., Keasling, J.D. Engineered polyketides: synergy between host and protein 
engineering, Synthetic and Systems Biotechnology, 2017, 2, 147-166. 
*authors contributed equally 
2.1. Abstract 
Metabolic engineering efforts toward rewiring metabolism of cells to produce 
new compounds often require the utilization of non-native enzymatic machinery that is 
capable of producing a broad range of chemical functionalities. Polyketides encompass 
one of the largest classes of chemically diverse natural products. With thousands of 
known polyketides, modular polyketide synthases (PKSs) share a particularly attractive 
biosynthetic logic for generating chemical diversity. The engineering of modular PKSs 
could open access to the deliberate production of both existing and novel compounds. 
In this review, we discuss PKS engineering efforts applied at both the protein and 
cellular level for the generation of a diverse range of chemical structures, and we 
examine future applications of PKSs in the production of medicines, fuels and other 
industrially relevant chemicals.  
2.2. Introduction 
Polyketides are one of the largest classes of natural products, possessing 
immense structural diversity and complex chemical architectures. Many polyketides 
(PKs) are among the most important secondary metabolites for their applications in 
medicine, agriculture, and industry. Examples include anticancer drugs (epothilone),1,2 
antibiotics (erythromycin),3 insecticides (spinosyn A)4 and antifungals (amphotericin B).5 
These particular examples of polyketides are biosynthesized by multimodular enzyme 
complexes known as type I modular polyketide synthases (PKSs). Working in an 
assembly-line fashion, multimodular PKSs assemble and tailor readily available acyl-
CoAs within the host cell into large, complex, chiral molecules.6 Each of these PKSs 
comprises a series of modules that can be further dissected into a series of domains 
responsible for the extension of the polyketide backbone through condensation and 
selective reductive processing of an acyl-CoA building block. The collinear architecture 
of these modules, apparent by inspection of the domains present and the predictive 
selectivity motifs harbored within, provide insights into the chemical connectivity and 
stereochemical configuration of the polyketide metabolite from analysis of its coding 
sequence.  
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One of the best-studied PKSs is the 6-deoxyerythronolide synthase (DEBS) (Figure 
2-1A), which is responsible for synthesizing the macrolactone core of the antibiotic, 
erythromycin.7 The catalytic domains of DEBS are expressed within modules that are 
each responsible for a single round of chain elongation and reductive processing. To 
this end, the loading acyltransferase (AT) domain loads the acyl carrier protein (ACP) 
with a starter unit derived from propionyl-CoA (Figure 2-1A). The ketosynthase (KS) 
within each module catalyzes decarboxylative carbon-carbon bond formation between 
an acyl precursor and the ACP-bound methylmalonyl derivative. Unlike fatty acid 
synthases (FASs), the occurrence of reductive domains within modules varies, and PKS 
intermediates typically exhibit various levels of reduction. If present, the ketoreductase 
(KR) converts the β-ketone to an alcohol using NADPH. The dehydratase (DH) eliminates 
the alcohol to form an olefin, and the enoylreductase (ER) utilizes NADPH to reduce the 
olefin to a methylene. Finally, a thioesterase (TE) domain, located at the terminal of DEBS 
3 module, catalyzes the release and cyclization to produce the macrolactone, 6-
deoxyerythronolide (6-dEB). The structure and mechanism of each PKS domain is 
reviewed in detail elsewhere.8–12 
With this collinear biosynthetic logic in mind, engineered PKSs have the potential 
to become an effective retrobiosynthetic platform to produce molecules that are 
difficult or too complex to acquire via traditional synthetic means (Figure 2-1B-C). From 
DNA sequence, one could control chemical structure by successfully modifying and 
rearranging existing polyketide modules and domains.13,14 Moreover, rationally-
designed PKSs could be introduced into a variety of engineered hosts15–17 capable of 
expressing these large PKS complexes while providing the necessary precursor 
metabolites to biosynthesize a target chemical. In this review, we highlight PKS 
engineering efforts at both the protein level and the host/cellular level. We further aim 
to describe PKS engineering efforts within the context of metabolic engineering and 
introduce the idea of successful PKS/host modifications for both traditional medicinal 
applications as well as the production of fuels and commodity chemicals. 
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Figure 2-1 Biosynthesis of 6-deoxyerythronolide and examples of both native and engineered polyketide 
synthases. A) Modular biosynthesis of 6-deoxyerythronolide by the well-studied 6-deoxyerythronolide 
polyketide synthase. B) The carboxylic acid starter unit promiscuity by the borrelidin PKS was utilized to 
produce adipic acid (C) from succinic acid and malonic acid using an engineered BorA2 containing a full 
reductive loop (highlighted in green circle) and a thioesterase. C) The broad starter unit selectivity of the 
lipomycin PKS was utilized to produce 3-hydroxyacid congeners from branched acids and methylmalonyl-
CoA (C). The carbon backbone for both the native and engineered polyketides are represented in bold. Grey 
domains represent the native pathway and blue domains represent engineered insertions.   
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2.3. PKS Protein Engineering 
The ability to tailor the molecular architecture of polyketide metabolites through 
the inclusion of various reductive domains or domains with altered selectivity has long 
been the promise of PKSs as a retrobiosynthetic platform. In this section, we discuss the 
current knowledge of PKS engineering at the protein level. We have divided the PKS 
protein engineering section into sections based on domain type. Within the types of 
domains, we have selected the most engineerable targets. We will not focus on KS or 
ACP domain engineering in this review, as they are arguably the least targetable 
domains based on the chemistry and functions they perform, respectively. In addition, 
methyltransferase domains, which transfer an S-adenosyl-methionine-derived methyl 
group to the α-carbon of the β-keto intermediate, are somewhat rare and less well 
characterized, and thus will not be discussed here. In each section, we will first give a 
basic overview of the current state of knowledge regarding the specific domain(s) in 
question. Next, we will highlight some significant accomplishments in engineering, both 
via site-directed mutagenesis and/or domain swapping experiments. Because of the 
extensive amount of published PKS research, we cannot include all examples of PKS 
engineering within the scope of this review. Nevertheless, numerous representative 
examples are highlighted. 
 
 
Figure 2-2 Summary of polyketide synthase engineering strategies highlighted in this chapter. A) Starter unit 
selectivity and incorporation is mediated by either native or non-native swapped LMs. Intermolecular linker 
regions allow for successful communications between domains. Chemical diversity is further increased by 
varying the extender building blocks. AT mutagenesis or AT swaps mediate incorporation of various 
extender units into a polyketide intermediate. Various degrees of reduction at the β-keto position can be 
accomplished by KR mutagenesis, KR swaps and/or the insertion of full or partially full reductive loops, 
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containing DH and ER domains. Release of the polyketide intermediate is mediated by various releasing 
domains, which further increase chemical diversity into the final product. 
2.3.1. Loading modules 
Nature has evolved several mechanisms for activating acyl substrates to initiate 
PK biosynthesis. To begin chain formation, modular type I PKSs employ a loading 
module (LM) to select the priming unit.  LMs are categorized based on their domain 
architecture and the mechanism by which each activates substrates to begin chain 
formation. Although LMs are not officially characterized within the field, for simplicity 
within this review we will refer to each class of LMs with a representative letter (e.g. 
“type A” or “A-type”) so as not to confuse the reader with the type I, II, or III PKS 
designations used to describe the entire assembly line systems.  
The most common LM organization consists of a condensation-incompetent KSQ 
(named for the active site C→ Q mutation), AT, and ACP domain (Type A LM). In type A 
LMs, the KSQ decarboxylates malonyl- or methylmalonyl-CoA to yield acetyl- or 
propionyl starter units, respectively (Figures 2-2, 2-3).18 The AT domains of these 
modules are strictly specific for CoA esters of dicarboxylic acids (malonyl- or 
methylmalonyl-CoA)18 and share a conserved arginine residue with extender AT 
domains that is used to stabilize the free carboxyl moiety of the substrate.19 Type B LMs 
prime polyketide biosynthesis with a much broader range of substrates (Figures 2-2, 2-
3), and their domain organization consists of an AT and ACP didomain. The AT domain 
selects a CoA-bound priming unit and transfers it to its cognate ACP where it is poised 
for transfer to the KS of the first extension module. Because type B LM ATs are not 
limited to utilizing β-carboxy-CoA starters, they tend to recognize a more diverse set of 
starter units derived from other acyl-CoAs. For example, the B-type avermectin LM 
natively primes with either 2-methylbutyryl-CoA or isobutyryl-CoA, and it can also 
accept a large number of other substrates.20 Similarly, while the related lipomycin LM 
primes biosynthesis with isobutyryl-CoA in vivo, in vitro it also loads a variety of other 
branched fatty acyl-CoAs (Figure 2-1 B-C).21 Nevertheless, type B domain architecture 
does not always guarantee promiscuity. Another B-type LM from the borrelidin PKS is 
selective for dicarboxylic acid starter units both in vivo22 and in vitro (Figure 2-1 B-C).23  
The final common organization (type C) of LMs consists of a CoA-Ligase-type 
(CoL) domain located upstream of an ACP, which activates a carboxylic acid substrate in 
an ATP-dependent fashion so that it can then be loaded onto the ACP (Fig. 2,3). While 
some LMs have the CoL domain in cis (e.g. rifamycin,24 rapamycin25), others have a 
separately encoded CoL domain that activates the ACP of the loading domain in trans in 
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a mechanistically similar fashion (e.g. aureothin,26 and several mycobacterial polyketide 
synthases27). It is also common to find other accessory domains within type C LMs, such 
as the enoylreductase domains observed in FK506 and rapamycin biosynthesis.25,28  
 
Figure 2-3 Examples of loading modules. In type A LMs, the KSQ decarboxylates malonyl- or methylmalonyl-
CoA to yield acetyl- or propionyl starter units, respectively. Type B LMs consist of an AT which selects a 
CoA-bound priming unit and transfers it to its cognate ACP. Type C LMs consists of a CoL domain located 
upstream of an ACP. The CoL activates a carboxylic acid substrate in an ATP-dependent fashion in order 
to load it onto the ACP, either in cis or in trans. It is also common to find other accessory domains within 
type C LMs, between the CoL and ACP domain (represented by the black line between the cis CoL and 
ACP). 
The inherent promiscuity of certain loading modules and the wide variety of 
potential starter units make the initial precursor loading process an attractive protein 
engineering target. To date, most LM engineering efforts have focused on swapping 
LMs with type A or type B architectures that incorporate short fatty acyl groups into 
polyketides. Possibly the first LM swap successfully placed the tylosin LM (type A) into 
the platenolide (type A LM) biosynthetic pathway, resulting in the production of 16-
methyl platenolide derived from propionyl-CoA (methylmalonyl-derived) instead of the 
native acetyl-CoA (malonyl-derived) starter unit.29 In a similar experiment, Leadlay and 
coworkers exchanged the native 6-deoxyerythronolide LM (type B) for the avermectin 
LM (type B), increasing the diversity of erythromycins produced in vivo.30 Both of these 
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early examples demonstrated the feasibility of swapping loading modules with 
consistent domain architectures.  
Mixed LM type swaps have also been explored. By replacing the type B LM of 
DEBS M1+TE with the type A LMs from the oleandomycin or tylosin pathways, 
production of triketide lactones (TKLs) derived from almost exclusively acetate- or 
propionate-derived starter units, respectively, was achieved.18 Under the same 
conditions, the native type B DEBS LM architecture lends itself to broader starter unit 
selectivity, resulting in the production of both types of TKLs.31 Therefore, by changing 
LM type, greater starter unit fidelity was achieved. In addition, an AT swap of the 
oleandomycin (type A LM) loading AT with the extending AT from the second rapamycin 
module (rapAT2, also conferring malonyl-CoA specificity) resulted in production of C13-
methyl erythromycins.18 A similar AT swap into the nystatin LM nysA (type A) resulted in 
the restoration of nystatin production in a nysA knockout strain of S. noursei, albeit at 
much lower titers than the native system. In addition, swapping in a methylmalonyl-
CoA-specific AT domain resulted in no production of the nystatin analog, perhaps due 
to the innate specificity of the downstream nysB module or the nysA KSQ domain.32 
These swaps illustrate the potential to exercise tighter control over starter units 
incorporated into polyketides that normally begin with type B LMs in order to engineer 
systems to precisely control the metabolites produced.  
LM swaps involving type C LMs could provide mechanisms for introducing even 
greater diversity into polyketides than type B LMs based on the range of starter units 
the type C LMs accept. Dihydroxycyclohexene-carboxoyl-CoA,33 benzoyl-CoA,34 and 3-
amino-5-hydroxybenzyl-CoA24 are just a few of the starter units incorporated via this 
type of LM. Attempts to switch the type C LM of the rimocidin PKS protein (RimA) with 
the type A LM from the nystatin PKS (NysA) showed that while RimA could initiate 
nystatin biosynthesis in the native S. noursei producer, nysA could not rescue rimocidin 
biosynthesis in a rimA knockout strain of S. diastaticus. In addition, RimA natively 
accepts both acetate and butyrate starter units, but only acetate units could be 
incorporated into the nystatin skeleton, suggesting that the downstream nys PKS is 
gatekeeping.35 However, a swap of the non-canonical soraphen LM SorA (ACP-KS-AT-AT 
architecture) into DEBS1+TE produced a small amount of the expected benzoyl-CoA-
derived TKL.36 In addition, a swap of the first SorA AT domain into the DEBS LM also 
resulted in the production of a TKL incorporating benzoyl-CoA. These 
experiments illustrate that more exotic LM swaps, including type C LM swaps and 
domain swaps within LMs, may be tolerated by modular PKSs. However, incorporation 
of non-native starter units via noncognate LMs could require additional engineering of 
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the downstream modules of the polyketide synthase, as they might not accept or act on 
unusual or bulky functionalities.37  
Currently, there is no flawless method for LM engineering to incorporate 
nonnative starter units into polyketides. The most common approach involves swapping 
a full LM (that selects for a desired starter) in place of the native LM. This has been met 
with limited success, and a more detailed understanding of where bottlenecks arise is 
needed before LM swaps can become a more common practice. Because LMs can occur 
in cis or in trans, the native protein-protein interactions that occur within each type of 
system should be considered. It might be best to retain the native intermodular linker 
for in cis LMs, and in the same way, LMs used to complement in trans may be more 
successful if domains are engineered with C-terminal linker domains from the native 
system (Figure 2-2). Other possibilities for retaining native protein-protein interactions 
include performing AT swaps within LMs instead of swapping full modules. We 
hypothesize that more conservative swaps (in terms of chemical structure) will be more 
successful because of the gatekeeping functions of the downstream PKS modules. 
Interactions between the LM ACP and the first KS of the downstream extension module 
should also be considered, as improper protein-protein interactions will prevent chain 
translocation to the first extension module. However, until a more detailed and 
systematic study of LM swaps is published, the importance of each of these factors for 
each unique system is unknown. Therefore, with the current state of knowledge, each 
LM engineering attempt should be optimized individually and should be attempted with 
multiple domain boundaries in order to find the most productive system. 
2.3.2. Acyltransferase domains 
 
The acyltransferase domain is responsible for selecting the CoA-based starter 
and/or extender units that form the majority of the carbon backbone of the growing 
polyketide. AT domains are attractive engineering targets for several reasons. First, we 
can easily predict the substrate specificity of most AT domains based on conserved 
residues. Secondly, AT domains are the primary sources of diversification at the ɑ-
carbon, a diversity that extends beyond the extent of the various oxidations states of the 
β-keto groups to include other heteroatoms, halogens, and unique functionalities that 
are otherwise unachievable via traditional polyketide chemistry.38–43 Finally, AT domains 
are naturally more promiscuous in comparison to other PKS domains,38,44,45 making 
precursor- directed mutagenesis viable. For these reasons, AT domains are the most 
well-studied of all PKS domains in terms of engineering via site-directed mutagenesis, 
domain swapping, and other host-level techniques (vide infra). 
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While nature uses numerous diverse extender units to form PKSs, the majority of 
known ATs select for either malonyl- or methylmalonyl-CoA.46 Well before the first KS-
AT didomains structures were solved for DEBS M347 and M5,48 consensus sequences 
were identified within the AT domain that correspond to malonyl-(HAFH) or 
methylmalonyl-CoA (YASH) specificity.49 With structural information in hand, 
identification of active site residues for targeted mutagenesis became much easier. Later 
on, more diverse extender units were identified, revealing other specificity motifs in the 
associated AT domains. The AT from module 3 of the epothilone cluster, for example, 
accepts both malonyl- and methylmalonyl-CoA and contains a “HASH” motif,50 while the 
allylmalonyl-CoA-specific AT from module 4 of the FK506 cluster has a “CPTH” motif at 
the same location.51 Several other ATs with unique specificity-conferring residues at this 
position have also been discovered and their cognate extender units identified, 
significantly expanding the chemistries accessible via PKS-mediated biosynthesis.46,52 
Nevertheless, simply mutating these residues to the appropriate specificity motif does 
not necessarily confer specificity to the desired extender unit. Mutation of the of the 
methylmalonyl-specific “YASH” motif to “HAFH” in DEBS AT1,45 AT4, and AT653 increased 
promiscuity, allowing the domains to accept and transfer both malonyl- and 
methylmalonyl-CoA. However, later in vitro investigations demonstrated that these 
modules had greatly reduced activity.54 Mutations outside the active site can also lead 
to more promiscuous AT domains, although a greater amount of retention of native 
substrate specificity is frequently observed.53,55,56 These types of mutations can even 
abolish the transacylation activity of the domain altogether.51 Evidence suggests that the 
specificity conferred by these conserved residues could be overcome if nonnative 
extender unit concentrations are high enough relative to the native extender.57 
 
The incorporation of rare extender units can also be achieved by targeting other 
residues with site-directed mutagenesis (Figure 2-2). For example, mutating an active 
site valine to an alanine in DEBS AT6 created a more promiscuous enzyme that was able 
to incorporate various nonnative extender units such as propargylmalonyl-, allylmalonyl-
, and ethylmalonyl-CoA into the erythromycin backbone.56 More recent work has 
revealed that targeted active site mutagenesis screens can be more effective at 
producing ATs that are more specific for nonnative extenders than the native substrate. 
Williams and coworkers showed that DEBS AT6 could be converted to a 
propargylmalonyl-CoA-specific domain by screening a library of active site mutants and 
identifying a Y → R mutation that changes the native specificity.43 Combined with 
exogenous feeding of precursors (vide infra), AT mutagenesis screens could be used to 
create diverse libraries of polyketides from just one engineered PKS. 
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AT swapping is also commonly undertaken as a method for constructing hybrid 
modules capable of producing new polyketides with novel ɑ-carbon substituents (Figure 
2-2). Traditionally, AT swaps were constructed via restriction enzyme-based cloning, thus 
relying on conserved restriction sites flanking the AT domain. One of the first attempts 
at a full AT swap was performed by Leadlay and coworkers in which the native AT 
domain from DEBS1-TE (malonyl-CoA specific) was replaced with the AT domain from 
module 2 of the rapamycin synthase (methylmalonyl-CoA specific).58 The hybrid protein 
was able to produce TKLs exclusively derived from methylmalonyl-CoA with little to no 
effect on yield, highlighting the significant potential of the technique for producing 
novel polyketides.  
 
Katz and coworkers showed that, when placed in the context of a full modular 
PKS system, AT domain exchanges are not as efficient as the native system.39 Swaps of 
malonyl-CoA-specific ATs from the pikromycin and rapamycin PKSs into DEBS modules 
1 and 2, in particular swaps into the second module, resulted in significantly lower titers 
of the expected erythromycin derivatives.40–42 In a similar study, a swap of the second 
rapamycin AT into module 6 of DEBS was capable of producing 25 mg/L of the 
appropriate 6-deoxyerythronolide B analogs, suggesting that the efficiency of AT-
swapped modules may be affected by the position of the module within the larger 
context of the assembly line.59 However, a successful swap of the ethylmalonyl-CoA-
specific AT domain from niddamycin in module 4 of DEBS, suggested that other factors 
may be at play.60 A functional rapamycin AT2 swap into DEBS module 4 finally illustrated 
that the domain boundaries for AT swaps (and any domain swap) may need to be 
optimized for each unique acceptor module-AT pairing.61 Several other examples of AT 
domain exchanges emerged, each reporting extremely low titers due to the engineered 
nature of the systems at hand.62,63 DEBS module 4 was the last module in the model 
system to be successfully engineered in this manner by varying the domain boundaries 
used, suggesting that modules with full reductive loops may necessitate different AT 
swap domain boundaries because of the difference in the domains and linkers that 
surround the AT.  
 
The mixed success observed with AT swaps led to the pursuit of a more 
fundamental understanding of the mechanisms of catalysis in native versus engineered 
AT systems. To this end, Khosla and coworkers systematically characterized the 
bottlenecks hindering successful AT swaps.42 By analyzing the kinetics of AT acylation 
and KS-mediated condensation in native and engineered systems, they concluded that 
condensation in the hybrid modules occurred at a rate over ten times slower than the 
native system. In addition, limited proteolysis experiments and the poor expression of 
  13 
the engineered proteins suggested that the AT swapped mutants are inherently less 
stable and adopt a different protein conformation. AT domain swaps may minimize or 
interfere with the important protein-protein contacts required for condensation. 
Swapped domains may disturb the orientation of stabilizing residues64 with respect to 
hydrogen bonding partners that help maintain the dimeric structure of the PKS or 
prevent the proper interaction of the ACP domain with the KS-AT linker.65 Most recently, 
Keasling and coworkers performed a detailed kinetic analysis of AT-swapped modules 
utilizing different domain boundaries and showed that the optimized boundaries could 
be applied to construct functional swaps of various heterologous AT domains.66 We 
hypothesize that more comprehensive biochemical and structural studies of AT domain 
swaps will reveal a less ambiguous set of design rules for AT replacements.  
 
A final method for AT domain engineering involves the complementation of 
inactivated cis-AT PKSs with trans-acting domains. Although this review does not focus 
on engineering trans-AT PKS systems, we will note that the freestanding AT domains 
from these PKSs can successfully communicate with cis-AT PKS modules.38 In trans-AT 
PKSs, the acyltransferase domain is not incorporated into the same polypeptide as the 
remaining catalytic domains of a typical PKS module. Instead, a freestanding trans AT 
typically transfers extender units to multiple ACP partners. The utilization of trans-ATs to 
generate polyketide diversity in place of the activity of a native domain has been 
demonstrated in several contexts. Typically, an AT null (AT0) mutant is generated by 
converting the conserved active site serine to an alanine, destroying the active site 
nucleophile responsible for initial attack of the extender unit thioester. Khosla and 
coworkers originally showed that trans-AT domains such as DszsAT from the disorazole 
PKS system could be used to complement an AT0 version of DEBS1 in vitro.38  It was later 
found that the DszsAT could also be used to produce fluorinated polyketides through 
the transfer of fluoromalonyl-CoA to several different AT-deficient modules of DEBS, 
both in vitro and in vivo.67 This technique has since been further extended to a 
bimodular system in which DszsAT was able to communicate with multiple ACPs at 
once, transferring fluoromalonyl-CoA to AT0 versions of DEBS module 2 and 3 to 
produce a difluorinated TKL.68 Other trans AT domains, such as the KirCII AT, have 
successfully been used to install propargyl and allyl groups into polyketides, albeit so far 
only within the native PKS system.44 
 
AT domain engineering has been extensively studied, yet similar to LMs, no 
consensus set of engineering rules exist. It is well established that mutation of the active 
site serine in a conserved “GHSxG” motif to alanine abolishes domain activity. Changing 
domain specificity with point mutations has also been successful, but rational 
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engineering in this case is still unpredictable. We believe that techniques such as 
saturation mutagenesis of active site residues can be successful but could require large 
screens of many mutants. AT domain swapping is currently also a viable method for 
changing α-carbon substituents. Based on recent experiments, it appears that screening 
and optimization of various swaps has yielded a potential set of widely applicable 
domain swap boundaries for ATs.66 It remains to be seen, however, if this method will be 
generalizable to all type I PKS systems given the potential for disrupted protein-protein 
interactions and gatekeeping from downstream processing.  
 
In order to incorporate rare functional groups via AT domain engineering, the 
desired extender unit must be provided either endogenously (integration of a 
biosynthetic pathway into the chosen heterologous host) or exogenously (feeding of an 
appropriate precursor that can be converted to a malonyl-CoA derivative). We refer the 
reader to the subsequent sections on host engineering for more details. Within this 
realm, it is important to note that many unusual polyketide extender units are 
constructed on freestanding ACPs. Although AT domain mutagenesis may result in more 
promiscuous AT domains, in the case of ACP-linked extender units (e.g. 
methoxymalonyl-ACP,69,70 hydroxymalonyl-ACP, aminomalonyl-ACP, etc.71), AT domain 
swaps may be a superior engineering method because proper protein-protein 
interactions between the extender unit-carrying ACP and AT domain can be 
maintained.72 
 
It remains to be seen whether domain swapping or site-directed mutagenesis will 
prove the more productive AT engineering method in a general. However, we anticipate 
that the continued improvement in DNA synthesis and sequencing technologies will 
facilitate more large-scale systematic experiments that result in the improved activities 
of engineered enzymes. 
 
2.3.3. Ketoreductase domains 
 
Ketoreductases perform the NADPH-mediated reduction of newly-formed β-keto 
groups after condensation. They are both stereospecific and stereoselective, and they 
are also known to epimerize α-substituents (if present) prior to reduction.73,74 KRs are 
characterized based on their stereochemical outcomes: A-type KRs generate L-
configured alcohols and B-type KRs D-configured (Figure 2-4). KRs are further described 
based on the final orientation of any α-substituents. A1 and B1 KRs produce D-
configured α-substituents, and A2/B2, L-configured.8 Finally, C-type KRs are reductase-
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incompetent but can retain epimerase activity.75 Structures are available for each type of 
KR: A1,76 A2,74 B1,77 B2,78 and C2.79  
 
A- and B-type KRs can be distinguished not only by function, but also through 
the presence of certain structural elements. The presence of an “LDD” motif ~57 
residues before the catalytic tyrosine indicates a B-type KR (although frequently only the 
final “D” of this motif is strictly conserved) whereas it is absent in A-type KRs. 
Additionally, A-type KRs typically contain a tryptophan eight residues before the 
catalytic tyrosine. Structural insight has guided mutagenesis efforts, leading to the 
generation of A2-type74 and nonstereospecific A-type KRs76 derived from A1-type KRs. 
Additionally, a B2-type KR was converted to an A2-type through a single point mutant.80 
Not only can KR specificity be modified through site-directed mutagenesis, but activity 
can be completely abolished as well. Mutation of the catalytic tyrosine of the DEBS 
module 6 KR lead to production of the expected ketone, illustrating that KR inactivation 
is a way to generate new polyketides.81  
 
In addition to site-directed methods for engineering KR domains, numerous 
experiments have illustrated the viability of full KR domain swaps to modulate the 
stereochemistry and oxidation state of a given polyketide. Preliminary experiments were 
performed in the model DEBS system. A swap of the inactive KR domain from module 3 
into module 2 resulted in the production of a TKL with a keto group in place of the 
alcohol generated by the native system.82 This preliminary result showed that the 
surrounding domains function in the presence of a non-cognate KR partner. Complete 
removal of KR domains and replacement with an AT-ACP linker, on the other hand, has 
produced completely inactive mutants.83 As the generation of loss-of-function mutants 
can easily be achieved via site-directed mutagenesis, it is the preferable method for KR 
inactivation because it allows for the retention of native protein-protein interactions and 
folding. Construction of KR-swapped PKSs with novel functions have also been reported. 
Successful gain-of-function KR swaps were implemented in a three module DEBS system 
in which KR domains from the rapamycin modules 2 or 4 were swapped into DEBS 
module 2, producing TKLs with non-native hydroxyl stereochemistry.84 In a similar set of 
experiments, researchers from the same group showed that KR swaps could also be 
performed by replacing the KR in DEBS module 2 with KR5 and KR6 of DEBS.85 
Interestingly, KR6 was nonfunctional in this context. Further applying these KR swap 
design principles, Ashley and coworkers subsequently used KR-swapped DEBS modules 
to produce various derivatives of 6-deoxyerythronolide B in vivo, albeit with significant 
titer losses compared to the wild type system.83 
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More recent efforts have focused on applying KR swaps to tailor the 
stereochemistry of both hydroxy groups and the adjacent α-methyl groups. Weissman 
and coworkers evaluated 14 total A2 and B2-type KR swaps into module 2 of DEBS1+TE 
using different swap sites.86 Interestingly, there were obvious differences in activity of 
swaps performed using the various junctions. In addition, the A-type KR swaps were 
more functional than B-type swaps, suggesting that domain replacements that retain 
the native KR type might be more successful (DEBS module 2 contains an A1-type KR). 
Finally, all of the KR domains were sourced from modules with KS-AT-KR-ACP domain 
organization, so swaps of KR domains with neighboring reductive domains may need to 
be optimized separately. A subsequent study also corroborated the results from the 
work by Weissman and coworkers. Only A-type KR domain exchanges into a lipomycin 
PKS derivative (LipPKS1+TE), natively containing an A2-type KR, were active whereas all 
attempts to swap in B-type KRs produced PKSs incapable of reduction.87 By comparing 
KR swaps of domains that contain or lack the newly-discovered KR dimerization element 
(DE), Keasling and coworkers also found that retaining the DE from the acceptor module 
almost always produced PKSs competent at performing condensation. Retaining the DE 
produced mutants with much higher activity than previous reports, suggesting that 
more systematic analyses of the structural implications of domain swaps might improve 
the activity of hybrid PKSs. 
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Figure 2-4 Potential product outcomes from PKS reducing domains. Potential stereochemical outcomes of 
each combination of β-carbon processing domains within a PKS module. 
 
A few trends emerge when comparing the various strategies for altering the 
stereochemical outcome conferred by the KR domain. An aspect that appears to be 
generally consistent between studies with small molecule substrates, mutagenesis, and 
domain swaps is that KRs that reduce longer substrates (presumably possessing larger 
binding pockets) tend to be either less active on smaller substrates or tend to generate 
predominantly the energetically favored A2 product. This was observed in studies by 
Keatinge-Clay and coworkers, wherein small N-acetylcysteamine (SNAC) mimics were 
treated with a panel of various type I KRs.74 This is also consistent with the work of 
Keasling and coworkers, where DEBS KR6 (the KR from the terminal module) was shown 
to retain the least amount of selectivity among the KR+DEs swapped.87 The notion that 
expanding the binding pocket affects stereochemical outcome was further corroborated 
by the work of Keatinge-Clay via enlarging active site through point mutations.80 This 
observation has implications for choice of donor KRs to exchange in KR swapping 
experiments. If the donor KR does not natively reduce a substrate of similar size to the 
target small molecule, it is unlikely to retain stereochemical fidelity, thus impacting the 
processing of downstream β-carbon processing domains (Figure 2-4). 
 
2.3.4. Dehydratase and enoylreductase domains 
 
Dehydratase domains are responsible for installing the majority of alkenes in 
polyketides. Dehydration proceeds via the syn-coplanar elimination of water and is 
therefore sensitive to the stereochemical configuration of the substrate.88 Thus, DH 
domains are tied to the KR domains that precede them. Most DHs follow B-type KRs 
and catalyze trans-olefin formation (Figure 2-4).8 However, both cis- and trans- alkenes 
are found in polyketide backbones. Post-PKS processing is implicated in formation of 
the cis-olefins in borrelidin89 and rifamycin.90 The cis-alkene of phoslactomycin, 
however, is likely installed by the DH of the first module of the synthase, Plm1.91 This DH 
succeeds an A-type KR, so syn-coplanar elimination of water from the resultant KR 
product would yield a cis alkene (Figure 2-4). Despite having several DH crystal 
structures,88,90,92 there is no clear trend in the active site residues that govern the 
stereochemistry of reduction or the preference for α-substituents.93  
 
Although DH engineering has not been as extensively pursued as the engineering 
of other PKS domains, several examples of both site-directed and swap-based 
engineering exist. There are several known examples of naturally-inactive DH domains, 
such as those observed in the amphotericin,94 avermectin,95 nystatin,96 and 
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nanchangmycin97 clusters. Each of the inactive domains exhibits a H→ R or H→ Y 
mutation within the conserved active site motif “HxxxGxxxxPP”. Installing the H→ Y 
mutation in a DH domain within the FR-008 PKS resulted in successful inactivation of the 
DH and production of solely the appropriately hydroxylated products.98 Using this same 
technique, a DH in the nystatin cluster could also be inactivated.99 DH swaps have also 
been attempted. The DH domain from DEBS was swapped into a module of the 
avermectin synthase in S. avermitilis, resulting in the exclusive production of C22,23-
unsaturated avermectins (although at much lower titers than the wild type).100 DH 
domain swaps were also employed in a polyketide synthase engineered to produce 
adipic acid, decreasing the amount of 3-hydroxyadipoyl product that had built up due 
to suspected non-optimal DH activity. Interestingly, the same group showed that DH 
domains can also be provided in trans to achieve the same effect (Figure 2-1C).101 
 
Even less is known about the ER domains, which reduce trans-α,β-unsaturated 
intermediates provided by DHs. ERs, like KR domains, exhibit epimerase activity on α-
substituents as well.93 ERs that produce L-oriented products possess a conserved 
tyrosine that is absent in D-type KRs.102 A crystal structure of the ER from the second 
module of the spinosyn PKS (Spn2) shows this characteristic L-type tyrosine residue 
proximal to 4-pro-R-hydride of the bound NADP+, suggesting its role as the proton 
donor.103 This structure also revealed a lysine-aspartate pair that was crucial for catalysis; 
the lysine is thought to act as the proton donor in D-type ERs. Finally, this structure 
revealed that the ER domain is inserted between the structural and catalytic domains of 
the KR, tying the ER to its cognate KR partner. 
 
Early mutagenesis studies of ER domains in DEBS module 4 targeted the 
conserved “HAAAGGVGMA” NADPH binding motif for engineering.104 Changing this 
sequence to “HAAASPVGMA,” based on the NADPH binding motif of the inactive KR 
domain from the same module, resulted in production of primarily Δ6,7-
anhydroerythromycin C, the expected product. Moreover, mutation of the conserved L-
type tyrosine in the same ER resulted in a change of stereochemistry at the α-methyl 
substituent, switching it from the S to R configuration.102 Nevertheless, it should be 
noted that the same mutation in the rapamycin ER failed to produce the expected 
inversion of stereochemistry in TKL products; therefore, more basic studies of 
stereocontrol in ERs are needed before a comprehensive method for switching α-
substituent orientation can be determined. Subsequent mutagenesis experiments 
performed by Keatinge-Clay et al. were unable to completely inactivate the Spn2 ER 
through a single mutation.103 Instead, mutations both slowed the rate of reduction and 
increased the rate of the hydroxylation side reaction.  
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When introducing a non-native DH and ER domain into a chimeric PKS, it is 
important to consider the DH stereoselectivity of the hydroxylated product exercised by 
the upstream KR domain (Figure 2-4). It might be best to pair DH domains with their 
cognate KR partners in order to ensure proper stereochemistry of the hydroxylated 
substrate. Alternatively, swaps of DH domains into modules with the same KR type could 
also be successful. Not only is proper substrate stereochemistry required, but 
substituents farther from the zone of reactivity could also come into play.101 Another 
study corroborated this hypothesis, presenting structural and functional data to suggest 
that DHs which natively act on long-chain (C28-30) substrates are unable to dehydrate 
shorter chain (C4) substrates.105 This was consistent with the structural information 
presented, highlighting a substrate channel that made hydrophobic interactions with the 
acyl chain of the long-chain substrates. Other issues involving protein-protein 
interactions could also arise, as different ACP partners can completely reverse the 
stereospecificity of DHs.90 
 
2.3.5. Reductive loops 
 
Reductive loops, here defined as any combination of reducing domains, 
determine the degree of reduction of the β-carbon formed post-condensation and also 
typically set the stereochemistry of any ɑ-substituents (see previous sections). Typically, 
site-directed mutagenesis is performed on single reductive domains to achieve a 
desired outcome, whether it be domain inactivation or a change in activity. Schulz and 
coworkers, however, systematically evaluated the feasibility of “domain skipping” 
mutations in every reducing domain in the monensin PKS in order to evaluate the ability 
of downstream modules to accept less reduced substrates.106 PKSs mutated in a way 
that produced less reduced intermediates were less likely to produce the desired final 
product. All ER inactivations reliably produced the expected products, but only two 
thirds of DH and one half of KR inactivations resulted in any detectable premonensin 
analogs. This suggests not only that downstream domains may display selectivity for 
their native substrates, but also that attempts to engineer more drastic changes of 
degree of reduction within the molecular structure may be less successful.   
 
Full reductive loop additions into modules with fewer (or no) native reducing 
domains have been successfully employed in a few cases. A series of reductive loop 
swaps into DEBS module 2 were promising examples, demonstrating that heterologous 
reducing domains can be feasibly employed.107 Excitingly, Leadlay and coworkers 
illustrated that the KR, DH and ER domains can not only be exchanged among PKSs, but 
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they can also be added to modules having a partial reductive loop, natively containing a 
KR domain. However, the junctions of each domain swap may need to optimized on a 
case-by-case basis, as no single set of boundaries was optimal for every hybrid PKS. By 
heeding this advice, Keasling and coworkers were successfully able to engineer a PKS 
capable of producing a novel polyketide, adipic acid, by introducing a full reductive loop 
into the first module of the borrelidin PKS (Figure 2-1B-C). A series of donor loops and 
junction sites were tested to find the most productive mutant. Although application of 
reductive loop swaps was promising, a significant bottleneck at the DH was observed.101  
 
In addition to full reductive loop swaps, other examples of reductive domain 
replacements have been published. A swap of the DH-KR didomain from module 11 to 
module 12 of the pimaricin PKS improved activity of the only slightly active module 11 
DH.108 The most successful mutant retained the linkers flanking the native DH-KR, while 
replacing simply the DH domain proved ineffective. Additional examples include a swap 
of the pikromycin module 4 DH-ER didomain into the avermectin PKS109 and 
replacement of the DEBS KR domains with the full reductive loop from rapamycin 
module 1,83 both of which resulted in significant decreases in product yield in vivo. Since 
having a match between substrate size and activities of both the KRs and DHs (vide 
supra) have been shown to impact their levels of activity on non-native substrates (the 
ER has been less extensively studied), it may be important to introduce reducing loops 
that act on native substrates of a similar size with regard to the target donor molecule. 
By continuing to parse the limitations of these types of swaps, we imagine that more 
successful implementations of reductive domain additions and replacements will arise.  
 
2.3.6. Offloading domains 
 
To complete PKS biosynthesis, a terminal domain must release the ACP-bound 
polyketide intermediate in the last module. Termination domains include thioesterase 
(TE) domains and reductase (R) domains (Figure 2-2, 2-5).  The more common of the two 
release mechanisms, TEs, belong to the α/β-hydrolase superfamily of proteins and can 
release the polyketide as a linear acid, macrolactone, macrolactam, or macrothiolactone9 
(Figure 2-2, 2-5). They are generally selective catalysts in the presence of native 
substrates, exemplified by the highly regio-83 and stereospecific110 cyclization performed 
by DEBS TE. Despite their native specificity, cyclization TEs are often promiscuous 
towards unnatural substrates.12 DEBS TE, for example, cyclizes various macrolactones 
derived from engineered versions of DEBS that produce non-native oxidized and 
substituted backbones.83 Additionally, non-native 6-, 8-, 12-, 14- and 16-membered 
rings have been produced by either DEBS TE fusions or mutasynthesis.85,111,112 Cyclizing 
  21 
TEs (especially the commonly used DEBS TE) are also known to hydrolyze nonnative 
substrates in engineered systems when cyclization is not feasible.12,21,101,113,114 
 
Figure 2-5 Offloading domains. Common TE-mediated release include products such as linear acids, 
lactones,lactams, thiolactones and olefins. The less common R-domains conduct a two-electron reduction 
to produce aldehyde final products or primary alcohols through a four electron reduction. 
 
A number of striking differences emerge between the TEs that natively hydrolyze 
their substrates and those that cyclize. The best studied of the hydrolytic TEs is from 
tautomycetin, which has been structurally characterized and shown to have a narrower 
substrate chamber than that observed in the structures of the cyclizing pikromycin and 
DEBS TEs.115 The selectivity of this TE was further elucidated with chemically-synthesized 
SNAC intermediates, which demonstrated that its hydrolytic activity is highly 
stereospecific for R-β-hydroxy moieties. Further probing the hydrolytic selectivity of the 
tautomycetin TE, Kim and coworkers swapped the tautomycetin TE domain with the 
macrocyclic polyketide pikromycin TE.116  The Pik-TE-swapped strain produced a mixture 
of both linear tautomycetin and a cyclized analog. 
 
A termination mechanism that is evolutionarily related to a thioesterase consists 
of tandem sulfotransferase (ST)-TE domains which yield terminal olefins, as is found in 
the curacin PKS (Figure 2-2, 2-5). The ST-TE didomains mechanistically employ the 
sulfotransferase domain to activate the β-hydroxy group formed by the terminal 
module.  The activated sulfate group then undergoes a decarboxylative elimination 
reaction to yield the terminal olefin as the released product.92,117,118 This biosynthetic 
logic is particularly attractive for applications of engineered polyketides to produce a 
variety of desirable chemicals, especially monomers for polymeric materials119 or 
synthetic handles for further functionalization of natural products.120 
The less common of the two releasing mechanisms, R domains, generally catalyze the 
NAD(P)H-dependent reductive release of polyketide and non-ribosomal peptide 
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intermediates via thioester reduction (Figure 2-2, 2-5). R domains possess a Rossmann 
fold,121 characteristic of nucleotide binding proteins which release acyl intermediates by 
either 1) a 2- electron reduction, yielding an aldehyde final product or by 2) a 4-electron 
reduction, yielding a primary alcohol final product. Examples of these include the 
reductive release of aldehyde-containing  product aureusimine122 and primary alcohols 
in glycopeptidolipid123 and myxalamid biosynthesis.9,124  Structure-guided mutagenesis 
of the terminal myxalamid R domain, MxaA, generated variants with increased activity 
towards hydrocarbon substrates that resulted in highly-reduced primary alcohols.125 The 
removal of bulky residues in the C-terminal substrate binding domain facilitated 
reduction of non-native 10-carbon intermediates, yielding a reduced 10-carbon alcohol 
product.125  This termination mechanism is of particular interest when trying to engineer 
polyketides that generate fuel molecules (e.g. n-butanol126). 
 
2.3.7. Intermodular linkers 
 
Intermodular linkers facilitate communication and chain translocation between 
two modules. They can take the form of C- and N-terminal docking helices that mediate 
contacts between modules on separate polypeptides, or they can consist of simple 
peptide linkers between two modules on the same polypeptide (Figure 2-2).10,127–129 
Early attempts to improve intermodular communication between PKSs focused on 
covalently fusing two non-covalently-linked modules together. The expected TKLs could 
be produced in S. coelicolor by fusing DEBS module 1 to DEBS modules 3 or 6 by 
conserving the natural intermodular linker between modules 1 and 2. This technique 
could also facilitate communication of module 1 with rifamycin module 5 (Rif M5). 
Finally, by appending the C-terminal linker domain from DEBS module 2 to the end of 
Rif M5, the hybrid DEBS M1-Rif M5 protein could be coaxed to communicate with the 
downstream DEBS M3. This preliminary work laid the foundation for combinatorial 
biosynthesis of polyketides utilizing modules, not domains, as the fundamental unit.130  
 
Khosla and coworkers demonstrated that the position of modules within their 
native context is an important consideration for intermodular linker engineering. 
Swapping linker regions between module 2 and module 3 of DEBS with the module 4 
and 5 linkers significantly increased the Km of the module-module interaction with little 
to no effect on the kcat of polyketide transfer between the modules.131 The Khosla group 
also suggested that the KS domains of C-terminal modules, such as DEBS module 2 and 
4, are less selective of substrates from upstream ACP partners than N-terminal modules 
because C-terminal KSs are already covalently tethered to the upstream ACP. The 
importance of ACP-KS interactions for chain transfer were again highlighted in the work 
  23 
of Santi and coworkers, where over 150 module-module interactions were tested for 
chain transfer.132 The efficacy of 11 upstream and 14 downstream module combinations, 
facilitated by the C- and N-terminal linker domains from DEBS module 2 and 3, 
respectively, were tested for production of the expected TKL products. Although most of 
the individual PKSs were active on some level, less than 50% of the combined two 
module systems produced any product. The best combinations were between native 
partners, suggesting that incorrect ACP-KS interactions were a limiting factor.133    
2.4. Engineering at the host/cellular level 
 
2.4.1. Precusor-directed biosynthesis and mutasynthesis 
 
Despite all of the current insights gained through PKS engineering at the amino 
acid, domain, and module level, progress has been slower than expected. This arises 
from a lack of understanding and inability to predict the tolerance of PKS enzymes to 
utilize non-native precursors as building blocks. Non-native precursor incorporation 
requires a deep understanding of the gate-keeping activities of PKS enzymatic 
machinery. Precursor-directed biosynthesis (PDB) has been a successful tool utilized to 
further understand and expand PKS substrate promiscuity by feeding analogues of their 
natural building blocks that are likely tolerated by the native biosynthetic PKS in the 
producing host. The efficiency of PDB can be enhanced by complementation with 
mutational biosynthesis (“mutasynthesis”), wherein the naturally occurring precursor 
pathways are inactivated, thus removing competition from natural precursors. In 
addition to precursor supplementation through feeding experiments, metabolic 
pathways that produce precursor analogs can be introduced heterologously to replace 
the deleted pathways.134 
 
One of the earliest and most successful examples of mutasynthesis targeted the 
avermectin PKS. A strain of Streptomyces avermitilis was generated wherein the 
enzymes required for generating the precursors 2-methylbutyryl-CoA and isobutyryl-
CoA were inactivated, more specifically the branched chain fatty acid dehydrogenase 
complex bkd.  Out of more than 800 potential precursors tested, over 40 starter unit 
analogs were tolerated by the avermectin PKS.20 Via this method, a cyclohexyl-
containing avermectin derivative (later named doramectin) was generated that exhibited 
increased antiparasitic activity against veterinary pathogens.135 Another group later 
identified a  shikimate-derived cyclohexyl-CoA biosynthetic pathway that, when re-
introduced into S. avermitilis Δbkd, enabled the production of doramectin without 
cyclohexanoic acid supplementation.136,137 Intriguingly, while other PKSs are primed with 
isobutyryl or 2-methylbutyryl-CoA (such as lipomycin and tautomycin), no analogous 
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experiments to generate other mutasynthetic analogs in Δbkd strains has been reported. 
While the lipomycin loading AT has been shown to be somewhat promiscuous, only six 
loading substrates have been characterized.21 Thus, it is unclear if the avermectin PKS 
has an unusually promiscuous loading AT, or if this extreme promiscuity is a general 
feature of loading ATs from type B LMs that accept bulkier acyl-CoA priming substrates. 
 
Other examples of PDB have targeted the macrolides rapamycin138,139  In 
rapamycin biosynthesis, Leadlay and coworkers conducted feeding experiments with 
starter-unit analogues. A series of 21 substrates consisting of monocyclic, polycyclic and 
branched aliphatic acids, substituted benzoic acids and heterocyclic acids, were fed to 
the rapamycin-producing strain of S. hygroscopicus.139 New metabolites were observed 
in the presence of three monocyclic aliphatic acids, demonstrating a certain degree of 
starter-unit promiscuity within the rapamycin LM and further suggesting some substrate 
tolerance within the downstream modules (Figure 2-6A).139 In a similar approach, Martin 
and coworkers explored carboxylic acid starter-unit tolerance in the spinosyn PKS 
appended with the avermectin or erythromycin LM.140 Supplementation with a range of 
carboxylic acids led to the successful production of new spinosyn analogues (Figure 2-
6B).140  In a similar example, the aureothin PKS pathway demonstrated starter unit 
tolerance towards various aromatic priming analogs.138 Lastly, Khosla and coworkers 
evolved an engineered erythromycin biosynthetic pathway in E. coli, yielding 
erythromycin analogs from SNAC precursors. Khosla and coworkers fed diketide SNAC 
precursors to E. coli cells harboring a truncated form of DEBS lacking the loading and 
first modules. They demonstrated the incorporation of the native substrate analog 
diketide SNAC and a novel diketide-SNAC containing an alkynyl moiety into the 
erythromycin final product (Figure 2-6C). These results support the tolerance of DEBS to 
utilize a nonnative substrate for priming, extension and modification by the downstream 
DEBS PKS machinery to produce an alkynyl-containing erythromycin derivative.141,142 
 
The selectivity and promiscuity of extending acyltransferase domains can also be 
targeted for PDB and/or mutasynthetic approaches to alter PKS scaffolds. While the AT 
domains that select for malonyl-CoA or methylmalonyl-CoA are typically quite selective 
for their respective extender units,40 it is common for ATs that naturally select for more 
uncommon and/or bulkier substrates to have more relaxed intrinsic substrate selectivity. 
For example, module 5 of the monensin PKS natively incorporates both methylmalonyl-
CoA as well as ethylmalonyl-CoA.143–145 In the salinosporamide PKS, while the major 
product is derived from SalA-AT-mediated chloroethylmalonyl-CoA incorporation 
(forming salinosporamide A), analogs containing ethylmalonyl-CoA (salinosporamide B) 
and methylmalonyl-CoA (salinosporamide D) are also generated (Figure 2-6D).146 This 
  25 
inherent promiscuity can be harnessed in concert with precursor pool engineering to 
bias the distribution of metabolites or generate new metabolites altogether.  Deletion of 
5-chlorodeoxyadenosine (a precursor for chloroethylmalonyl-CoA) biosynthetic genes 
coupled with exogenous supplementation of 5-fluorodeoxyadenosine147 or 
heterologous expression of the heterologous precursor pathways148 resulted in the 
generation of a fluorinated analog, fluorosalinosporamide . 
 
Likewise, the promiscuity of the monensin AT5 was explored to generate 
premonensin analogs (Figure 2-6E). Schulz and coworkers determined that MonAT5 
accepts propargylmalonyl, allylmalonyl, propylmalonyl, and butylmalonyl-SNAC when 
supplemented in the media.145 Similar promiscuity was shown for an ethylmalonyl-CoA 
selective AT in the kirromycin pathway, KirCII (Figure 2-6F). In vitro, KirCII accepts a 
range of longer malonyl derivatives including allylmalonyl-CoA, propargylmalonyl-CoA, 
and to a lesser extent azidoethyl-CoA.149,150 Rather than supplementing the culture with 
SNAC analogs, Williams and coworkers introduced a highly promiscuous mutant of the 
malonyl-CoA ligase, MatB, from Rhizobium trifolii150,151 into the host strain S. collinus Tü 
365 and supplemented exogenous allylmalonate and propargylmalonate. The malonate 
derivatives were then activated by MatB and incorporated into the polyketide to 
generate kirromycin analogs.44 Propargyl-containing extender units were introduced in 
one additional polyketide scaffold through targeted mutagenesis. A combination of 
structural modeling and sequence comparisons of ATs with specificity for bulkier 
substrates (such as ethylmalonyl-CoA) was used to expand the promiscuity of a 
methylmalonyl-selective AT.53,56  
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Figure 2-6 Examples of precursor-directed biosynthesis. A) Starter unit PDB in the rapamycin PKS. B) Starter 
unit tolerance in spinosyn biosynthesis. C) Extender unit PDB using a diketide SNAC precursor in the 
erythromycin PKS. D) Incorporation of fluoromalonyl-CoA through mutasynthesis of the salinosporamide 
pathway. E) Incorporation of propargyl-, propyl- and allylmalonyl-SNAC into the monensin polyketide 
backbone. F) Incorporation of propargyl- and allylmalonyl-CoA into the kirromycin polyketide backbone. 
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2.4.2. Metabolic engineering for improved precursor pools 
Outside the limitations of directly engineering of PKSs, one approach to 
improving polyketide production involves increasing the availability of polyketide 
precursors. Pathways for the biosynthesis of polyketide metabolites often use precursors 
synthesized during glycolysis, the tricarboxylic acid cycle, and the pentose-phosphate 
pathway.152 Metabolic engineering has successfully improved selected bottlenecks in 
various strains, increasing intracellular precursor pools, and thus redirecting flux towards 
the desired polyketide biosynthetic pathway. The deletion of the S. coelicolor 
phosphofructokinase gene plfkA or the S. lividans glucose-6-phosphate dehydrogenase 
genes zwf1 and awf2 achieved higher production of actinorhodin and 
undecylprodigiosin,  respectively.153 Inactivation of the glyceraldehyde-3-phosphate 
dehydrogenase gap1 in S. clavuligerus resulted in more clavulanic acid production.154,155 
In contrast to deletion or knockout of genes, overexpression and knockin of genes has 
been utilized more often as a strategy to increase specific precursors for polyketide 
production. Such polyketide precursors include well-known and unique starter-
/extender-units. For many type I assembly-line PKS pathways, such as DEBS, priming 
begins with one propionyl-CoA starter unit and extension is performed with (2S)-
methylmalonyl-CoA. E. coli does not naturally produce (2S)-methylmalonyl-CoA, posing 
a bottleneck for expression of the erythromycin pathway in this host.156 Hillenmeyer and 
coworkers have worked to overcome E. coli’s (2S)-methylmalonyl-CoA limitation by 
introducing heterologous propionyl-CoA carboxylases (PCCs) (Figure 2-7A).157 The 
propionyl-CoA carboxylase is a biotin-dependent enzyme that catalyzes the 
carboxylation of propionyl-CoA to form (2S)-methylmalonyl-CoA. The core PCC complex 
consist of two genes encoding the biotin carboxyl carrier α-subunit protein and a β-
subunit containing the carboxylase activity.158,159 Hillenmeyer and coworkers examined 
the effect of heterologous expression of various PCCs on erythromycin production in E. 
coli by optimizing both expression of the S. coelicolor PCC complex and screening 13 
homologous PCCs from diverse species.157 The hybrid PCC complex from Myxococcus 
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fulvus and S. coelicolor outperformed all other PCC complexes in stimulating 
erythromycin production. 
 
Figure 2-7 Examples of metabolic engineering for improved precursor pools. A) Overexpression of PCC for 
the conversion of propionyl-CoA to (2S)-methylmalonyl-CoA allowed for the production of 6-
deoxyerythronolide B in bacteria that don’t natively produce methylmalonyl-CoA (such as E. coli). B) 
Expression of the methoxymalonyl-ACP biosynthetic pathway in a platenolide producer generated a 
platenolide analog containing the methoxy moiety. C) Higher titers of mithramycin were achieved by 
increasing the precursor supply of malonyl-CoA and glucose-1-phosphate. Green boxes denote 
upregulated pathways and red cross marks denote downregulation or knockout pathways. D) Post-
translational modification of apo-ACPs by PPTases generated active holo-ACPs which can activate FAS 
biosynthetic pathways in primary metabolism or PKS pathways in secondary metabolism. 
 
Unlike E. coli, where certain acyl-CoA extender units may be limited or 
nonexistent, Streptomyces already contain the common precursors to support 
polyketide biosynthesis. The diverse precursor pools that Streptomyces produce 
facilitate the heterologous expression and engineering of full pathways in these 
hosts.  For example, in S. coelicolor and S. lividans strains heterologously expressing the 
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DEBS PKS, Floss and coworkers constructed strains capable of producing 3 mg/L of 2-
desmethyl-2-methoxy-6-deoxyerythronolide via the introduction of the 
methoxymalonyl-ACP biosynthetic pathway from Actinosynnema pretiosum.63  The 
incorporation of methoxymalonyl-ACP was also utilized in S. fradiae, a host that natively 
produces three of the most common polyketide precursors: malonyl-CoA, 
methylmalonyl-CoA, and ethylmalonyl-CoA.160 By introducing the biosynthetic pathway 
for  methoxymalonyl-ACP into an S. fradiae strain heterologously expressing the 
midecamycin pathway, Katz and coworkers produced a methoxymalonate-platenolide 
analog (Figure 2-7B).160  More recently, precursor pool engineering was also successfully 
employed to improve salinomycin production in S. albus. Metabolomic analysis 
suggested that intracellular ethylmalonyl-CoA concentrations were limiting titer, so an 
additional copy of the crotonyl-CoA carboxylase gene responsible for generating 
ethylmalonyl-CoA was integrated into the producing strain. This approach improved 
titers over tenfold.161 
Méndez and coworkers improved precursor metabolite pools for the production of the 
antitumor compound/polyketide mythramycin in S. argillaceus by increasing the 
precursor supply of malonyl-CoA and glucose-1-phosphate (Figure 2-7C).155 The 
mythramycin PKS uses ten malonyl-CoA units for chain extension and cyclizes the 
extended polyketide to a tetracyclic intermediate. The tetracyclic intermediate is 
subsequently glycosylated by five deoxysugars derived from glucose-1-phosphate, 
generating mythramycin as the final product.155 By either overexpressing the S. 
coelicolor phosphoglucomutase gene pgm or by inactivating the ADP-glucose 
pyrophosphorylase gene glgCa, they were able to increase glucose-1-phosphate 
production (Figure 2-7C). Moreover, they were able to increase malonyl-CoA by 
overexpressing the acetyl-CoA carboxylase ovmGIH gene or by inactivating the acyl-CoA 
diacylglycerol acyltransferase gene aftAa, the latter strategy being superior for 
improving mythramycin production.155  
 
2.4.3. Phosphopantetheinyl transferase expression and regulation 
 
Another frequent issue encountered when heterologously expressing PKSs is the 
need for post-translational activation of each ACP domain with a prosthetic 
phosphopantetheine arm. All ACP domains must be converted to the holo form by 
phosphopantetheinyltransferases (PPTases), which install the phosphopantetheinyl 
prosthetic group of ACP domains. PPTases can have a range of substrate selectivities, 
depending on whether they evolved to activate a carrier protein from a specific 
biosynthetic pathway or whether they have a pleiotropic role in the cell, activating 
multiple pathways.162–164 PPTases are classified by whether they activate fatty acid 
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biosynthetic pathways from primary metabolism (AcpS-type PPTases) or polyketide and 
nonribosomal peptides from secondary metabolism (Sfp-type PPTases) (Figure 2-7D).165 
In host organisms that do not natively harbor multiple polyketide and/or non-ribosomal 
peptide biosynthetic pathways (such as E. coli or S. cerevisiae) integration of a 
promiscuous Sfp-type PPTase is critical to enable the heterologous production of 
polyketide metabolites. The promiscuous PPTase Sfp, from the surfactin biosynthetic 
pathway in Bacillus subtilis, has historically been the most common choice for 
application in heterologous systems.166-167 Sfp has been integrated into E. coli to 
generate strains engineered  specifically for polyketide production: BAP1168 and K207-
3.169 Successful production of polyketide metabolites has also been accomplished in S. 
cerevisiae strains containing genomically-integrated Sfp.170–172 The usefulness of many B. 
subtilis laboratory strains for heterologous PKS production is diminished because of a 
common frameshift within the sfp gene, effectively shutting down the production of 
multiple secondary metabolites.163,173,174 Indeed, to successfully heterologously produce 
6-dEB in the commonly used B. subtilis Marburg 168 strain, restoration of Sfp activity 
was required.174 As an alternative to Sfp, the similarly promiscuous PPTase, Svp, from S. 
verticullus ATCC15003 has also been used to post-translationally modify a wide range of 
ACPs.175 
 
In most Streptomyces, heterologous polyketide production can be achieved 
without integration of an exogenous PPTase,176 suggesting that most Streptomyces 
species natively harbor promiscuous PPTases. This is unsurprising, given the wealth of 
secondary metabolites that are produced by Actinomycetes. However, more recently the 
overexpression of PPTases has been explored as a means of boosting polyketide 
production in various Actinomycetes. Li and coworkers demonstrated that 
overexpression of the endogenous PPTase SchPPT in S. chattanoogensis L10 increased 
the production of the polyketide natamycin by over 40%.177  Other experiments suggest 
that PPTases may play a major role in the regulation of PKS expression. For example, 
overexpression of either Sfp or Svp in over 33 Actinomycetes activated the expression of 
silent biosynthetic pathways.178 Although a basal level of PPTase expression is typically 
sufficient for polyketide production, these experiments suggest that overexpression of 
these enzymes can significantly enhance or alter the regulation and production PKS 
metabolites. Thus, to achieve extremely high titers of polyketide products in 
Streptomyces and related Actinomycetes, manipulating the expression of both 
endogenous and exogenous PPTases is likely an underexplored approach. 
 
2.4.4. Transcriptional regulation and refactoring of PKS genetic components 
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Polyketide biosynthetic gene clusters commonly contain pathway-specific 
regulatory elements that act as activators or repressors of various genetic elements 
within the cluster. In the biosynthesis of tylosin, for example, both activators and 
repressors have been identified and characterized.179,180 Activator elements often belong 
to the Streptomyces Antibiotic Regulatory Protein (SARP) family, a group of proteins 
known to enhance the production of polyketides such as daunorubicin, mithramycin and 
tylosin.153 These SARPs can be effectively used as tools to increase polyketide 
production. Tylosin production, for example, is increased when the SARP regulators tylS 
and tylR are overexpressed in the native producer S. fradiae.180 Mithramycin production 
in S. argillaceus can also be enhanced by overexpressing two SARPs, mtrY and mtmR, on 
multicopy plasmids.181,182 Other families of transcriptional regulators, such as the LysR-
type transcriptional regulators (LTTRs), can serve as additional tools for controlling 
polyketide production. The role of LTTRs has been studied in the ascomycin biosynthetic 
cluster; in particular, Wen and coworkers have characterized the role of the LTTR 
fkbR1.183 Inactivation of fkbR1 leads to a reduction of ascomycin production, which can 
be restored by complementation with fkbR1. Overexpression of fkbR1, on the other 
hand, results in increased ascomycin production, suggesting that fkbR1 acts as a 
positive regulator.183 Manipulation of negative regulators can also be used as a tool for 
manipulating polyketide pathways. For example, inactivation of a transcriptional 
repressor (tylQ) from the tylosin pathway causes production to begin at an earlier stage 
of S. fradiae growth.184 On the other hand, disruption of the tylP gene that encodes a γ-
butyrolactone receptor increases production.179  
 
The use of DNA-based regulatory elements can be used to complement the 
manipulation of protein-based positive and negative regulators for the optimization of 
polyketide production. The introduction of heterologous promoters, for example, has 
been effectively used to activate multiple silent polyketide clusters in various hosts. 
Eliciting expression of silent polyketide pathways is often challenging due to poorly 
understood regulation mechanisms. In addition, these silent polyketide gene clusters 
often remain inactive under typical culturing conditions. With the goal of developing a 
generalizable method to elucidate the function of cryptic biosynthetic gene clusters, 
Zhao and coworkers developed a synthetic biology approach  to activate silent 
biosynthetic gene clusters.185 The entire silent biosynthetic gene pathway was refactored 
using a plug-and-play scaffold, containing a set of heterologous functional promoters 
and placed in a heterologous host under more traditional culturing conditions. Using 
this strategy, Zhao and coworkers successfully activated the previously silent 
spectinabilin pathway from S. orinoci.185  
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More recently, Apel and coworkers used a similar plug-and-play method for the 
assembly of artificial genes into functional biosynthetic gene clusters.186 As a proof of 
concept, the novobiocin pathway was disassembled and genetically reorganized using 
the artificial gene operon assembly method, a tool that consecutively assembles artificial 
genes into a destination vector and subsequently expresses them under the control of a 
de-repressed promoter in a Streptomyces host. By completely refactoring the pathway 
in S. coelicolor, Apel and coworkers were able to observe production of novobiocin 
precursors and novobiocin.186  
 
The increasing promise of the CRISPR-Cas9 system for rapid and targeted genetic 
manipulations187,188 has led to the development of protocols for using the technique in 
natural product-producing bacteria such as Streptomyces. Several groups laid the 
foundation for work with CRISPR-Cas9, first with the development of methods for 
performing knockouts.189,190 Later, Zhao and coworkers extended the usefulness of this 
CRISPR-Cas9 platform, using it to perform knockins to activate silent biosynthetic gene 
clusters in Streptomyces.191 In a one-step strategy, multiple biosynthetic gene clusters of 
type I, II and III PKSs in five Streptomyces species were activated. Moreover, by 
introducing strategically-placed constitutive promoters, they elicited the production of a 
new metabolite in S. viridochromogenes: a multicyclic type II polyketide.191 
2.5. Host, precursor, and protein engineering synergy 
 
Ultimately, for PKS protein engineering to be feasibly employed to produce 
target chemicals, it must be evaluated whether the engineered PKS activity in vivo is 
similar to its activity in model systems, such as biochemical in vitro assays.  In vitro 
studies afford absolute control of substrate and cofactor concentrations, which is not 
feasible in vivo. Thus, combinations of host and engineered PKS can result in various 
(and sometimes unanticipated) substrate incorporations. A study that exemplifies this 
phenomenon dissects the LM of DEBS. While in the native Saccharopolyspora erythrea 
DEBS is primed exclusively by propionyl-CoA,192 the LM of DEBS incorporates other 
priming units in heterologous systems.193 Depending on the host, TKLs from DEBS1+TE 
can form via priming by acetyl-CoA (in S. coelicolor194 and S. venezuelae193) or 
isobutryryl-CoA (in S. venezuelae ), albeit as minor products. Reynolds and coworkers 
interrogated the relationship between PKS architecture and starter unit incorporation in 
variations of DEBS1+TE expressed in S. venezuelae. It was determined that placing the 
LM and module 1 on separate polypeptides (with the use of heterologous docking 
domains) changed the distributions of acetyl, propionyl, and isobutyryl priming units 
incorporated in comparison to the ratios observed with both modules on the same 
polypeptide (i.e. the selectivity shifted from predominantly propionyl selective to 
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isobutyryl-selective). This was rationalized through biochemical studies suggesting that 
the loading AT selects isobutyryl-CoA as the thermodynamic product. However, DEBS 
KS1 has faster kinetics for propionate compared to isobutyrate. When the loading 
domain is placed on a separate polypeptide from module 1, there is a resulting kinetic 
stall. This kinetic stall shifts the product formation towards thermodynamic control, 
especially when higher levels of isobutyl-CoA are present.193 This example demonstrates 
that the apparent selectivity of PKS domains can be altered depending on the 
architecture of the PKS in concert with the precursor availability. Therefore, results of 
both in vitro and in vivo experiments for engineered polyketide production should be 
evaluated with a careful consideration of the advantages and limitations of each 
experimental approach. 
2.6. Conclusions 
 
With all the current success in PKS/host engineering, the gap between our 
understanding of PKS biosynthetic logic and the application of PKSs as a retrosynthetic 
platform is narrowing. In the past, our ability to design, build and test chimeric PKSs was 
limited by DNA sequencing and assembly techniques. Currently, our ability to discover 
and generate PKS genotypic diversity, enabled by DNA sequencing and synthesis 
technologies, allows us to rapidly build sizeable libraries of engineered PKSs.195,196 
However, our ability to screen the resulting libraries lags. There is a need for more high-
throughput approaches to test engineered PKS scaffolds. Analytical methods such as 
liquid chromatography coupled with mass spectrometry are improving and new 
techniques are being developed which allow for increased throughput with limited 
sample preparation.14,197–199 Transcription factor-based biosensors could be potentially 
employed to screen and select for successful engineered PKSs constructs.200 
Additionally, there are an increased number of computational and bioinformatic tools 
which aid the identification of candidate swaps as well as the curation and annotation of 
PKS pathways.201–206 With the increasing success of chimeric PKSs scaffolds, there will 
also be a need for optimization of precursor flux within the target host. The metabolic 
engineering pathways for polyketide precursors must be integrated into hosts that 
express highly soluble and active engineered PKSs. By building on existing polyketide 
engineering and characterization strategies, harnessing current synthetic biology 
technologies and utilizing advances in metabolic/host engineering we anticipate future 
successes in engineering PKSs capable of producing designer polyketides for 
applications in medicine, fuels and industrial products.  
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3.1. Abstract 
 
Terminal alkenes are easily derivatized, making them desirable functional group 
targets for polyketide synthase (PKS) engineering. However, they are rarely encountered 
in natural PKS systems. One mechanism for terminal alkene formation in PKSs is through 
the activity of an acyl-CoA dehydrogenase (ACAD). Herein, we use biochemical and 
structural analysis to understand the mechanism of terminal alkene formation catalyzed 
by an γ,ẟ-ACAD from the biosynthesis of the polyketide natural product FK506, TcsD. 
While TcsD is homologous to canonical α,β-ACADs, it acts regioselectively at the γ,ẟ-
position and only on α,β-unsaturated substrates. Furthermore, this regioselectivity is 
controlled by a combination of bulky residues in the active site and a lateral shift in the 
positioning of the FAD cofactor within the enzyme. Substrate modeling suggests that 
TcsD utilizes a novel set of hydrogen bond donors for substrate activation and 
positioning, preventing dehydrogenation at the α,β position of substrates. From the 
structural and biochemical characterization of TcsD, key residues that contribute to 
regioselectivity and are unique to the protein family were determined and used to 
identify other putative γ,ẟ-ACADs that belong to diverse natural product biosynthetic 
gene clusters. These predictions are supported by the demonstration that a 
phylogenetically distant homolog of TcsD also regioselectively oxidizes α,β-unsaturated 
substrates. This work exemplifies a powerful approach to understand unique enzymatic 
reactions and will facilitate future enzyme discovery, inform enzyme engineering, and 
aid natural product characterization efforts.  
 
3.2. Introduction 
Natural products often have complex chemical structures which can confer 
potent biological activity. Evolution selects for the diversification of these secondary 
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metabolites, making natural product biosynthetic pathways rich resources for the 
discovery of both lead compounds for drug discovery and also enzymes with unique 
functions.207–209 Next-generation sequencing has led to the identification of numerous 
biosynthetic gene clusters (BGCs), but the pool of “orphan” BGCs (i.e. BGCs with no 
cognate natural product identified) remains largely untapped. Predicting natural product 
structures from primary DNA sequence is challenging, as the in silico functional 
annotation of enzymes within BGCs is limited. Amino acid sequence homology can 
suggest a general function, but without in depth structural and biochemical 
characterization of one or more members of an enzyme family, precise predictions of 
the final natural product structure are difficult. The identification of specificity-conferring 
motifs in polyketide synthase (PKS) acyltransferase (AT) and ketoreductase (KR) domains, 
for example, has allowed for more precise predictions of final polyketide natural product 
structure, including the identity of the alkyl substituents incorporated by (AT) and final 
stereochemical outcome (KR) of a given PKS module.210 While much effort has been 
dedicated to elucidating signature motifs within PKS domains, many PKS-associated 
enzymes that generate less common functional groups (such as non-canonical starter 
and extender units) are not as well annotated or understood. Better characterization of 
the enzymes implicated in the biosynthesis of unique and reactive moieties would 
facilitate the engineering of novel polyketides with applications in medicine, in 
agriculture, or as commodity chemicals.207,211,101 
One particular moiety of interest for PKS engineering is the alkene, as alkenes 
could easily be chemically derivatized to introduce a multitude of other desirable 
functionalities into a natural product.119,212–223 Alkenes are often generated within a 
polyketide via the action of reductive domains, but they are sequestered within the 
polyketide backbone8 and are therefore less sterically accessible for chemical 
modification than terminal alkenes.224–232 Terminal alkenes, in addition to their innate 
reactivity, can also confer improved biological activity to polyketides that display 
biological activity, as is exemplified by the improved drug tolerability and efficacy of a 
synthetic epothilone analog sagopilone (anti-cancer activity).233,234 There are few known 
examples of polyketides that contain terminal alkenes, including FK506, haliangicin, 
curacin A, and tautomycetin (Figure 3-1A).235-236,237 In curacin A, a terminal alkene is 
generated through a unique off-loading mechanism involving a sulfotransferase (ST) 
and thioesterase domain.118 The tautomycetin terminal alkene is known to be formed 
after the chain has been released from the PKS but the process has yet to be fully 
characterized.238,239 
  37 
A different mechanism for terminal alkene formation occurs via the action of an 
acyl-CoA dehydrogenase (ACAD) that oxidizes the γ,δ-position of a fatty acyl-CoA or 
acyl carrier protein (ACP), as observed in the haliangicin and FK506 pathways.240,241 The 
identification of other terminal alkene-forming ACADs is difficult, though, because of 
the enzymes’ homology to canonical ACADs. Thus, identifying important sequence 
motifs is critical to more accurate annotation. ACADs are oxidoreductase flavoenzymes 
well known for catalyzing the first oxidative step of fatty acid β-oxidation: the 
dehydrogenation of saturated fatty acyl-Coenzyme A (CoA) thioesters to form the 
corresponding α,β-unsaturated product (Figure 3-1B).242 The ACADs from the haliangicin 
and FK506 biosynthetic pathways, however, oxidize the γ,ẟ-position of a substrate. In 
order to facilitate better annotation of γ,ẟ-ACADs and, in turn, the identification of 
polyketide natural products that potentially contain terminal alkenes, a better functional 
characterization of γ,ẟ-ACADs is necessary. Herein, we report on our studies of the basis 
for the shift in regiochemistry of one of these unusual ACADs, TcsD, which forms the 
terminal alkene of the allylmalonyl-CoA extender unit in the biosynthesis of the 
polyketide FK506.241 
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Figure 3-1 Terminal alkene-containing natural products and alkene formation by acyl-CoA dehydrogenases. 
A) Examples of terminal alkene-containing polyketide natural products. Terminal alkenes are highlighted in 
red. B) Process of fatty acid β-oxidation. The canonical activity of acyl-CoA dehydrogenases (ACADs) is the 
dehydrogenation of saturated fatty acyl-CoAs to form α,β-unsaturated products with concomitant 
reduction of FAD, highlighted in red. C) Proposed steps of allylmalonyl-CoA biosynthesis (adapted from 
reference 241). KS = ketosynthase domain, AT = acyltransferase domain, ACP = acyl carrier protein, FAS = 
fatty acid synthase. 
The allylmalonyl-CoA biosynthetic pathway was initially proposed as a hybrid PKS-
fatty acid synthase (FAS) pathway in which a free-standing ketosynthase, TcsB, first 
condenses a propionate group with a malonyl-CoA-derived extender unit selected by the 
AT domain of TcsA to form 3-oxo-pentanoyl-TcsA (Figure 3-1C, upper pathway).241 After 
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reduction by the producing organism’s FAS, it was proposed that the final two enzymes 
TcsC (a crotonyl-CoA reductase) and TcsD (an ACAD) work interchangeably to convert 2-
pentenoyl-TcsA to allylmalonyl-TcsA, with TcsD forming the unique terminal alkene 
moiety (lower pathway).  
The sequence homology that TcsD shares with other ACADs suggests that it utilizes 
the same chemical mechanism to form the γ,ẟ-alkene of the allyl functional group. ACADs 
employ a catalytic base, typically a glutamate residue, to deprotonate the acidic α-proton 
of a fatty acyl-CoA substrate.242–245 The concomitant transfer of a hydride from the β-
carbon of the substrate to FAD results in the formation of an α,β-unsaturated product and 
the reduced flavin, FADH2.246 The reaction is mediated by pKa perturbations of both the 
catalytic glutamate residue and the substrate α-protons that occur within the active site 
of the enzyme. The pKa of the glutamate is raised from ~6 to ~9 due to desolvation of the 
active site upon the binding of a hydrophobic substrate,247–249 while the substrate protons 
are activated via hydrogen bonds of the substrate thioester carbonyl group with the 
amide backbone of the glutamate and the 2’-hydroxyl group of FAD.250–253 While this 
mechanism of substrate activation is plausible for the γ-protons of a substrate such as 2-
pentenoyl-TcsA (which contains an α,β-alkene that can propagate electronic effects from 
the thioester to the γ-carbon), the activation of propylmalonyl-TcsA and its conversion to 
allylmalonyl-TcsA (Figure 3-1C, pathway A2) is highly unlikely due to the aliphatic nature 
of the substrate. 
Here we interrogate the activity of TcsD on both potential substrates and show 
that pathway B1 (Figure 3-1C) is the only route of allylmalonyl-ACP formation. 
Additionally, we show that TcsD oxidizes only α,β-unsaturated substrates and is 
regioselective for the γ,ẟ position of these substrates. Further, we present a high resolution 
TcsD crystal structure and propose a structural mechanism by which it exhibits precise 
regiocontrol over this transformation. Combined structural and biochemical analyses of 
this enzyme revealed signature residues that contribute to its unique regioselectivity and 
facilitate the identification of homologs that display the same biochemical activity. A 
better understanding of this unique enzyme’s activity will not only inform the 
characterization of other homologs and their associated BGCs, but the insights gained 
herein can also aid future enzyme engineering efforts. 
3.3. Results 
3.3.1. Biochemical Activity of TcsD 
In order to understand the mechanisms underlying TcsD activity, we initially 
sought to determine the native substrate(s) of the enzyme by biochemically 
  40 
interrogating both pathway B1 and A2 (Figure 3-1C). The substrates 2-pentenoyl-ACP 
(pathway B1) and propylmalonyl-ACP (pathway A2) were incubated with TcsD in the 
presence of the external electron acceptor ferrocenium hexafluorophosphate to 
facilitate enzyme turnover.254 Assays were analyzed using targeted LC-MS/MS to 
monitor for the characteristic phosphopantetheine ejection transition (Figure 3-2A).255 
As expected, TcsD converted nearly all of the the 2-pentenoyl substrate to the 
corresponding 2,4-pentadienoyl-TcsA product, with no activity detected in boiled TcsD 
controls (Figure 3-2B). However, TcsD was unable to convert propylmalonyl-TcsA to 
allylmalonyl-TcsA under identical assay conditions (Figure 4-6). We therefore concluded 
that the biosynthesis of allylmalonyl-CoA can only proceed through route B, in which 
TcsD first oxidizes 2-pentenoyl-TcsA to 2,4-pentadienoyl-TcsA (B1) and subsequently 
TcsC performs a reductive carboxylation to form allylmalonyl-TcsA (B2).  
Due to the noncanonical regiochemistry of the TcsD-mediated dehydrogenation 
of 2-pentenoyl-TcsA, we further investigated whether TcsD is regioselective for the γ,δ-
position or if it simply oxidizes any appropriately activated substrate. It is known that 
some ACADs can abstract the acidic γ-proton of α,β-unsaturated substrates after 
dehydrogenation.243,244,256 Accordingly, it is plausible that TcsD is a promiscuous enzyme 
that dehydrogenates any substrate present on TcsA-ACP and that any specificity it 
exhibits in vivo arises from the sequestration of substrates on a protein (TcsA) instead of 
Coenzyme A. We therefore probed TcsD activity on a panel of α,β-unsaturated and fully 
saturated substrates. The enzyme was active on another α,β-unsaturated substrate, 2-
hexenoyl-TcsA, but inactive on the seven carbon 2-heptenoyl-TcsA (Figure 3-2B). On the 
substrates butyryl-TcsA and pentanoyl-TcsA, where possible α,β-unsaturation could be 
expected, no oxidation activity was observed which indicated that TcsD acts 
regioselectively at the γ,δ-position (Figure 3-2B, 4-7, 4-8).  
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Figure 3-2 Biochemical activity of TcsD on ACP-bound substrates. A) Experimental design for 
phosphopantetheine ejection assays of TcsD activity on TcsA-bound substrates B) LC-MS/MS 
chromatograms of TcsD activity assays on various substrates. Substrates from left to right: 2-pentenoyl-
TcsA, 2-hexenoyl-TcsA, 2-heptenoyl-TcsA, pentanoyl-TcsA. Top row: negative controls with boiled TcsD (-). 
Bottom row: assays with intact TcsD (WT). 
 
3.3.2. Crystal Structure of TcsD 
 The strict substrate specificity of TcsD at the γ,δ-position suggested that there are 
structural elements within the enzyme’s active site that control regioselectivity. To test 
this hypothesis, we obtained a crystal structure of TcsD, which was solved to 1.75Å 
resolution. The TcsD structure displays many similarities to those of other ACADs, such 
as the conserved ACAD fold consisting of a tetrameric quaternary structure, which is 
further organized into two sets of homodimers (Figure 4-9). Each subunit contains a 
single FAD cofactor and is composed of 3 subdomains consisting of a set of N- and C-
terminal alpha helix domains that surround a middle beta sheet domain. The FAD 
cofactor adopts an extended conformation and is situated in a pocket formed by the C-
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terminal alpha helix domain, the middle beta sheet domain, and the C-terminal domain 
of the adjacent subunit (Figure 4-9).  
 
The active site of TcsD also shares a similar overall organization with α,β-ACADs. 
Like the structures of the human, rat, pig, and bacterial ACADs, the catalytic base of 
TcsD, Glu364, sits poised at the top of the active site pocket immediately above the fatty 
acyl binding chamber.242,245,257–259 The back side of the pocket that bounds the fatty acyl 
binding region is shaped by the residue immediately upstream of the catalytic 
glutamate, Ile363, and three residues from helix 5: Phe79, Leu83, and Leu86. The FAD 
cofactor sits at the bottom of the active site, positioned below Glu364 (Figure 3-3A).  
 
The isoalloxazine ring of FAD is anchored via conserved hydrogen bonds with 
residues Thr116, Gly118, Ser119, and Thr151, while the adenosine pyrophosphate 
portion of the molecule extends into a cavity formed between the loop that follows β-
sheet 1 and helices 10 and 11 of the adjacent subunit; it is positioned through polar 
interactions with Ser125 and Glu337 of the same subunit and Met338, Gly340, and 
Gly341 of the adjacent monomer (Figure 4-10). Similar to other ACAD structures, an 
aromatic residue, Phe149, is positioned on the si face of the isoalloxazine ring. The FAD 
is positioned adjacent to the substrate binding cavity which is bound on the opposite 
side by several conserved residues from helix 7 and the loop following sheet 1, including 
Gly118, Ser119, Glu120, Ser125, Leu127, Leu224, and Leu228 which form the 
phosphopantetheine binding region.  
 
Although similar in overall structure, TcsD possesses many features that 
distinguish it from canonical ACADs. The residues surrounding the TcsD active site 
entrance have diverged from the corresponding residues that are conserved in α,β-
ACADs and contribute to the positioning of the adenosine portion of the coenzyme A 
substrate. TcsD does not possess the conserved Asp and Thr residues that form 
hydrogen bonds with the adenine base of Coenzyme A (Figure 4-11), nor the small helix 
between β-sheets 5 and 6 that often hydrogen bonds with the coenzyme A phosphate 
groups (Figure 4-12). The loop between β-sheets 5 and 6 in TcsD has instead been 
shortened. Additionally, a short helix, helix 9, is present in the TcsD structure in a 
position that would collide with the  
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Figure 3-3 Unique active site features of TcsD and activity of active site mutants. A)  Shape of the fatty acyl 
binding region of TcsD. B) Shape of the fatty acyl binding region of the Megasphaera elsdenii butyryl-CoA 
dehydrogenase (pdb entry 1buc), which was co-crystallized with acetoacetyl-CoA (CAA) C) Sequence 
alignment of TcsD with HliR,237 FkbI,260 M. elsdenii butyryl-CoA dehydrogenase (SCAD_Me, 1buc),259 
Pseudomonas putida KT2440 short chain acyl-CoA dehydrogenase (SCAD_Pp),261 and rat short chain acyl-
CoA dehydrogenase (SCAD_Rn, 1jqi).258 The residues in red correspond to residues that form the acyl-
binding region of the enzyme active site (Phe79, Leu83, Leu86, and Ile363 in TcsD). The active site glutamate 
is highlighted in blue. D), E), F) TcsD mutant activity on 2-pentenoyl-TcsA* (D), 2-hexenoyl-TcsA* (E), and 2-
heptenoyl-TcsA* (F) calculated as the LC-MS/MS peak area of the product normalized to a control peptide 
from TcsA (Normalized peak area, see Methods in SI). Data displayed are the average of three replicates. 
AU = arbitrary units *Note: TcsD activity on 5 carbon substrates cannot be compared to TcsD activity on 6 
or 7 carbon substrates.   
adenine base of Coenzyme A as it is positioned in α,β-ACAD structures. While helix 9 in 
the TcsD structure seems to interfere with Coenzyme A binding, it is also present in the 
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TcsD homolog from the haliangicin pathway, HliR, suggesting that this helix might 
contribute to the regiochemical shift observed in both enzymes (Figure 4-13). 
TcsD has unique structural features that form the fatty acyl binding region of the 
active site pocket. In particular, Ile363 and the residues of helix 5 that line the back side 
of the active site pocket protrude further into the active site than other ACADs, forming 
a much shallower binding pocket (Figure 3-3A & 3-3B). More specifically, Phe79 and 
Leu83 protrude directly into the active site pointing toward the fatty acyl binding 
position. In addition, these two residues are bulkier than the residues forming the active 
site of canonical ACAD homologs, contributing to the reduced active site pocket depth 
seen in the TcsD structure. The difference in active site shape and depth is further 
illustrated by comparing TcsD with the structures and sequences of α,β-ACADs 
containing co-crystallized substrates. Alignment and superposition of the Megasphaera 
elsdenii butyryl-CoA dehydrogenase (BCAD) in complex with acetoacetyl-CoA259 with 
the TcsD active site shows that Phe79, Leu83, Leu86, Ile363 or a combination of these 
residues would sterically clash with substrates longer than acetoacetyl-CoA if they were 
to bind within the TcsD active site in a similar manner. The M. elsdenii BCAD and other 
short chain α,β-ACADs contain less bulky residues at the positions corresponding to 
Phe79, Leu83, and Ile363, but Leu86 is generally conserved in TcsD, HliR, and α,β-ACADs 
(Figure 3-3B & 4-13).71,237,258,260,261 In addition, the bulky residues Phe79 and Leu83 
distinguish TcsD from FkbI, the hydroxymalonate semialdehyde dehydrogenase from 
the methoxymalonyl-ACP biosynthetic pathway of FK506 which has serines at both of 
these positions.260 
 
Given the unique structural characteristics of TcsD, we hypothesized that the 
positioning of the amino acids Phe79, Leu83, and Ile363 could control the 
regioselectivity of TcsD by preventing either proton abstraction by Glu364 or hydride 
transfer to FAD through steric repulsion. More specifically, these large residues would 
prohibit a five-carbon substrate from entering the active site far enough so that Glu364 
can access the protons bound to the substrate α-carbon or for the β-carbon to transfer 
a hydride to N5 of FAD. Rather, the substrate would be pushed towards the active site 
entrance, positioning Glu364 above the γ-carbon and the δ-carbon within an 
appropriate distance of N5 of FAD. As the substrates pentanoyl-ACP and 2-pentenoyl-
ACP are similarly chemically activated (the pKas of the α- and γ-protons are similar), the 
regioselectivity of TcsD would be controlled purely by steric interactions, not an 
electronic preference for one substrate. 
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3.3.3. Biochemical activity of TcsD mutants 
In order to verify whether the regioselectivity of TcsD is sterically controlled, a 
mutant of TcsD with a larger active site pocket that can accommodate a longer 
substrate is required. Specifically, TcsD mutants that act upon a substrate with two 
additional carbons should also be able to bind pentanoyl-ACP in a manner that properly 
positions the α- and β-carbons within an accessible distance of Glu364 and FAD, 
respectively, as the α-carbon is two carbons removed from the γ-carbon.  The residues 
that surround the active site of TcsD were therefore selectively mutated to alanines in 
order to accommodate longer substrates. Individual alanine mutants of Phe79, Leu83, 
and Ile363 in addition to double mutants of neighboring residues (e.g. F79A/L83A and 
F79A/I363A) were generated, and the dehydrogenation activity of mutants was then 
probed on a panel of α,β-unsaturated substrates. The active site mutants were generally 
less active on 2-pentenoyl-ACP than the wild type enzyme (Figure 3-3D). However, the 
I363A and L83A mutants displayed nearly equal or equivalent activity to the wild type on 
2-hexenoyl-ACP (Figure 3-3E). Proteins containing the L83A mutation were also active 
on the 2-heptenoyl-ACP substrate (Figure 3-3F). This indicates that Leu83 controls the 
chain length of the substrate. 
 
After demonstrating that the active site of the L83A mutant had been enlarged to 
accommodate two additional carbons, we next probed its activity on 4- and 5-carbon 
fully saturated substrates to test if the enzyme was now capable of dehydrogenating the 
α,β-position in the absence of the wild type steric interactions. We found that the 
mutant enzyme was still inactive on butyryl- and pentanoyl-ACP (data not shown), 
suggesting that the observed regioselectivity is not controlled exclusively by steric 
interactions with the fatty acyl tail of a substrate. 
 
3.3.4. Substrate modeling into TcsD active site 
Given the retention of selectivity of the TcsD L83A mutant, we hypothesized that 
the regioselectivity of dehydrogenation could instead be controlled by intermolecular 
forces affecting the positioning of the thioester end of the substrate, which is 
determined by two hydrogen bonds (H-bonds) within the active site. We hypothesized 
that the canonical ACAD H-bonds should be conserved in TcsD as they are crucial to the 
chemical mechanism of the enzyme. To test this, we attempted to co-crystallize TcsD 
with 2-pentenoyl-CoA and 2-hexenoyl-CoA in order to show the substrate positioning 
within the active site. However, we were unable to observe density corresponding to 
either substrate in the TcsD active site pocket, possibly because an unknown E. coli 
metabolite consistently co-crystallized in the active site and occupied the space where a 
substrate should bind (Figure 4-3). 
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Instead, we computationally modeled the native TcsD substrate into the active 
site to understand which structural features might affect substrate binding. The 
positioning of the thioesters in the structures of several ACADs (which were co-
crystallized with substrate analogs) was used to guide the placement of a substrate into 
the TcsD active site. More specifically, the structures of several homologs and TcsD were 
superimposed by aligning the peptide backbones of the three-residue loop that 
contains the catalytic glutamate (e.g. Ile363, E364, and G365). This three-residue loop 
was chosen as an anchor point because it is highly conserved and contains one of the 
H-bond donors that contributes to thioester positioning, so the relative positioning of 
structural elements within the ACAD active sites can be used to infer relative substrate 
positioning. Not only was this type of alignment useful for appropriately positioning 
modeled substrates, but it also allowed for a more precise determination of slight 
structural differences that were not as obvious when analyzing global structural 
alignments. In particular, it highlighted stark differences in the positioning of the FAD 
cofactor in TcsD relative to several homologs (Figure 3-4A & 3-4B).  
 
In relation to the active site glutamate (Glu364), the FAD molecule bound within 
the TcsD active site is shifted laterally, moving it in the direction of the pantetheine-
binding region of the enzyme (Figure 3-4A & 3-4B). This movement of the ribityl side 
chain of FAD is accompanied by a shift in α-helices 10 and 11 and the loop that follows 
β-sheet 1, which interact with the FAD through various H-bonds. The repositioning of α-
helices 10 and 11 results in a change in the conformation of the FAD ribose ring due to 
H-bonding interactions of the 2’ and 3’-OH groups with the amide backbone of Met338 
and of Glu337 and Gly339 of the adjacent subunit, respectively. The conformational 
change pushes the FAD phosphate groups towards the β-sheet domain of the enzyme. 
As a result of these structural changes, the positioning of the 2’-hydroxyl group of the 
FAD ribityl side chain is shifted closer to the nitrogen of the Glu364 amide bond (Figure 
3-4A). We hypothesized that this would result in a concomitant shift in the positioning 
of the substrate thioester moiety, making TcsD act at the γ,δ-position instead at the 
canonical α,β-position of substrates. 
 
In order to better understand how the change in FAD positioning affects 
substrate binding, we modeled a substrate analog consisting of a 2-pentenoyl thioester 
into the active site. Initially, we positioned the thioester carbonyl oxygen within 
hydrogen bonding distance of both the 2’-OH of the FAD and the nitrogen of the amide 
bond of Glu364 (Figure 3-4C). Anchoring the carbonyl group in this location would force  
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Figure 3-4 FAD shift and substrate modeling in TcsD active site. Shift in positioning of the 2’-OH group of 
FAD in TcsD (teal) relative to the active site glutamate and compared to the pig (Sus scrofa) medium chain 
ACAD in the apo (pdb code 3mdd)43 and substrate-bound (pdb code 1udy)55 forms (both white). Dotted 
lines represent distances between 2’-OH groups of FAD and amide nitrogens of active site glutamates. B) 
Lateral shift of FAD in TcsD (teal) with respect to the active site glutamate and compared to the pig (Sus 
scrofa) medium chain ACAD in the apo (pdb code 3mdd) and substrate-bound (pdb code 1udy) forms (both 
white) C) TcsD active site* containing a modeled 2-pentenoyl thioester group in the cis conformation. 
Dotted lines = distances between the substrate thioester carbonyl group and the 2’-OH of FAD and amide 
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nitrogen of Glu364 D) TcsD active site* containing a modeled 2-pentenoyl thioester group in the trans 
conformation. Dotted lines = distances between the substrate thioester carbonyl group and the 2’-OH and 
4’-OH of FAD E) Distance from carbonyl carbon to the tail carbon of various α,β-unsaturated fatty acyl 
substrates. *Note: Glu364 was omitted from C) and D) in order to visualize the hydrogen bonding 
interactions of the substrate with FAD. 
the substrate alkene into a cis conformation, as this is the only conformation that places 
the ẟ-carbon in close enough proximity to N5 of FAD. However, while this conformation 
enforces the proper positioning of the substrate with respect to FAD, it places the ẟ-
carbon too close to residues Phe79 and Ile363 which would result in unfavorable steric 
repulsion between the substrate and the amino acid side chains lining the active site. 
Moreover, with this substrate conformation there is no additional space within the active 
site to accommodate a sixth carbon on the substrate which conflicts with our 
biochemical data.   
 After eliminating the possibility of substrate binding in the cis conformation, a 
trans substrate was next modeled into the TcsD active site. When the substrate alkene 
bond adopts a trans conformation, its positioning is more consistent with the 
biochemical activity of the enzyme as it places the fatty acyl tail turned toward Leu83 
and the ẟ-carbon in proximity to the N5 of FAD (Figure 3-4D). However, with the 
substrate in this extended position, H-bonding of the substrate with the canonical ACAD 
H-bond donors cannot occur without a steric clash between Leu83 and the fatty acyl tail 
of the substrate. We therefore modeled the carbonyl carbon of the substrate so that it 
H-bonds with the 2’ and 4’-OH groups of FAD, not with the canonical amide nitrogen of 
Glu364. Given the size dimensions of the active site and the biochemical data presented 
herein, this appears to be the most probable positioning of the substrate within the 
active site, suggesting that TcsD utilizes a novel H-bond donor pair to achieve its unique 
regioselectivity. 
3.3.5. Genome mining reveals previously unidentified γ,δ-ACADs 
After identifying structural features that contribute to the unique regioselectivity 
of TcsD, we applied this mechanistic knowledge to find unidentified or misannotated 
γ,δ-ACADs among sequenced bacteria. In particular, we used the presence of bulky 
residues at positions corresponding to Phe79, Leu83, and Ile363 and helix 9 as 
requirements for the identification of γ,δ-ACADs. With these constraints, approximately 
100 likely γ,δ-ACADs were identified using a combination of Hidden Markov Model 
(HMM), local sequence alignment (protein BLAST), and CORASON-BGC searches (Table 
3-9 & 4-1).262–264 
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Notably, both TcsD and HliR, the only γ,δ-ACADs associated with known natural 
products, were re-identified in our search. Of the newly-identified enzymes, one feature 
in particular was strongly conserved: the presence of helix 9, which we had identified as 
a unique feature in the TcsD structure (Figure 5A and B). The exact purpose of this loop 
remains unclear and will be the subject of further investigation. Additionally, we found 
that the presence of bulky residues at positions in the substrate acyl binding region 
were highly conserved across the family, with 98% of homologs displaying a Phe residue 
(2% Leu) and 96% displaying a Leu or Ile residue (4% Val) at the positions corresponding 
to Phe79 and Leu83 in TcsD (Figure 5C and S6). The residues immediately preceding the 
catalytic glutamate (i.e. residue Ile363 in TcsD) were all bulky aliphatic residues as well 
(87% Val, 11% Ile, 2% Phe). However, bulky residues at this position are not unique to 
the γ,δ-ACAD family as they are also observed in hydroxymalonate semialdehyde 
dehydrogenases such as FkbI. 
 
Most of the TcsD homologs were associated with identifiable BGCs, although 
some were not located near any obvious secondary metabolite genes. The majority of 
the BGC-associated genes were located within type I PKS (T1PKS) clusters, but several 
were also identified within type II PKS (T2PKS) and NRPS clusters (Figure 3-5D, 4-15 & 4-
16). None of the newly-identified BGCs containing the putative γ,δ-ACADs have been 
experimentally characterized, but many show significant homology to known clusters 
(Table 4-1). Of the clusters that include putative γ,δ-ACADs, several contained proteins 
with homology to BGCs with known products, including the arsenopolyketides (T1PKS), 
oligomycin (T1PKS), E-837 (T1PKS), chlorothricin (T1PKS), butyrolactols (T1PKS), 
polyoxypeptin (T1PKS-NRPS), hedamycin (T2PKS), and erythrochelin (NRPS). Many of the 
homologous BGCs identified by antiSMASH have fatty acyl tails that could be potential 
substrates for γ,δ-ACADs in the uncharacterized clusters we identified. 
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Figure 3-5 Genome mining and characterization of γ,δ-ACADs. A) Global overlay of TcsD with M. elsdenii 
butyryl-CoA dehydrogenase (BCAD_Me, 1buc)259 and Streptomyces hygroscopicus hydroxymalonate 
semialdehyde dehydrogenase, FkbI (1r2j)260 highlighting the insertion of helix 9 into γ,δ-ACAD structures. 
The colored regions are helix 9 of TcsD (blue, labeled α9) and the corresponding regions in BCAD_Me 
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(purple) and FkbI (orange). FAD is depicted as sticks. B) Sequence alignment of TcsD with HliR,237 FkbI, 
M. elsdenii butyryl-CoA dehydrogenase (SCAD_Me, 1buc), Pseudomonas putida KT2440 short chain acyl-
CoA dehydrogenase (SCAD_Pp),261 and rat short chain acyl-CoA dehydrogenase (SCAD_Rn, 1jqi).258 The 
sequence alignment highlights the presence of helix 9 in γ,δ-ACADs which is not encountered in other 
ACAD families.  C) Amino acid position weight matrix showing the relative abundance of amino acids at 
each position within γ,δ-ACADs. Positions 96 and 100 correspond to the positions of Phe79 and Leu83 of 
TcsD, respectively. Logo was generated from a sequence alignment of all γ,δ-ACADs identified in this 
work. D) Genomic contexts and synteny of a representative set of γ,δ-ACADs identified in this work.TcsD 
homologs (putative γ,δ-ACADs) are shown in red and aligned. Other notable genes are annotated by color. 
E) Targeted LC-MS/MS chromatograms showing the activity of the Nocardia mexicana NBRC 108244 
putative γ,δ-ACAD on 2-pentenoyl-ACP  F) Targeted LC-MS/MS chromatograms showing the activity of 
the Nocardia mexicana NBRC 108244 putative γ,δ-ACAD on 2-hexenoyl-ACP. (-) is used to mark negative 
controls with boiled N. mexicana ACAD, while assays are marked as N. mex ACAD. Chromatograms 
representing the 2,3-enoyl-, 2,4-dienoyl-, and 3-hydroxy transitions are color-coded below each set of 
chromatograms. The 3-hydroxyacyl groups are normal degradation products of 2,3-enoyl-thioesters in 
aqueous environments where hydration of the alkene can occur. 
 
Within the identified BGCs, analysis of the genomic contexts of the putative γ,δ-
ACADs showed several patterns of syntenic genes (Figure 3-5D, 4-15, & 4-16). The 
syntenic genomic regions can be grouped based on the type of gene cluster (e.g., 
probable butyrolactol or arsenopolyketide BGC) within which the putative γ,δ-ACADs 
occur. The groups of genes that are found near γ,δ-ACADs can also be used to 
postulate the enzymes’ native substrates and even certain aspects of the molecular 
structure of the final natural product. The γ,δ-ACADs found in the erythrochelin-like 
gene clusters in Saccharothrix sp., for example, are consistently clustered with a free-
standing ketosynthase (KS) and acyl carrier protein (ACP) pair (Figure 3-5D). It is 
plausible that the KS domain forms a 5 carbon ACP-bound substrate upon which the 
γ,δ-ACAD can act after it is reduced to a 2-pentenoyl form. The genomic context of this 
and many of the other putative γ,δ-ACADs can be used to infer function and will inform 
future biosynthetic studies on the pathways and enzymes. 
The presence of conserved residues and helix 9 in the putative γ,δ-ACADs is 
highly suggestive that they would exhibit the same activity as TcsD. To interrogate this 
hypothesis, we biochemically characterized a TcsD homolog. We chose the putative γ,δ-
ACAD from Nocardia mexicana NBRC 108244 because it is located on a distant branch 
of the γ,δ-ACAD phylogenetic tree (Figure 3-5D, 4-15, & 4-16) and has low sequence 
identity relative to TcsD (50.7%). Though sharing only 51% sequence identity, the N. 
mexicana homolog (Nmex-ACAD) possesses the conserved Phe, Leu, and Ile residues 
that line the TcsD active site (Figure 4-17). It is located within a gene cluster that is 
predicted to encode a ladderane/butyrolactone-like natural product BGC (Figure 4-18). 
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There are several related biosynthetic genes located immediately next to the Nmex-
ACAD, including an acyl carrier protein, a ketosynthase, and a putative 3-oxoacyl-ACP 
reductase. Based on its genomic context we hypothesized that, like TcsD, the Nmex-
ACAD may act on ACP-bound substrates. We therefore expressed and purified both the 
Nmex-ACAD and its neighboring acyl carrier protein (Nmex-ACP) and assayed Nmex-
ACAD activity on the same panel of substrates. The Nmex-ACAD showed the same 
activity profile as TcsD, converting 2-pentenoyl-Nmex-ACP (Figure 5E) and 2-hexenoyl-
Nmex-ACP (Figure 3-5F) to the corresponding dienoyl-ACP products, but it showed no 
activity on butyryl-, pentanoyl-, or 2-heptenoyl-ACP (Figure 4-19). While this data does 
not confirm that all the putative enzymes we have identified are γ,δ-ACADs, it strongly 
supports the prediction that these enzymes have the same activity as they are more 
closely phylogenetically related to TcsD than the Nmex-ACAD and share the conserved 
bulky residues that form the enzyme fatty acyl binding pocket. 
3.4. Conclusion 
Terminal alkenes in polyketide natural products can be formed in several ways, 
including through the action of an acyl-CoA dehydrogenase. In this work we have 
described the biochemical and structural characterization of TcsD, the terminal alkene-
forming γ,δ-ACAD from the biosynthesis of the allylmalonyl-CoA extender unit 
implicated in the biosynthesis of the polyketide FK506. We showed that TcsD acts on 2-
pentenoyl-TcsA but not on propylmalonyl-TcsA, suggesting that the bottom half of the 
allylmalonyl-CoA pathway proceeds only through pathways B1 and B2. TcsD only acts 
on 5- and 6-carbon α,β-unsaturated substrates and is regioselective for the γ,δ-position.  
    
 A crystal structure of TcsD revealed the unique features of the active site of the 
enzyme. Residues Phe79, Leu83, and Ile363 form a bulky wall in the substrate binding 
region of the enzyme, preventing the entrance of long fatty acyl substrates. Leu83 
controls the chain length of the substrate. A TcsD L83A mutant acts on 2-heptenoyl-
TcsA, but even with a larger active site pocket the mutant remains regioselective for the 
γ,δ-position of substrates. Closer analysis of the protein structure revealed that the 
enzyme regioselectivity is likely due to a shift in the positioning of the FAD cofactor. We 
show through substrate modeling that, because of the FAD shift and the dimensions of 
the TcsD active site, TcsD most likely employs a novel hydrogen bond donor pair (the 2’-
OH and 4’-OH groups of FAD) to position and activate substrates. While Leu83 does not 
exclusively control regioselectivity, it contributes to regioselectivity by reducing the size 
of the active site.  
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    The structural and biochemical conclusions from biochemically and structurally 
characterizing TcsD allowed us to determine key residues that define γ,δ-ACADs. 
Through HMM and local alignment searches, approximately 100 putative γ,δ-ACADs 
were identified in sequenced bacterial genomes. Nearly all of the homologs contained a 
Phe-Leu/Ile pair at the positions corresponding to Phe79-Leu83 in TcsD, respectively. 
The identification of other homologs also highlighted the conservation of helix 9, which 
appears to be a feature that is unique to the γ,δ-ACAD family. Most of the homologous 
enzymes were encountered in identifiable secondary metabolite BGCs, but some were 
notably located near no other canonical specialized metabolic enzymes. The synteny of 
genes located near the γ,δ-ACADs and the type of BGC to which they belong correlates 
strongly with their phylogenetic clustering and can be used to group the enzymes into 
several subfamilies. Finally, we showed that one of the TcsD homolog from Nocardia 
mexicana, which is phylogenetically one of the most distant enzymes from TcsD, also 
performs a regioselective dehydrogenation of the γ,δ-carbon of 2-pentenoyl- or 2-
hexenoyl-ACP substrates, suggesting that this activity is conserved across the entire 
family. 
 
This work exhibits how selective pressure causes enzymes to diverge not only at 
the amino acid sequence level, but also how it can result in significant shifts in protein 
structure to generate enzymes with divergent functions. Furthermore, it exemplifies how 
an understanding of the mechanisms employed by unique enzymes can be used as a 
means to refine the definitions of enzyme families and identify uncharacterized 
homologs. It will inform future efforts to characterize the identified homologs and the 
BGCs they residue within and can be used as a guide for the future discovery of natural 
products that contain terminal alkene handles.  
3.5. Materials and methods 
3.5.1. Materials, reagents, and strains 
All strains used and generated in this work are listed in Table 3-2. Routine E. coli 
cultures were grown at 37°C in Luria-Bertani (LB) Miller medium (BD Biosciences, USA) 
and were supplemented with kanamycin (50 mg/L, Sigma Aldrich, USA), or carbenicillin 
(100mg/L, Sigma Aldrich, USA). Pseudomonas putida KT2440 was grown at 30°C in 
Luria-Bertani (LB) Miller medium (BD Biosciences, USA), and Streptomyces tsukubaensis 
NRRL 18488 was grown at 30°C in BD Bacto tryptic soy broth (TSB) medium (Fisher 
Scientific). All chemicals and reagents were purchased from Sigma Aldrich unless 
otherwise noted.   
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3.5.2. DNA Manipulation 
All plasmids used and generated in this work are listed in Table 3-1. The genomic 
DNA samples from Pseudomonas putida KT2440 were purified using a DNeasy Blood 
and Tissue Kit (Qiagen, USA). Plasmids and PCRs were routinely isolated using the 
Qiaprep Spin Miniprep kit (Qiagen, USA) and DNA Clean & Concentration Kit (Zymo 
Research, USA). All primers were purchased from Integrated DNA Technologies (IDT, 
Coralville, IA). Constructs were generated using restriction enzyme cloning (TcsD, TcsA 
wildtype coding sequences), Gibson assembly (TcsD mutants, PP2216), or Golden Gate 
assembly (N. mex ACAD and ACP) as previously described.265,266   
 
3.5.3. Construct cloning: TcsD and TcsA 
Genomic DNA of Streptomyces tsukubaensis NRRL 18488 was prepared by 
resuspending cells grown in TSB medium in LC-grade DMSO. The coding sequences of 
TcsD and TcsA were amplified from this genomic DNA sample using Q5 Hotstart high-
fidelity polymerase using primers which incorporated flanking NdeI and XhoI restriction 
sites. The genes were then ligated into a pET28a backbone which had been linearized 
with the FastDigest enzymes NdeI and XhoI (Thermo Scientific, USA), appending a C-
terminal 6x histidine tag onto each. Targeted mutations were generated in TcsA and 
TcsD using Golden Gate cloning. Mutations were embedded in the overlap regions of 
the Golden Gate primers listed in Table 3-3. 
 
3.5.4. Construct cloning: PP2216 
 PP2216 was amplified from Pseudomonas putida KT2440 genomic DNA and 
cloned into a pBbE7a backbone with a C-terminal 6x histidine tag using Gibson 
assembly.  
 
3.5.5. Construct cloning: Nocardia mexicana ACAD and ACP 
PThe coding sequences for the Nocardia mexicana NBRC 108244 putative γ,δ-
acyl-CoA dehydrogenase (GenBank accession WP_068019852.1) and the neighboring 
acyl carrier protein (GenBank accession WP_068019854.1) were reverse translated and 
codon-optimized for E. coli using BOOST.267 Genes were designed with flanking Golden 
Gate sites and purchased from Genscript (Piscataway, NJ, USA). The genes were then 
inserted into a pBbE7a backbone with a C-terminal 6x histidine tag using Golden Gate 
assembly. The sequences of the synthetic gene fragments are listed in Table 3-4. 
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Table 3-1 Plasmids used in this study 
ICE Entry 
Number 
Plasmid name Description Source 
JPUB_013738 pET28a-TcsA TcsA in pET28a This 
study 
JPUB_013740 pET28a-
TcsAS98A 
TcsA S98A in pET28a This 
study 
JPUB_013728 pET28a-TcsD TcsD in pET28a This 
study 
JPUB_013730 pET28a-
TcsDL83A 
TcsD L83A in pET28a This 
study 
JPUB_013732 pET28a-
TcsDF79A 
TcsD F79A in pET28a This 
study 
JPUB_013734 pET28a-
TcsDI363A 
TcsD I363A in pET28a This 
study 
JPUB_013736 pET28a-
TcsDF79AL83A 
TcsD F79AL83A in pET28a This 
study 
JPUB_013744 pET28a-
TcsDF79AI363A 
TcsD F79AI363A in pET28a This 
study 
JPUB_013742 pBbE7a-PP2216-
6xHis 
PP2216 in pBbE7a with a C-terminal 
6xHis tag 
This 
study 
JPUB_013842 pBbE7a-
NmexACP-6xHis 
Acyl carrier protein from Nocardia 
mexicana NBRC 108244 (E. coli 
codon-optimized)  in pBbE7a with a 
C-terminal 6xHis tag 
This 
study 
JPUB_013844 pBbE7a-
NmexACAD-
6xHis 
Acyl-CoA dehydrogenase from 
Nocardia mexicana NBRC 108244 (E. 
coli codon-optimized)  in pBbE7a 
with a C-terminal 6xHis tag 
This 
study 
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N/A pET-Sfp Sfp in a pET vector Reference 
169 
N/A pLK54 MatB mutant  Reference 
150 
N/A pBbE7a-RFP RFP behind a T7 promoter in a 
BglBrick plasmid 
Reference 
289 
 
Table 3-2 Strains used in this study 
ICE Entry 
Number 
Strain 
name 
Description/Genotyp
e 
Source 
N/A E. coli 
DH5α 
F– endA1 glnV44 thi-1 
recA1 relA1 gyrA96 
deoR nupG purB20 
φ80dlacZΔM15 
Δ(lacZYA-argF)U169, 
hsdR17(rK–mK+), λ– 
QB3 Macrolab 
(http://qb3.berkeley.edu/macrola
b/) 
N/A E. coli NEB 
Turbo 
F' proA+B+ lacIq 
∆lacZM15 
/ fhuA2  ∆(lac-
proAB)  glnV galK16 
galE15  R(zgb-
210::Tn10)TetS  endA1 
thi-1 ∆(hsdS-mcrB)5 
New England Biolabs 
N/A E. coli BL21 
(DE3) 
F– ompT gal dcm lon 
hsdSB(rB–mB–) λ(DE3 
[lacI lacUV5-T7p07 
ind1 sam7 nin5]) 
[malB+]K-12(λS) 
New England Biolabs 
N/A Streptomyce
s 
tsukubensis 
Wild type strain  US Department of Agriculture, 
Agricultural Research Service 
Culture Collection (NRRL), 
Patent Collection 
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NRRL 
18488 
N/A Pseudomona
s putida 
KT2440 
(ATCC 
47054) 
Wild type strain American Type Culture 
Collection (ATCC) 
JPUB_01373
7 
JBEI-107002 E. coli DH5α 
containing pet28a-
TcsA 
This study 
JPUB_01373
9 
JBEI-107003 E. coli DH5α 
containing pet28a-
TcsA S98A 
This study 
JPUB_01372
7 
JBEI-106997 E. coli NEB Turbo 
containing pet28a-
TcsD 
This study 
JPUB_01372
9 
JBEI-106998 E. coli DH5α 
containing pet28a-
TcsD L83A 
This study 
JPUB_01373
1 
JBEI-106999 E. coli DH5α 
containing pet28a-
TcsD F79A 
This study 
JPUB_01373
3 
JBEI-107000 E. coli DH5α 
containing pet28a-
TcsD I363A 
This study 
JPUB_01373
5 
JBEI-107001 E. coli DH5α 
containing pet28a-
TcsD F79AL83A 
This study 
JPUB_01374
3 
JBEI-107005 E. coli DH5α 
containing pet28a-
TcsD F79AI363A 
This study 
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JPUB_01374
1 
JBEI-107004 E. coli DH5α 
containing pBbE7a-
PP2216-6xHis 
This study 
JPUB_01384
1 
JBEI-133594 E. coli DH5α 
containing pBbE7a-
NmexACP-6xHis 
This study 
JPUB_01384
3 
JBEI-133595 E. coli DH5α 
containing pBbE7a-
NmexACAD-6xHis 
This study 
 
Table 3-3 Primers used in this study 
Primer name Sequence (5’→ 3’) 
TcsA-NdeI-F TATACATATGGCGTTCCTCTTCCCCGGC 
TcsA-XhoI-R TATACTCGAGCGCCGCCCGGAAACGGAA 
TcsD-NdeI-F AAACATATGAGCGAATCCGAACGCCTCGGTA 
TcsD-XhoI-R TTTCTCGAGGGTACGTTTCGCGGTGGGGACG 
TcsA-AT0-F-1 tcgccgggcacgctctcgggga 
TcsA-AT0-R-1 ccactggtaacaggattagcagagcgaggtatgt 
TcsA-AT0-F-2 caccgcctacatacctcgctctgctaatcc 
TcsA-AT0-R-2 gctccgaactccccgagagcgtgc 
TcsD-mut-F CTCTGTAGCACCGCCTACATACCTCGC 
TcsD-mut-R ACTGGTAACAGGATTAGCAGAGCGAGG 
TcsD-F79A-F GGTGGCGGCCACCCTGTTTCTGC 
TcsD-F79A-R AGGACGGGCAGAAACAGGGTGGCCGCC 
TcsD-L83A-F accctgtttgcgcccgtcctgac 
  60 
TcsD-L83A-R gctggtcgtcaggacgggcgcaaacagggt 
TcsD-I363-bb-F GACCCAGAGCGCTGCCGGCACCT 
TcsD-I363-bb-R ctcgtaggacaggtgccggcagcgc 
TcsD-I363A-F cacgcttcgatcgccgagggcggcgacgac 
TcsD-I363A-R gtcgtcgccgccctcggcgatcgaagcgtg 
PP2216-E7a-F 
CAAAAGATCTTTTAAGAAGGAGATATACATATGCTGGTAAA
TGACGAGCAACAAC 
PP2216-E7a-R 
CTCGAGCCGCCGCCCGGAAACGGAACCGGTAAGATTGCGCG
CAATGACCATGC 
E7a-link-His-F GGATCTGGCACTGGTAGT 
E7a-link-His-R CATATGTATATCTCCTTCTTAAAAGATCT 
E7a-link-GG-F CAGGTCTCAGGATCTGGCACTGGTAGT 
BioB-GG-R CAGGTCTCACATATGTATATCTCCTTCTTAAAAGATCTT 
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Table 3-4 Synthetic DNA fragments used in this study 
DNA fragment 
name 
Sequence (5’-->3’) 
Nocardia mexicana 
ACP 
caggtctcatATGAACGCGATAACTACAACCGAGATCGCCGAGGGCCT
GCGGAGCATCGCCGATCGTCTGGACCTGGAACTCGAGAATGTCG
ATATTTCCGCGACGTCGTCGCTGGAAGACGACCTCGAGATGGACT
CGCTGAACCTGATGGACTTCCTGGTGTATCTCGAGAAGAGATATC
ACGTGCAGGTCACCGACGAGCGCCTGCACGAGGTCGACACCATC
GGCGATGTCGTGAACCTGCTCAACGACCTGCTGGCATCGTCGCGC
GACACCCCGCAGCCGTCCCGAGTCGGAAGTCGTgg 
atatgagacctg 
Nocardia mexicana 
ACAD 
caggtctcatATGGGCGACATTGTCGAGCAGGCCCGCCATTTTGGACGT
ACAGTTCTAGCTGCTGCCCCAGCACCTGATGTAGAAACCGTCTAC
GACGACCGGCACCCACTGTGGGAGCAGTTCCGATCGGCCGACCT
CGCCGACTGGTGGGTGCCCGCCGAATACGGCGGACGGGGTGTCG
GACTGTGCGAGTCGGTGAACGTCGTCTCCGAACTCTCCTACCACG
ACGCCGGATTCGCGTTCGCCGCGTTTCTGCCGATCCTCGCGTCACG
AATGCTCGAGCTCTACGGTCCCGAGGAGTTGGCGCGCCGCTACTT
GGCGGAGATGGCCACCCATGGATCCTTTGCAGCAGCGTTGGGAA
GTGAAGCTGAAGCTGGAAGTGAATTAGCTAGAACGCAGACCACG
TTCCGCCGCGACGGCGATGTGCTGCACATCAACGGCGATAAGCA
GTTCTCGACCAACTTGGCGTTCGCGCGGTTCTGCCTCGTGCTGGCC
CGCGACGTCGACAACCCCCGAGATTTCGCCCTGATCCTGGTCCCG
TCGGACAGTCCGGGATTTGTTGTCGGCCAACGGTGGCCGATGTCG
GGCCTGCACGGTACTGCCACGTACCCGGCAACTTTCACCGATTGC
GTCGTCCCGGCAGCAAATCGGTTGTCGGGCAACGGTATTCGGATC
CTGGAGGTCGGGCTCGACGCGAGCCGGATCCTGATGGCCTCGATC
GCGATCGGTCTGACCCGGCGGATTCGGGATCTGAGCATGGACTAC
GCGGCGAGCAAGCGGCTCGGTGGGCAACCGCTGAACCGCAACGC
CGTCTTCGGCGCCCGCATGGGTCAGCTCGAGATGGAACTCGAAAC
GATGAAGGCCCAGTGCCGGTGCGCCGCGGCCGAATACGACGACA
TCTACCAGCGATCCGATCGGGCGGCGGTGTTCTATGCCGACGGCG
TGCTGAAGTCGGCGATTGTGGCCAAGATGCATTGTGGTCAGGTCG
GCTGGCGGGTCGCGAGTCGGGCGTCGGAGGCGTTCGGCGGTCTGG
GCTACACCGCGGGCCACGACATCCAGCGGTGCCTGCGGGACATG
CGGCACATCGCGATCGTCGAGGGCGGCGACGACGTGCTGCGTGA
ACTGCTCTACGGACGCTACGTCAAGCGCGCATCGCGACGAGGAgg
atatgagacctg 
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3.5.6. Protein expression 
All proteins were expressed in E. coli BL21 (DE3) cells using the following 
protocol. An overnight culture of Luria Broth containing the appropriate antibiotic was 
used to inoculate 0.8 L of Terrific Broth (EMD Millipore) in a 2 L flask. Cells were grown 
at 37oC to an OD of 0.6-0.8 then induced with 250 µM IPTG (Teknova, USA). Cells were 
grown for approximately 18 hours at 18oC then pelleted and stored at -20°C until 
purification. 
3.5.7. Protein Purification for biochemical assays and substrate biosynthesis 
Frozen cell pellets were resuspended in lysis buffer that had been prechilled to 
4°C. For TcsD, TcsD mutants, and the Nocardia mexicana ACAD, lysis buffer consisted of 
50 mM Tris pH 9.0, 300 mM NaCl, 10 mM imidazole, 8% glycerol. For all other proteins 
(TcsAS98A, Sfp, PP2216, MatB T207G/M306I, Nocardia mexicana ACP), a lysis buffer 
composed of 50 mM sodium phosphate pH 7.2, 300 mM NaCl, 10 mM imidazole, 8% 
glycerol was used. After resuspension in lysis buffer, cells were sonicated on ice to lyse. 
Lysates were then centrifuged at 4°C at 40,000g for 30 minutes to pellet insolubles. The 
supernatants were then applied to Ni-NTA resin in an Econo-Pak column (Bio-Rad, USA) 
that had been pre-equilibrated with 10 column volumes of lysis buffer. The resin was 
washed with several column volumes of lysis buffer and subsequently with several 
column volumes of lysis buffer containing 50 mM imidazole. The proteins were then 
eluted using a stepwise gradient of lysis buffer containing 100 mM, 200 mM and 400 
mM imidazole. Fractions were analyzed via SDS-PAGE, and fractions containing >90% 
pure protein were pooled and concentrated using Amicon Ultra 100 kDa (TcsD, 
TcsDmutants, and Nocardia mexicana ACAD), 3kDa (Nocardia mexicana ACP)10 kDa (all 
other proteins) Molecular Weight Cutoff (MWCO) centrifuge filters (Millipore). Proteins 
were transferred to storage buffer (lysis buffer containing no imidazole, 100 mM NaCl, 
and 8-10% glycerol) by buffer exchanging in the centrifuge filters and frozen in liquid 
nitrogen. Proteins were stored at -80oC until assays. 
3.5.8. Protein purification for crystallography 
A frozen cell pellet of E. coli BL21 (DE3) expressing TcsD was purified using Ni-
NTA affinity chromatography as described above. After concentration to a minimal 
volume, the protein was further purified using size exclusion chromatography. It was 
loaded onto a HiPrep 26/60 Sephacryl S-300 High Resolution column that had been 
pre-equilibrated with size exclusion buffer (50 mM Tris pH 9, 500 mM NaCl, 10% 
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glycerol) at 4°C. The protein was eluted and concentrated again then dialyzed overnight 
at 4°C into crystallization buffer (50 mM Tris pH 9, 100 mM NaCl). 
3.5.9. Protein Crystallization and Structure Determination 
An initial crystallization screen was set up using a Phoenix robot (Art Robbins 
Instruments, Sunnyvale, CA) using the sparse matrix screening method.268 The purified 
TcsD protein sample was concentrated to 9 mg/mL and crystallized at 25°C using the 
sitting drop method in 0.4 µL drops containing a 1:1 ratio of protein to crystallization 
solution: 0.1 M Sodium Citrate tribasic dihydrate, pH 5.0, and 10% PEG 6,000. Crystals 
were transferred to crystallization solution containing 20% glycerol prior to flash 
freezing in liquid nitrogen. X-ray diffraction data was collected at the Berkeley Center for 
Structural Biology on beamline 5.0.2 of the Advanced Light Source at the Lawrence 
Berkeley National Laboratory. The TcsD structure was determined by the molecular-
replacement method with the program PHASER269 using medium-chain acyl-CoA 
dehydrogenase from Thermus thermophilus (PDB ID: 1UKW) as the search model, which 
showed 32% sequence identity. Structure refinement was performed by phenix.refine 
program.270 Manual rebuilding using COOT271 and the addition of water molecules 
allowed for construction of the final model. The final models of the TcsD structure 
showed an R-work of 14.6% and R-free of 17.9%. Root-mean-square deviations from 
ideal geometries for bond lengths, angles, and dihedrals were calculated with Phenix.272 
The overall stereochemical quality of the final models for tcsD was assessed using the 
MolProbity program.273 The structural analysis was performed in COOT and PyMOL.274 
Table 3-5 Summary of crystal parameters, data collection, and refinement statistics. 
Values in parentheses are for the highest resolution shell. 
Crystal parameters 
Space group P 1 21 1 
Unit cell 
69.52 100.06 148.51 90 100.31 
90 
Data collection statistics 
Wavelength (Å) 1.00000 
Resolution range (Å) 68.4  - 1.75 (1.813  - 1.75) 
Total reflections 835542 (85389) 
Unique reflections 196484 (19281) 
Multiplicity 4.3 (4.4) 
Completeness (%) 97.65 (96.41) 
Mean I/sigma(I) 8.99 (1.39) 
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Wilson B-factor 19.7 
R-merge 0.1119 (1.063) 
R-meas 0.1277 (1.207) 
R-pim 0.06086 (0.5664) 
CC1/2 0.997 (0.524) 
CC* 0.999 (0.829) 
Refinement and model statistics 
Reflections used in 
refinement 196470 (19281) 
Reflections used for R-free 9864 (1003) 
R-work 0.1462 (0.2810) 
R-free 0.1787 (0.3138) 
CC(work) 0.974 (0.807) 
CC(free) 0.959 (0.765) 
Number of non-hydrogen 
atoms 13452 
  macromolecules 11781 
  ligands 212 
  solvent 1459 
Protein residues 1546 
RMS(bonds) 0.012 
RMS(angles) 0.98 
Ramachandran favored (%) 99.28 
Ramachandran allowed (%) 0.72 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 0.08 
Clashscore 3.04 
Average B-factor 27.08 
  macromolecules 26.03 
  ligands 17.5 
  solvent 36.93 
Number of TLS groups 31 
 
3.5.10. Synthesis of valeroyl-Coenzyme A 
Valeroyl-Coenzyme A was prepared using the anhydride method.275 
Approximately 0.02 mmol of Coenzyme A was added to a solution of saturated sodium 
bicarbonate in water. The solution was chilled to 0°C, then 1 mmol of valeric anhydride 
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(Sigma Aldrich) was added. The reaction was allowed to proceed at 0°C with constant 
mixing. After approximately 6 hours, HCl was added to bring the pH to ~2. The solution 
was extracted twice with an equal volume of ethyl acetate, then the remaining aqueous 
solution was frozen until further purification.  
Valeroyl-CoA was purified using an Agilent 1260 series preparatory HPLC system 
equipped with a 900µL sample loop and a UV detector coupled to a fraction collector. 
The product was isolated over an Agilent Prep-C18 column (21.2 x 150 mm, 5 µm pore 
size) using a mobile phase composed of 10 mM ammonium formate, pH 4.5 (solvent A) 
and methanol (solvent B) using the following method:  
 
Table 3-6 Preparatory LC gradient for purification of valeroyl-Coenzyme A 
Time (min) %A %B Flow rate (mL/min) 
0 95 5 10 
1 95 5 10 
8 5 95 10 
10 5 95 10 
11 95 5 10 
16 95 5 10 
 
The fraction collector was programmed to collect all peaks that absorbed at 280 
nm. Fractions containing valeroyl-CoA were identified by direct infusion into an Applied 
Biosystems 4000 QTRAP mass spectrometer with the following mass spectrometer 
parameters: Q1 MS mode, scan range 100-1000 m/z, declustering potential: 70, entrance 
potential: 10, curtain gas: 10, IonSpray Voltage: 4800, Temperature: 300, Ion Source 
Gases: 40. The fractions containing the correct m/z for valeroyl-Coenzyme A ([M+H]) 
were then combined and lyophilized, leaving behind valeroyl-CoA as a white powder. 
The product was resuspended in LC grade water and quantified using the absorbance at 
280 nm compared to a standard curve of hexanoyl-CoA in water (Sigma-Aldrich) 
measured on a Nanodrop ND-1000 Spectrophotometer. The identity of the Coenzyme A 
ester was additionally verified by targeted LC-MS/MS after loading the purified 
substrate onto TcsA S98A (methods described below).  
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Figure 3-6 Mass spectrum of synthesized valeroyl-CoA. An m/z of 852.18 [z=1] represents the [M+H] ion, 
while the m/z of 874.5 [z=1] represents the [M+Na] ion. 
 
3.5.11. Trans-2-pentenoyl-, trans-2-hexenoyl-, and trans-2-heptenoyl-Coenzyme A. 
The 2,3-unsaturated CoA substrates were generated in vitro from valeroyl-CoA 
(synthesized in this work), hexanoyl-CoA (Sigma Aldrich), or heptanoyl-CoA (CoALA 
Biosciences, USA) using the short chain acyl-CoA dehydrogenase PP2216.261 Reactions 
contained the following components: 100mM sodium phosphate (pH 7.2), 500 µM Acyl-
Coenzyme A, 1 mM ferrocenium hexafluorophosphate (FeHFP, Sigma Aldrich), 225 µM 
PP2216 in a final volume of 1 mL. FeHFP was always prepared fresh by dissolving solid 
FeHFP in 10mM HCl and sonicating in a water bath to dissolve solid particles.254  
Reactions were incubated at 25°C for 2 hours (2-pentenoyl-CoA) or 6 hours (2-hexenoyl 
and 2-heptenoyl-CoA) then filtered through 3kDa MWCO Amicon microcentrifuge filters 
(Sigma Aldrich) to remove the remaining PP2216 protein. Samples were then aliquoted 
and lyophilized. After lyophilization, samples were stored at -20°C and resuspended in 
HPLC water (Honeywell) at a concentration of 4mM (assuming maximum theoretical 
yield) immediately prior to use. 
 
3.5.12. Allylmalonyl- and propylmalonyl-Coenzyme A. 
Allylmalonyl-CoA and propylmalonyl-CoA were biosynthesized from the 
corresponding malonic acids using an engineered mutant of the Streptomyces 
coelicolor malonyl-Coenzyme A transacylase MatB, MatB T207G/M306I.150 Reactions 
contained the following components: 100 mM sodium phosphate (pH 7.2), 2 mM MgCl2, 
 +Q1: 0.352 to 0.553 min from Sample 1 (Valeroyl-CoA) of 20180519 val-coA frac 16.wiff (Turbo Spray) Max. 3.6e6 cps.
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8 mM ATP, 4 mM Coenzyme A, 4 mM diacid, 100 µM MatB T207G/M306I in a final 
volume of 0.5 mL. Prior to addition to assays, allylmalonic acid (Sigma Aldrich) and 
propylmalonic acid (VWR, BeanTown Chemical) were dissolved in 50 mM sodium 
phosphate buffer, pH 7.2. Reactions were incubated for 3 hours the filtered through 
3kDa MWCO Amicon microcentrifuge filters (Sigma Aldrich) to remove the remaining 
MatB protein. Mixtures were aliquoted and frozen at -20°C until use in TcsD assays. 
 
3.5.13. Enzyme Assays: TcsD and mutants 
Assays of TcsD activity on TcsAS98A-bound substrates were carried out as 
follows: First, purified TcsAS98A was loaded with acyl-Coenzyme A substrates via the 
action of the promiscuous phosphopantetheinyl transferase Sfp.166 Loading reactions 
(150 µL) contained 60 µM TcsAS98A, 10 µM Sfp, 250 µM acyl-Coenzyme A, 20 mM 
MgCl2, and 50 mM sodium phosphate, pH 7.2. Reactions were initiated by the addition 
of Sfp and allowed to proceed at 37°C for 30 minutes. The loaded protein was then 
immediately used for TcsD assays, each of which contained: 45 µL of loading reaction, 
0.5 mM FeHFP (dissolved in 10 mM HCl), and 2 µM TcsD mutant (or boiled TcsD 
mutant). FeHFP was prepared as described above. Reactions were allowed to proceed 
for 16 hours then quenched with and equal volume of HPLC methanol (Sigma Aldrich) 
and either stored at -20°C or immediately processed for LC-MS analysis.  
 
3.5.14. Enzyme assays: Nocardia mexicana ACAD 
The Nocardia mexicana ACP was loaded with butyryl-, pentanoyl-, 2-pentenoyl-, 
2-hexenoyl, or 2-heptenoyl-CoA using Sfp.166 Loading reactions (120 µL) consisted of 50 
µM N. mexicana ACP, 10 µM Sfp, 250 µM acyl-Coenzyme A, 20 mM MgCl2, and 40 mM 
Tris buffer, pH 8. Reactions were initiated by the addition of Sfp and allowed to proceed 
at 37°C for 1 hour. The loading reactions were then used for N. mexicana ACAD assays 
which consisted of: 40 µL of loading reaction, 0.5 mM FeHFP,254 and 2 µM N. mexicana 
ACAD. Reactions were allowed to proceed at 37°C for 16 hours then quenched with 
HPLC methanol and immediately processed for LC-MS analysis. 
 
3.5.15. Sample preparation for LC-MS/MS analysis 
Samples were prepared for proteomics analysis by chloroform/methanol 
extraction as previously reported.276 Briefly, 150 µL of LC-grade methanol and 50 µL of 
LC-grade chloroform were sequentially added to the methanol-quenched samples, and 
samples were vortexed after each addition. Then, 150 µL LC-grade water was added, 
samples were vortexed to mix, and they were subsequently centrifuged at 21,000g for 1 
minute to promote phase separation. After removal and disposal of the top (aqueous) 
layer, another 150 µL of LC methanol was added, samples were vortexed, then they were 
centrifuged again at 21,000g for 2 minutes. After removal of the supernatant, samples 
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were allowed to dry for 5 minutes in a fume hood. Then, they were resuspended in 
freshly-prepared 100 mM ammonium bicarbonate buffer (N. mexicana ACAD assays) or 
100 mM ammonium bicarbonate containing 20% LC-grade DMSO (TcsD assays). Protein 
concentrations were analyzed via the DC Assay (Bio-Rad). After quantification, samples 
were digested with an appropriate protease. Samples digested with only trypsin (Sigma-
Aldrich) or only chymotrypsin (Promega) were digested at a ratio of 1:50 w/w 
protease:protein sample at 37°C for at least 6 hours. For Asp-N/trypsin dual digestions 
(TcsD and TcsD mutant assays), proteins were digested with 1:25 w/w Asp-N (New 
England Biolabs) in the presence of 0.75 mM ZnSO4 for 2-4 hours at 37°C then 
immediately digested again with 1:10 w/w trypsin for 1 hour at 37 oC. The N. mexicana 
ACAD assays were digested with Glu-C (Promega) at a ratio of 1:50 protease:protein 
sample at 37°C for 6 hours. After digestion, the samples were either frozen for future 
analysis or directly analyzed via LC-MS/MS.255  
 
3.5.16. Shotgun LC-MS/MS Analysis of TcsA-bound substrates 
Samples prepared for shotgun proteomic analysis were analyzed using Agilent 
6550 iFunnel Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA) coupled 
to an Agilent 1290 UHPLC system. Twenty (20) μg of peptides were separated on a 
Sigma–Aldrich Ascentis Peptides ES-C18 column (2.1 mm × 100 mm, 2.7 μm particle 
size, operated at 60°C) at a 0.400 mL/min flow rate and eluted with the following 
gradient: initial condition was 95% solvent A (0.1% formic acid) and 5% solvent B (99.9% 
acetonitrile, 0.1% formic acid). Solvent B was increased to 35% over 5.5 min, and then 
increased to 80% over 1min, and held for 3.5 min at a flow rate of 0.6 mL/min, followed 
by a ramp back down to 5% B over 0.5 min where it was held for 2 min to re-equilibrate 
the column to original conditions. Peptides were introduced to the mass spectrometer 
from the LC by using a Jet Stream source (Agilent Technologies) operating in positive-
ion mode (3,500 V). Source parameters employed gas temp (250°C), drying gas (14 
L/min), nebulizer (35 psig), sheath gas temp (250°C), sheath gas flow (11 L/min), VCap 
(3,500 V), fragmentor (180 V), OCT 1 RF Vpp (750 V). The data were acquired with 
Agilent MassHunter Workstation Software, LC/MS Data Acquisition B.06.01 operating in 
Auto MS/MS mode whereby the 20 most intense ions (charge states, 2–5) within 300–
1,400 m/z mass range above a threshold of 1,500 counts were selected for MS/MS 
analysis. MS/MS spectra (100–1,700 m/z) were collected with the quadrupole set to 
“Medium” resolution and were acquired until 45,000 total counts were collected or for a 
maximum accumulation time of 333 ms. Former parent ions were excluded for 0.1 min 
following MS/MS acquisition. The acquired data were exported as mgf files and 
searched against a customized protein database with Mascot search engine version 
2.3.02 (Matrix Science). 
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3.5.17. Targeted LC-MS/MS Analysis 
Samples were analyzed using an Agilent 1290 Infinity II liquid chromatography 
system coupled to an Agilent 6460 QQQ mass spectrometer (Agilent Technologies, 
Santa Clara, CA). Peptide samples (10 µg) were separated on an Ascentis Express Peptide 
ES-C18 column (2.7 μm particle size, 160 Å pore size, 50 x 2.1mm) fitted with a guard 
column (5 mm x 2.1 mm, Sigma Aldrich). The column was heated to 60°C. The mobile 
phase consisted of 0.1% formic acid in H2O (A) and 0.1% formic acid in acetonitrile (B). 
Peptides were eluted via the following gradient method:  
 
Table 3-7 LC gradient for targeted LC-MS/MS analysis of phosphopantetheine-
bearing peptides 
Time (min) %A %B Flow rate (mL/min) 
0 95 5 0.4 
2.2 95 5 0.4 
7.7 65 35 0.4 
8 20 80 0.4 
10 20 80 0.4 
10.5 95 5 0.4 
12 95 5 0.4 
15 95 5 0.4 
 
Peptides were ionized using an Agilent Jet Stream ESI source operating in 
positive-ion mode with the following source parameters: Gas Temperature = 250°C, Gas 
Flow = 13 L/min, Nebulizer Pressure = 35 psi, Sheath Gas Temperature = 250°C, Sheath 
Gas Flow = 11 L/min, and Capillary Voltage = 3,500 V. Dwell times were set to 10ms. 
Data were acquired using Agilent MassHunter Data Acquisition (Version B.08.02, Build 
8.2.8260.0). The mass spectrometry method was built using the Skyline targeted mass 
spectrometry environment (version 4.2.0 19072).277 Collision energies were predicted by 
Skyline with the exception of phosphopantetheine-bearing peptides for which the 
collision energy was set to 30eV. The specific transitions monitored and the collision 
energies for each are listed in Tables 3-8 & 3-9.  
  
  70 
 
Table 3-8 Transitions used for the targeted LC-MS/MS-based detection of TcsA-
bound intermediates 
Protein Peptide 
Precur
sor 
m/z 
Precurso
r Charge 
Produ
ct m/z 
Product 
Charge 
Collision 
Energy 
(eV) 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A APPPTGGMLAVK 
569.818
084 2 
970.53
9014 1 18.7 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A APPPTGGMLAVK 
569.818
084 2 
873.48
625 1 18.7 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A APPPTGGMLAVK 
569.818
084 2 
430.30
2396 1 18.7 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A AGELIAAAR 
436.253
434 2 
501.31
4357 1 14.5 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A AGELIAAAR 
436.253
434 2 
388.23
0293 1 14.5 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A AGELIAAAR 
436.253
434 2 
317.19
3179 1 14.5 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A DASALYATTMR 
600.289
887 2 
742.35
5236 1 19.6 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A DASALYATTMR 
600.289
887 2 
579.29
1907 1 19.6 
tr|E9KTG6|E9KTG6
_9ACTN_TcsAS98A DASALYATTMR 
600.289
887 2 
508.25
4793 1 19.6 
sp|P39135|SFP_BAC
SU TKPISLEIAK 
550.339
706 2 
870.52
9495 1 18.1 
sp|P39135|SFP_BAC
SU TKPISLEIAK 
550.339
706 2 
573.36
0639 1 18.1 
sp|P39135|SFP_BAC
SU TKPISLEIAK 
550.339
706 2 
460.27
6575 1 18.1 
sp|P39135|SFP_BAC
SU TKPISLEIAK 
550.339
706 2 
331.23
3982 1 18.1 
Holo-ACP 
DLGVDSLAMTELQA
HALQR[+340.085794] 
1204.57
1117 2 
261.12
6739 1 30 
Holo-ACP 
DLGVDSLAMTELQA
HALQR[+340.085794] 
803.383
17 3 
261.12
6739 1 30 
Holo-ACP 
DSLAMTELQAHALQ
R[+340.085794] 
1012.47
0675 2 
261.12
6739 1 30 
Holo-ACP 
DSLAMTELQAHALQ
R[+340.085794] 
675.316
209 3 
261.12
6739 1 30 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
1034.52
822 2 
1297.6
68131 1 33.1 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
1034.52
822 2 
1166.6
27646 1 33.1 
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Apo-ACP 
DLGVDSLAMTELQA
HALQR 
1034.52
822 2 
1065.5
79967 1 33.1 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
1034.52
822 2 
936.53
7374 1 33.1 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
1034.52
822 2 
823.45
331 1 33.1 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
690.021
239 3 
936.53
7374 1 20 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
690.021
239 3 
823.45
331 1 20 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
690.021
239 3 
695.39
4733 1 20 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
690.021
239 3 
624.35
7619 1 20 
Apo-ACP 
DLGVDSLAMTELQA
HALQR 
690.021
239 3 
487.29
8707 1 20 
Apo-ACP 
DSLAMTELQAHALQ
R 
842.427
778 2 
1166.6
27646 1 27.1 
Apo-ACP 
DSLAMTELQAHALQ
R 
842.427
778 2 
1065.5
79967 1 27.1 
Apo-ACP 
DSLAMTELQAHALQ
R 
842.427
778 2 
936.53
7374 1 27.1 
Apo-ACP 
DSLAMTELQAHALQ
R 
842.427
778 2 
823.45
331 1 27.1 
Apo-ACP 
DSLAMTELQAHALQ
R 
842.427
778 2 
695.39
4733 1 27.1 
Apo-ACP 
DSLAMTELQAHALQ
R 
561.954
277 3 
823.45
331 1 15.4 
Apo-ACP 
DSLAMTELQAHALQ
R 
561.954
277 3 
695.39
4733 1 15.4 
Apo-ACP 
DSLAMTELQAHALQ
R 
561.954
277 3 
624.35
7619 1 15.4 
Apo-ACP 
DSLAMTELQAHALQ
R 
561.954
277 3 
487.29
8707 1 15.4 
Apo-ACP 
DSLAMTELQAHALQ
R 
561.954
277 3 
416.26
1593 1 15.4 
2-pentenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+422.127659] 
1245.59
205 2 
343.16
8604 1 30 
2-pentenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+422.127659] 
830.730
459 3 
343.16
8604 1 30 
2-pentenoyl-ACP 
DSLAMTELQAHALQ
R[+422.127659] 
1053.49
1607 2 
343.16
8604 1 30 
2-pentenoyl-ACP 
DSLAMTELQAHALQ
R[+422.127659] 
702.663
497 3 
343.16
8604 1 30 
  72 
2_4-pentadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+420.112009] 
1244.58
4225 2 
341.15
2954 1 30 
2_4-pentadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+420.112009] 
830.058
575 3 
341.15
2954 1 30 
2_4-pentadienoyl-
ACP 
DSLAMTELQAHALQ
R[+420.112009] 
1052.48
3782 2 
341.15
2954 1 30 
2_4-pentadienoyl-
ACP 
DSLAMTELQAHALQ
R[+420.112009] 
701.991
614 3 
341.15
2954 1 30 
Hydroxypentanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+440.138224] 
1254.59
7332 2 
361.17
9169 1 30 
Hydroxypentanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+440.138224] 
836.733
98 3 
361.17
9169 1 30 
Hydroxypentanoyl-
ACP 
DSLAMTELQAHALQ
R[+440.138224] 
1062.49
689 2 
361.17
9169 1 30 
Hydroxypentanoyl-
ACP 
DSLAMTELQAHALQ
R[+440.138224] 
708.667
019 3 
361.17
9169 1 30 
Dihydroxypentanoyl
-ACP 
DLGVDSLAMTELQA
HALQR[+456.133138] 
1262.59
4789 2 
377.17
4083 1 30 
Dihydroxypentanoyl
-ACP 
DLGVDSLAMTELQA
HALQR[+456.133138] 
842.065
618 3 
377.17
4083 1 30 
Dihydroxypentanoyl
-ACP 
DSLAMTELQAHALQ
R[+456.133138] 
1070.49
4347 2 
377.17
4083 1 30 
Dihydroxypentanoyl
-ACP 
DSLAMTELQAHALQ
R[+456.133138] 
713.998
657 3 
377.17
4083 1 30 
3-hydroxy-45-
pentenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+438.122574] 
1253.58
9507 2 
359.16
3519 1 30 
3-hydroxy-45-
pentenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+438.122574] 
836.062
097 3 
359.16
3519 1 30 
3-hydroxy-45-
pentenoyl-ACP 
DSLAMTELQAHALQ
R[+438.122574] 
1061.48
9065 2 
359.16
3519 1 30 
3-hydroxy-45-
pentenoyl-ACP 
DSLAMTELQAHALQ
R[+438.122574] 
707.995
135 3 
359.16
3519 1 30 
2-hexenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+436.143309] 
1252.59
9875 2 
357.18
4254 1 30 
2-hexenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+436.143309] 
835.402
342 3 
357.18
4254 1 30 
2-hexenoyl-ACP 
DSLAMTELQAHALQ
R[+436.143309] 
1060.49
9432 2 
357.18
4254 1 30 
2-hexenoyl-ACP 
DSLAMTELQAHALQ
R[+436.143309] 
707.335
38 3 
357.18
4254 1 30 
Hydroxyhexanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+454.153874] 
1261.60
5157 2 
375.19
4819 1 30 
Hydroxyhexanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+454.153874] 
841.405
864 3 
375.19
4819 1 30 
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Hydroxyhexanoyl-
ACP 
DSLAMTELQAHALQ
R[+454.153874] 
1069.50
4715 2 
375.19
4819 1 30 
Hydroxyhexanoyl-
ACP 
DSLAMTELQAHALQ
R[+454.153874] 
713.338
902 3 
375.19
4819 1 30 
3-hydroxy-45-
hexenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+452.138224] 
1260.59
7332 2 
373.17
9169 1 30 
3-hydroxy-45-
hexenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+452.138224] 
840.733
98 3 
373.17
9169 1 30 
3-hydroxy-45-
hexenoyl-ACP 
DSLAMTELQAHALQ
R[+452.138224] 
1068.49
689 2 
373.17
9169 1 30 
3-hydroxy-45-
hexenoyl-ACP 
DSLAMTELQAHALQ
R[+452.138224] 
712.667
019 3 
373.17
9169 1 30 
Dihydroxyhexanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+470.148788] 
1269.60
2614 2 
391.18
9733 1 30 
Dihydroxyhexanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+470.148788] 
846.737
502 3 
391.18
9733 1 30 
Dihydroxyhexanoyl-
ACP 
DSLAMTELQAHALQ
R[+470.148788] 
1077.50
2172 2 
391.18
9733 1 30 
Dihydroxyhexanoyl-
ACP 
DSLAMTELQAHALQ
R[+470.148788] 
718.670
54 3 
391.18
9733 1 30 
2_4-hexadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+434.127659] 
1251.59
205 2 
355.16
8604 1 30 
2_4-hexadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+434.127659] 
834.730
459 3 
355.16
8604 1 30 
2_4-hexadienoyl-
ACP 
DSLAMTELQAHALQ
R[+434.127659] 
1059.49
1607 2 
355.16
8604 1 30 
2_4-hexadienoyl-
ACP 
DSLAMTELQAHALQ
R[+434.127659] 
706.663
497 3 
355.16
8604 1 30 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD DAPLALYER 
524.277
106 2 
861.48
2879 1 17.3 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD DAPLALYER 
524.277
106 2 
580.30
8937 1 17.3 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD DAPLALYER 
524.277
106 2 
467.22
4873 1 17.3 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD DAPLALYER 
524.277
106 2 
304.16
1545 1 17.3 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD YTAVTVPR 
453.755
809 2 
472.28
7808 1 15.1 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD YTAVTVPR 
453.755
809 2 
371.24
013 1 15.1 
tr|E9KTG9|E9KTG9
_9ACTN_TcsD YTAVTVPR 
453.755
809 2 
272.17
1716 1 15.1 
2-heptenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+450.158959] 
1259.60
77 2 
371.19
9904 1 30 
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2-heptenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+450.158959] 
840.074
225 3 
371.19
9904 1 30 
2-heptenoyl-ACP 
DSLAMTELQAHALQ
R[+450.158959] 
1067.50
7257 2 
371.19
9904 1 30 
2-heptenoyl-ACP 
DSLAMTELQAHALQ
R[+450.158959] 
712.007
264 3 
371.19
9904 1 30 
2_4-heptadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+448.143309] 
1258.59
9875 2 
369.18
4254 1 30 
2_4-heptadienoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+448.143309] 
839.402
342 3 
369.18
4254 1 30 
2_4-heptadienoyl-
ACP 
DSLAMTELQAHALQ
R[+448.143309] 
1066.49
9432 2 
369.18
4254 1 30 
2_4-heptadienoyl-
ACP 
DSLAMTELQAHALQ
R[+448.143309] 
711.335
38 3 
369.18
4254 1 30 
Hydroxyheptanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+468.169524] 
1268.61
2982 2 
389.21
0469 1 30 
Hydroxyheptanoyl-
ACP 
DLGVDSLAMTELQA
HALQR[+468.169524] 
846.077
747 3 
389.21
0469 1 30 
Hydroxyheptanoyl-
ACP 
DSLAMTELQAHALQ
R[+468.169524] 
1076.51
254 2 
389.21
0469 1 30 
Hydroxyheptanoyl-
ACP 
DSLAMTELQAHALQ
R[+468.169524] 
718.010
785 3 
389.21
0469 1 30 
Dihydroxyheptanoyl
-ACP 
DLGVDSLAMTELQA
HALQR[+484.164439] 
1276.61
044 2 
405.20
5384 1 30 
Dihydroxyheptanoyl
-ACP 
DLGVDSLAMTELQA
HALQR[+484.164439] 
851.409
385 3 
405.20
5384 1 30 
Dihydroxyheptanoyl
-ACP 
DSLAMTELQAHALQ
R[+484.164439] 
1084.50
9997 2 
405.20
5384 1 30 
Dihydroxyheptanoyl
-ACP 
DSLAMTELQAHALQ
R[+484.164439] 
723.342
424 3 
405.20
5384 1 30 
3-hydroxy-45-
heptenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+466.153874] 
1267.60
5157 2 
387.19
4819 1 30 
3-hydroxy-45-
heptenoyl-ACP 
DLGVDSLAMTELQA
HALQR[+466.153874] 
845.405
864 3 
387.19
4819 1 30 
3-hydroxy-45-
heptenoyl-ACP 
DSLAMTELQAHALQ
R[+466.153874] 
1075.50
4715 2 
387.19
4819 1 30 
3-hydroxy-45-
heptenoyl-ACP 
DSLAMTELQAHALQ
R[+466.153874] 
717.338
902 3 
387.19
4819 1 30 
Pentanoyl-ACP 
DLGVDSLAMTELQA
HALQR[+424.1] 
1246.59
9875 2 
345.18
4254 1 30 
Pentanoyl-ACP 
DLGVDSLAMTELQA
HALQR[+424.1] 
831.402
342 3 
345.18
4254 1 30 
Pentanoyl-ACP 
DSLAMTELQAHALQ
R[+424.1] 
1054.49
9432 2 
345.18
4254 1 30 
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Pentanoyl-ACP 
DSLAMTELQAHALQ
R[+424.1] 
703.335
38 3 
345.18
4254 1 30 
Butyryl-ACP 
DLGVDSLAMTELQA
HALQR[+410.1] 
1239.59
205 2 
331.16
8604 1 30 
Butyryl-ACP 
DLGVDSLAMTELQA
HALQR[+410.1] 
826.730
459 3 
331.16
8604 1 30 
Butyryl-ACP 
DSLAMTELQAHALQ
R[+410.1] 
1047.49
1607 2 
331.16
8604 1 30 
Butyryl-ACP 
DSLAMTELQAHALQ
R[+410.1] 
698.663
497 3 
331.16
8604 1 30 
Crotonyl-ACP 
DLGVDSLAMTELQA
HALQR[+408.1] 
1238.58
4225 2 
329.15
2954 1 30 
Crotonyl-ACP 
DLGVDSLAMTELQA
HALQR[+408.1] 
826.058
575 3 
329.15
2954 1 30 
Crotonyl-ACP 
DSLAMTELQAHALQ
R[+408.1] 
1046.48
3782 2 
329.15
2954 1 30 
Crotonyl-ACP 
DSLAMTELQAHALQ
R[+408.1] 
697.991
614 3 
329.15
2954 1 30 
Hydroxybutyryl-
ACP 
DLGVDSLAMTELQA
HALQR[+426.1] 
1247.58
9507 2 
347.16
3519 1 30 
Hydroxybutyryl-
ACP 
DLGVDSLAMTELQA
HALQR[+426.1] 
832.062
097 3 
347.16
3519 1 30 
Hydroxybutyryl-
ACP 
DSLAMTELQAHALQ
R[+426.1] 
1055.48
9065 2 
347.16
3519 1 30 
Hydroxybutyryl-
ACP 
DSLAMTELQAHALQ
R[+426.1] 
703.995
135 3 
347.16
3519 1 30 
Propylmalonyl-ACP 
DLGVDSLAMTELQA
HALQR[+468.1] 
1268.59
4789 2 
389.17
4083 1 30 
Propylmalonyl-ACP 
DLGVDSLAMTELQA
HALQR[+468.1] 
846.065
618 3 
389.17
4083 1 30 
Propylmalonyl-ACP 
DSLAMTELQAHALQ
R[+468.1] 
1076.49
4347 2 
389.17
4083 1 30 
Propylmalonyl-ACP 
DSLAMTELQAHALQ
R[+468.1] 
717.998
657 3 
389.17
4083 1 30 
Allymalonyl-ACP 
DLGVDSLAMTELQA
HALQR[+466.1] 
1267.58
6964 2 
387.15
8433 1 30 
Allymalonyl-ACP 
DLGVDSLAMTELQA
HALQR[+466.1] 
845.393
735 3 
387.15
8433 1 30 
Allymalonyl-ACP 
DSLAMTELQAHALQ
R[+466.1] 
1075.48
6522 2 
387.15
8433 1 30 
Allymalonyl-ACP 
DSLAMTELQAHALQ
R[+466.1] 
717.326
773 3 
387.15
8433 1 30 
Note: peptides with added masses in brackets (e.g. “DSLAMTELQAHALQR[+466.1]”) 
depict modified peptides with phosphopantetheine arms/substrates.  
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Table 3-9 Transitions used for the targeted LC-MS/MS-based detection of NmexACP-
bound intermediates 
Protein Peptide 
Precurso
r Ion 
Precursor 
charge 
Product 
Ion 
Product 
charge 
Collision 
Energy (eV) 
Holo-Nmex-ACP 
MDSLNLMDFLVYLE[+340
.085794].light 
1021.949
86 2 
261.126
74 1 30 
Holo-Nmex-ACP 
MDSLNLMDFLVYLE[+340
.085794].light 
681.6356
68 3 
261.126
74 1 30 
Nmex-ACP GLRSIADRLDLE.light 
679.3753
4 2 
760.383
56 1 22.1 
Nmex-ACP GLRSIADRLDLE.light 
679.3753
4 2 
645.356
62 1 22.1 
Nmex-ACP GLRSIADRLDLE.light 
679.3753
4 2 
489.255
51 1 22.1 
Nmex-ACP GLRSIADRLDLE.light 
453.2526
52 3 
489.255
51 1 11.5 
Nmex-ACP GLRSIADRLDLE.light 
453.2526
52 3 
376.171
44 1 11.5 
Nmex-ACP GLRSIADRLDLE.light 
453.2526
52 3 
261.144
5 1 11.5 
Nmex-ACP NVDISATSSLEDDLE.light 
804.3677
72 2 
820.357
07 1 25.9 
Nmex-ACP NVDISATSSLEDDLE.light 
804.3677
72 2 
733.325
04 1 25.9 
Nmex-ACP NVDISATSSLEDDLE.light 
804.3677
72 2 
620.240
98 1 25.9 
Pentanoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+424
.143309].light 
1063.978
62 2 
345.184
25 1 30 
Pentanoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+424
.143309].light 
709.6548
4 3 
345.184
25 1 30 
Pentenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+422
.127659].light 
1062.970
8 2 
343.168
6 1 30 
Pentenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+422
.127659].light 
708.9829
56 3 
343.168
6 1 30 
Pentadienoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+420
.112009].light 
1061.962
97 2 
341.152
95 1 30 
Pentadienoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+420
.112009].light 
708.3110
73 3 
341.152
95 1 30 
Hydroxypentanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+440
.138224].light 
1071.976
08 2 
361.179
17 1 30 
Hydroxypentanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+440
.138224].light 
714.9864
78 3 
361.179
17 1 30 
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Butyryl-Nmex-ACP 
MDSLNLMDFLVYLE[+410
.127659].light 
1056.970
8 2 
331.168
6 1 30 
Butyryl-Nmex-ACP 
MDSLNLMDFLVYLE[+410
.127659].light 
704.9829
56 3 
331.168
6 1 30 
Crotonyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+408
.112009].light 
1055.962
97 2 
329.152
95 1 30 
Crotonyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+408
.112009].light 
704.3110
73 3 
329.152
95 1 30 
Hydroxybutyryl-
Nmex-ACP 
MDSLNLMDFLVYLE[+426
.122574].light 
1064.968
25 2 
347.163
52 1 30 
Hydroxybutyryl-
Nmex-ACP 
MDSLNLMDFLVYLE[+426
.122574].light 
710.3145
95 3 
347.163
52 1 30 
Hexanoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+438
.158959].light 
1070.986
45 2 
359.199
9 1 30 
Hexanoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+438
.158959].light 
714.3267
23 3 
359.199
9 1 30 
Hexenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+436
.143309].light 
1069.978
62 2 
357.184
25 1 30 
Hexenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+436
.143309].light 
713.6548
4 3 
357.184
25 1 30 
Hexadienoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+434
.127659].light 
1068.970
8 2 
355.168
6 1 30 
Hexadienoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+434
.127659].light 
712.9829
56 3 
355.168
6 1 30 
Hydroxyhexanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+454
.153874].light 
1078.983
9 2 
375.194
82 1 30 
Hydroxyhexanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+454
.153874].light 
719.6583
61 3 
375.194
82 1 30 
Heptanoyl-ACP 
MDSLNLMDFLVYLE[+452
.174609].light 
1077.994
27 2 
373.215
55 1 30 
Heptanoyl-ACP 
MDSLNLMDFLVYLE[+452
.174609].light 
718.9986
06 3 
373.215
55 1 30 
Hydroxyheptanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+468
.169524].light 
1085.991
73 2 
389.210
47 1 30 
Hydroxyheptanoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+468
.169524].light 
724.3302
45 3 
389.210
47 1 30 
Heptenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+450
.158959].light 
1076.986
45 2 
371.199
9 1 30 
Heptenoyl-Nmex-
ACP 
MDSLNLMDFLVYLE[+450
.158959].light 
718.3267
23 3 
371.199
9 1 30 
Heptadienoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+448
.143309].light 
1075.978
62 2 
369.184
25 1 30 
Heptadienoyl-
Nmex-ACP 
MDSLNLMDFLVYLE[+448
.143309].light 
717.6548
4 3 
369.184
25 1 30 
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sp|P39135|SFP_BA
CSU YSDLLAKDKDE.light 
648.8195
32 2 
705.341
36 1 21.1 
sp|P39135|SFP_BA
CSU YSDLLAKDKDE.light 
648.8195
32 2 
634.304
25 1 21.1 
sp|P39135|SFP_BA
CSU YSDLLAKDKDE.light 
648.8195
32 2 
506.209
28 1 21.1 
 
3.5.18. Targeted LC-MS/MS Data Availability 
Raw data were imported into Skyline and are available on the LC-MS data sharing 
platform Panorama Public at the following link: 
https://panoramaweb.org/Structural%20control%20of%20bacterial%20acyl-
CoA%20dehydrogenase.url.278 Sample names for TcsD assays are labeled as “protein-
substrate-replicate.” For example, replicate one of the assay of wild type TcsD on 
pentanoyl-ACP is labeled “WT-val-01.” Substrate abbreviations are as follows: val = 
pentanoyl-ACP, but = butyryl-ACP, 2pent = 2-pentenoyl-ACP, 2hex = 2-hexenoyl-ACP, 
2hept = 2-heptenoyl-ACP, allylmal = allylmalonyl-ACP, propmal = propylmalonyl-ACP. 
The data for TcsD wild type assays on 2-pentenoyl-ACP, 2-hexenoyl-ACP, and 2-
heptenoyl-ACP is located in the file named “WT assays_set 1_pub data.skyd.” The data 
for TcsD wild type assays on propylmalonyl-ACP is located in the file named “Malonate 
assays_pub data.skyd.” The data for TcsD wild type assays on butyryl-ACP and 
pentanoyl-ACP and the data for all mutant TcsD proteins on all substrates is located in 
the file named “Mutants assays_WT-but-val_pub data.skyd.”  
Sample names for N. mexicana ACAD assays are labeled as “substrate_replicate,” and 
substrate abbreviations are the same as for TcsD assays. The data for butyryl-, 
pentanoyl-, and 2-pentenoyl-ACP are located in the file named “NmexACP_C4_C5_pub 
data.skyd,” and data for 2-hexenoyl- and 2-heptenoyl-ACP are located in the file named 
“NmexACP_C6_C7_pub data.skyd.” 
 
3.5.19. Targeted LC-MS/MS Data Analysis: TcsD assays 
After importing data, chromatograms were manually curated. Correct peaks were 
identified by comparison of their retention times to control peaks (i.e. the 2-pentenoyl-
ACP active site peptide should elute before the pentanoyl-ACP active site peptide). For 
phosphopantetheine ejection peaks, only the transition derived from the peptide 
“DLGVDSLAMTELQAHALQR” was used for analysis and quantification. Peaks that were 
not correctly automatically selected were manually selected in Skyline and integrated 
using the built in Skyline integration function. For negative controls, an area 
corresponding to the same retention time as the peak of interest was integrated. After 
integrating, all phosphopantetheine ejection ion peak areas were normalized to an 
internal control peptide from the within the TcsA protein (a peptide that does not 
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contain catalytic residues) to account for differences in the amount of protein injected. 
The reported values in Figure 3-3 were averages of three normalized replicate peak 
areas. Error bars represent standard deviations of each set of replicates.  
 
3.5.20.  Targeted LC-MS/MS Data Analysis: N. mexicana ACAD assays 
After importing data into Skyline, chromatograms were manually curated 
(including manual integration where necessary) as described above for TcsD assays. 
Plots in Figures 3-5E and 3-5F and Figure 4-13 correspond to the LC-MS/MS 
chromatograms of the phosphopantetheine ejection transition from the parent peptide 
“MDSLNLMDFLVYE” in the +2 charge state. 
 
3.5.21. Preparation of denatured TcsD supernatants for untargeted LC-MS analysis 
TcsD was expressed and purified via nickel affinity chromatography as described 
above. The highest purity nickel affinity elution fractions were pooled, and protein was 
concentrated to approximately 17 mg/mL or 375 µM (determined by absorbance using 
a Nanodrop and the molar absorbance of TcsD). After concentration, 150 µL of protein 
was denatured by either boiling for 10 minutes or the addition of 300 µL of LC grade 
acetonitrile. The denatured protein was pelleted by centrifuging at maximum speed in a 
benchtop centrifuge for 2 minutes. Supernatants were removed and lyophilized 
overnight. After lyophilization, supernatants were resuspended in 75 µL of LC grade 
water for an effective metabolite concentration of 750 µM. Samples were diluted to an 
effective metabolite concentration of 50 µM in 50:50 (v/v) LC grade water:methanol 
prior to untargeted LC-MS analysis. Standards of flavin adenine dinucleotide (FAD), 
Coenzyme A, pantetheine, pantothenate, and butyryl-CoA were prepared in 50:50 (v/v) 
LC grade methanol:water to a concentration of 20 µM. 
 
3.5.22. High resolution untargeted LC-MS analysis of denatured TcsD supernatants 
Supernatants of denatured TcsD samples were analyzed using an Agilent 6545 
LC-QTOF system as previously described.279 Analytes were separated using a SeQuant 
ZIC hydrophilic interaction chromatography (HILIC) column (150 mm length, 4.6 mm 
internal diameter, 5 µm particle size) coupled to a SeQuant ZIC-pHILIC guard column 
(20 mm length, 2.1 mm internal diameter, 5 µm particle size). The mobile phase 
consisted of 10 mM ammonium carbonate and 118.4 mM ammonium hydroxide in 
acetonitrile-water (60.2:39.8 v/v). Analytes were separated isocratically using the 
following pump parameters: 
 
Table 3-10 LC gradient for untargeted LC-MS of denatured TcsD supernatants 
Time (min) Mobile phase (%) Flow rate (mL/min) 
0 100 0.45 
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6 100 0.45 
6.5 100 0.605 
12.5 100 0.605 
 
The mass spectrometer source was operated with the following parameters: Gas 
Temperature = 300°C, Drying Gas = 10 L/min, Nebulizer Pressure = 20 psi, Sheath Gas 
Temperature = 350°C, Sheath Gas Flow = 12 L/min, and Capillary Voltage = 3500 V, 
Nozzle Voltage = 2000 V. The TOF mass spectrometer was programmed to operated in 
scan mode with the following parameters: Fragmentor Voltage = 100 V, Skimmer 
Voltage = 50 V, Oct 1 RF Vpp = 400 V, Mass Range = 70 m/z – 1100 m/z, Acquisition 
Rate = 0.86 spectra/s, Acquisition Time = 1162.8 ms/spectrum, and Transients/spectrum 
= 9532 (negative ion mode) or 9485 (positive ion mode). All samples were analyzed in 
both negative ion mode and subsequently in positive ion mode. Data analysis was 
performed in Agilent MassHunter Qualitative Analysis (v B.05.00). 
 
3.5.23. Substrate modeling into TcsD active site 
Substrates for modeling were drawn using ChemDraw, and ligand restraints were 
generated using eLBOW in the Phenix software suite. Substrates were manually placed 
into the TcsD active site using Coot. Real Space Refinements of the substrates were 
performed using the unknown density in the substrate-binding region of the enzyme 
active site. The refinements resulted in the generation of both cis and trans isomers of 
the substrate with planar fatty acyl tails. After substrate generation, the TcsD structure 
was aligned with the structures of ACADs which had been co-crystallized with thioester 
substrates. Alignments were performed using the least squares fit LSQ superpose 
function of Coot. Proteins were aligned using the 3-residue loop containing the catalytic 
glutamate and the residues immediately upstream and downstream of the glutamate 
(Table 3-11). These alignments were used for analysis of the relative positioning of FAD 
cofactors and for substrate modeling. After alignment, the 2-pentenoyl substrates were 
manually translated and rotated into a position within the TcsD active site that 
corresponds to approximately the equivalent position of substrates in the aligned 
homolog structures. The feasibility of hydrogen bonding interactions was confirmed 
using the Measure tool in Coot considering a maximum distance of 3.5Å between 
heteroatoms. Substrate lengths were also determined using the Measure tool to 
calculate the distance from the carbonyl carbon of a given molecule to the distal carbon 
of the fatty acyl tail. The length of the 2-hexenoyl substrate was calculated using a 
substrate molecule that was generated using Ligand Builder in Coot. The approximate 
length of the 2-heptenoyl substrate was calculated by adding half the distance between 
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the fourth and sixth (saturated) carbons of the 2-hexenoyl substrate to the total length 
of the 2-hexenoyl substrate.  
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Table 3-11 ACAD structures used in alignment for substrate modeling 
PDB code Host organism Protein description Amino acids used 
for LSQ alignment 
6U1V Streptomyces 
tsukubensis NRRL 
18488 
TcsD Ile 363 
Glu 364 
Gly 365 
1jqi Rattus norvegicus Rat short chain 
ACAD 
Tyr 367 
Glu 368 
Gly 369 
2vig Homo sapiens Human short chain 
ACAD 
Tyr 391 
Glu 392 
Gly 393 
1udy Sus scrofa Pig medium chain 
ACAD 
Tyr 375 
Glu 376 
Gly 377 
1buc Megasphaera 
elsdenii 
Bacterial butyryl-
CoA ACAD 
Tyr 366 
Glu 367 
Gly 368 
3mdd Sus scrofa Pig medium chain 
ACAD 
Tyr 375 
Glu 376 
Gly 377 
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3.5.24. Bioinformatic identification of TcsD homologs 
First, a Hidden Markov Model (HMM) that describes γ,δ-ACADs was generated 
using the sequences of several TcsD enzymes from various FK506 producers and HliR 
(Table 3-12).264 The HMM was then used to search for homologs among all proteins in 
the Uniprot database, after which the genomes of organisms that contain potential γ,δ-
ACADs were analyzed using antiSMASH.280 An additional search was performed by 
querying the results of the HMM search against GenBank using protein BLAST.263 Finally, 
CORASON-BGC was used for the identification of the syntenic genomic contexts of the 
identified genes.262 The results from each of these searches were then manually curated 
based on the presence of key motifs identified through the structural and biochemical 
characterization of TcsD. 
 
Table 3-12 Protein sequences used to build γ,δ-ACAD HMM used in genome mining 
GenBank 
Accession 
Number 
Host 
organism 
Sequence 
ADU56309.1 Streptomyc
es sp. KCTC 
11604BP 
MSESERLGIVRDFVAREILGREGILDSLADAPLALYERFAETGL
MNWWVPKEHGGLGLGLEESVRIVSELAYGDAGVAFTLFLPV
LTTSMIGWYGSEELKERFLGPLVARRGFCATLGSEHEAGSELA
RISTTVRRDGDTLVLDGTKAFSTSTDFARFLVVIARSADDPAR
YTAVTVPRDAPGLRVDKRWDVIGMRASATYQVSFSDCRVP
GDNALNGNGLRLLEIGLNASRILIAASALGVARRIRDVCMEY
GKTKSLKGAPLVKDGVFAGRLGQFEMQIDVMANQCLAAAR
AYDATAARPDAARVLLRQGAQKSALTAKMFCGQTAWQIAS
TASEMFGGIGYTHDMVIGKLLRDVRHASIIEGGDDVLRDLVY
QRFVVPTAKRT 
WP_0555510
85.1 
Streptomyc
es 
kanamycetic
us 
MSEPEHLDTVRKFVAQEVLGRETHLDSLADAPLALYERFAET
GLMNWWVPEEHGGLGLGLEDSVRIVSELAYGDAGVAFTLFL
PILTTSMVSWYGSAELKEKLLDPLVAHRGFCATLGSEHEAGSE
LAKISTVVRRDGEGLVLDGTKAFSTSTDFAQFLVVIARSAENP
TRYLAVAVERDAPGLRIDKRWDVIGLRASATYQVSFSDCHVP
AGNALDGHGLRLLEIGLNASRILIAATALGVARRIRDLCMEYA
KTKSLKGAPLVNDAVFAGRLGQFEMQIEVMANQCLAAART
YDATAARPDAARTLLRQGAQKSALTAKMFCGQTAWQIAST
ASEMFGGIGYTHDVPIGKLLRDVRHASIIEGGDDVLRDLVFH
RFVVPTAKRT 
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WP_0063508
39.1 
Streptomyc
es 
tsukubensis 
MSESERLGIVRDFVAREILGREGILDSLADAPLALYERFAETGL
MNWWVPKEHGGLGLGLEESVRIVSELAYGDAGVAFTLFLPV
LTTSMIGWYGSEELKERFLGPLVARRGFCATLGSEHEAGSELA
RISTTVRRDGDTLVLDGTKAFSTSTDFARFLVVIARSADDPAR
YTAVTVPRDAPGLRVDKRWDVIGMRASATYQVSFSDCRVP
GDNALNGNGLRLLEIGLNASRILIAASALGVARRIRDVCMEY
GKTKSLKGAPLVKDGVFAGRLGQFEMQIDVMANQCLAAAR
AYDATAARPDAARVLLRQGAQKSALTAKMFCGQTAWQIAS
TASEMFGGIGYTHDMVIGKLLRDVRHASIIEGGDDVLRDLVY
QRFVVPTAKRT 
AMM72019.
1 
Haliangium 
ochraceum 
DSM 14365 
MSADTTKKNPLIEPIRGFVREHVLGREQQLDAGGELPLDIYEA
FRKAGLANWWLPESYGGHGLSLEQSVDIVAELAYGDAGLAF
AFFLPILSTSVIEQFGSEEQKQRYLPALAKSGGSCATMASEEK
AGSELIRTEALARGSAEEGFKLSGDKYFSTNADTAELLIVYARI
AGPTPAYGAFLVPRSADGIRIVRRWEMNGLRASGTYELELRD
CPAESQLAGNGLRILEVGLNSSRTLMAACAVGIARRVRDVCL
GYARNKEIKNTKLFNNHVFGAKLGQMEAELDGMMAVCRT
AAREMDEIASREDAAKVFFREGTLKSVIVAKMLCGQLGWKIA
SVGSESLGGLGYTHDSIIGKLLRDVRYVSLVEAGDDVLRDLVF
SRHVLPRFMSEIE 
 
  
3.5.25. Sequence alignment of TcsD homologs 
A sequence alignment of TcsD, HliR, and several α,β-ACADs was generated using 
Clustal Omega.281 The sequence alignment was visualized with respect to the TcsD 
structure using ESPript 3.0.282 To calculate the positional occupancy of amino acids 
within the γ,δ-ACADs, a sequence alignment of the identified proteins was generated 
using MAFFT.283  Positional occupancies were calculated using the bioinformatics tool 
UGene.284  
 
3.5.26. Position weight matrix 
The Shannon entropy of the aligned γ,δ-ACADs was calculated at each position 
within a sequence alignment. All of the identified γ,δ-ACAD sequences were aligned 
using MAFFT.283 The MSA was then refined so that all positions maintained at least 10% 
occupancy using the ProDy python library. The Shannon entropy was then calculated 
using ProDy.285,286 The sequence logo was generated using Weblogo 
(https://weblogo.berkeley.edu/logo.cgi). 
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3.6.3. Structural data deposition 
The atomic coordinates and structural factors of TcsD have been deposited in the 
Protein Data Bank, PDB ID code 6U1V. 
 
  86 
3.6.4. LC-MS/MS data deposition 
All targeted LC-MS/MS data from TcsD assays has been uploaded to Panorama Public278 
and is publicly available at the following link: 
https://panoramaweb.org/Structural%20control%20of%20bacterial%20acyl-
CoA%20dehydrogenase.url 
 
Chapter 4. Supplementary information for Chapter 3 
4.1. LC-MS/MS Phosphopantetheine ejection assay method development 
In order to assay TcsD activity on TcsA-bound substrates, we first developed a 
targeted proteomics assay for the identification of substrates tethered to the 
phosphopantetheinyl arm of the acyl carrier proteins (ACP) domain of TcsA. In a typical 
“phosphopantetheine ejection” experiment,255 a protein of interest is digested with 
trypsin and the digested peptides are analyzed via LC-MS/MS (main text Figure 2A). 
However, after digesting TcsA with trypsin we were unable to detect an ion representing 
the ACP active site peptide, most likely because the large size (~40 residues) of the 
tryptic peptide placed it outside of the detectable range of our mass spectrometer 
(Figure 4-1). Similarly, the active site peptide could not be detected after digestion with 
another commonly-used protease, chymotrypsin. In order to obtain an appropriately-
sized peptide, we performed a sequential digestion of TcsA with two proteases, Asp-N 
then trypsin, and identified the resulting “holo” and “acyl” active site peptides using high 
resolution untargeted LC-MS (Figure 4-1 & 4-2). Surprisingly, Asp-N did not consistently 
cleave at the predicted residue D373 of the conserved “DSL” motif of the acyl carrier 
protein (ACP) of TcsA but instead at the preceding D369, possibly due to steric effects 
arising from the presence of the phosphopantetheine arm appended to S374. 
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Figure 4-1 Development of a phosphopantetheine ejection method for studying intermediates bound to 
TcsA-ACP. A) Digestion of TcsA with trypsin results in an active site peptide 40 amino acids in length which 
is not detectable using targeted LC-MS/MS. B) Dual digestion of TcsA with Asp-N and trypsin results in a 
detectable peptide from which phosphopantetheine ejection can be observed. C) Predicted TcsA active site 
peptide resulting from TcsA digestion with Asp-N and trypsin. D) Observed TcsA active site peptide resulting 
from TcsA digestion with Asp-N and trypsin (verified with data in Figure 4-2). 
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Figure 4-2 Product ion mass spectrum showing phosphopantetheine ejection ion resulting from holo-TcsA 
digested with Asp-N and trypsin. The product ion is derived from a parent ion with m/z = 803.394 [z=3], 
representing the peptide “DLGVDSLAMTELQAHALQR” in which Asp-N misses one cleavage, not the 
expected “DSLAMTELQAHALQR” active site peptide (see Figure 4-1). 
4.2. Unidentified density in active site of TcsD crystal structure 
An unknown metabolite consistently co-crystallized in the TcsD active site, occupying 
the space where substrates are predicted to bind (Figure 4-3). We attempted to identify 
this unknown density by performing untargeted high resolution LC-MS of denatured 
protein samples (Figures 4-4 & 4-5), but were unable to identify any unique masses in 
the supernatants of denatured TcsD samples. We also compared the denatured protein 
supernatant LC-MS chromatograms to several standards, including flavin adenine 
dinucleotide (FAD), Coenzyme A, pantetheine, pantothenate, and butyryl-CoA, but only 
the m/z corresponding to FAD could be detected in extracted ion chromatograms of 
either sample. We additionally used the Ligand Identification function of the Phenix 
software suite,287,288 attempting to model 180 of the most common ligands from the 
Protein Data Bank into the density, but none of the ligands fit appropriately. 
 
 
 
 
  89 
 
Figure 4-3 Unidentified density in active site of TcsD and modeling of PEG trimer into density. A) and B) Shape 
of the unidentified density (in orange mesh) in the TcsD active site (Fo – Fc map at 3σ) C) and D) Model of 
TcsD after refinement with a PEG trimer (purple sticks) occupying the unknown density, showing that this 
PEG fragment does not fit properly within the density. The 2Fo – Fc  map is shown in blue mesh at 1σ. The 
Fo – Fc map is shown in green at 3σ and in red at -3σ.   
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Figure 4-4 High resolution untargeted LC-TOF analysis of denatured purified TcsD samples in negative ion 
mode. Samples are as follows: A) Crystallization buffer B) Supernatant from boiled TcsD C) Supernatant from 
acetonitrile-denatured TcsD. Peaks pertaining to PEG (a common LCMS contaminant) and Tris are labeled. 
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Figure 4-5 High resolution untargeted LC-TOF analysis of denatured purified TcsD samples in positive ion 
mode. Samples are as follows: A) Crystallization buffer B) Supernatant from boiled TcsD C) Supernatant from 
acetonitrile-denatured TcsD, D) lysis buffer. Peaks pertaining to PEG (a common LCMS contaminant) and 
Tris are labeled. 
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4.3. Supplementary Figures and Tables 
 
 
Figure 4-6 TcsD activity on propylmalonyl-ACP (pathway A2 from Figure 1) analyzed via targeted LC-
MS/MS. WT = wild type TcsD, (-) = negative control, Stnd = standard. The chromatograms shown depict: 
A) the allylmalonyl-ACP transition for the negative control reaction B) the allylmalonyl-ACP transition for 
the wild type TcsD reaction C) an allylmalonyl-ACP standard D) the propylmalonyl-ACP transition for the 
negative control reaction E) the propylmalonyl-ACP transition for the TcsD wild type reaction  
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Figure 4-7 Activity of TcsD wild type and L83A mutant on butyryl-ACP analyzed by targeted LC-
MS/MS. WT = wild type TcsD, (-) = negative control, L83A = TcsD L83A mutant. Chromatograms 
representing different transitions are color coded (key is shown on right side of figure). The chromatograms 
shown depict: A) butyryl-ACP, B) crotonyl-ACP, or C) 3-hydroxybutyryl-ACP for each assay (negative 
control, TcsD wild type, or TcsD L83A). 
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Figure 4-8 Activity of TcsD wild type and L83A mutant on pentanoyl-ACP analyzed by targeted LC-
MS/MS. WT = wild type TcsD, (-) = negative control, L83A = TcsD L83A mutant. Chromatograms 
representing different transitions are color coded (key is shown on right side of figure). The chromatograms 
shown depict: A) pentanoyl-ACP, B) 2-pentenoyl-ACP, C) the 3-hydroxypentanoyl-ACP, or D) 2,4-
pentadienoyl-ACP for each assay (negative control, TcsD wild type, or TcsD L83A). 
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Figure 4-9 Overall structure of TcsD. A) Tetrameric structure of TcsD. Each subunit is shown in a different 
color. FAD cofactors are shown as sticks. B) A single TcsD subunit. The N-terminal α-helix domain 
(purple), middle β-sheet domain (teal), and C-terminal α-helix domain (orange) are highlighted. C) A single 
TcsD monomer colored in a progressive rainbow from its N- (blue) to C-terminus (red). Helices and sheets 
are numbered. 
  96 
 
Figure 4-10 FAD-interacting residues of TcsD. The 2Fo – Fc electron density map of FAD is shown with 
gray mesh and is contoured at 1σ. Residues that interact with FAD via hydrogen bonds are shown as sticks, 
with hydrogen bonds depicted as black dashed lines. Residues pertaining to the same subunit as FAD 
(T116, L117, G118, S119, S125, F149, T151) are shown in blue, while residues pertaining to the adjacent 
subunit (K257, D337, M338, F339, G340, G341) are shown in green.   
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Figure 4-11 Residues of ACADs that hydrogen bond with the nucleotide portion of CoA. Showing 
corresponding region in A) TcsD, B) M. esldenii butyryl-CoA dehydrogenase (1buc), C) M. esldenii butyryl-
CoA dehydrogenase overlaid with TcsD, D) Sus scrofa medium chain ACAD (1udy), E) rat short chain 
ACAD (1jqi), F) human isovaleroyl-CoA dehydrogenase (1ivh). TcsD has an Asn residue in the place of the 
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conserved Asp of α,β-ACADs. Helix 9 occupies some of the space where the nucleotide portion of CoA 
would normally bind. The conserved Thr residue is replaced with a Leu residue.  
 
Figure 4-12 CoA phosphate-binding region of acyl-CoA dehydrogenases and TcsD. Showing 
corresponding regions with the structures of: A) TcsD, B) rat short chain ACAD (1jqi), C) rat short-chain 
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ACAD overlaid with TcsD, D) M. esldenii butyryl-CoA dehydrogenase (1buc), E) Sus scrofa medium chain 
ACAD (1udy), F) human isovaleroyl-CoA dehydrogenase (1ivh). The loop that approaches the phosphate 
groups is colored in a different shade in each panel.    
 
Figure 4-13 Sequence alignment of TcsD with homologs. Structural elements noted above the alignment 
are based on the TcsD structure. Proteins included in the alignment and their Genbank accession numbers 
are: γ,δ-ACADs TcsD (ADU56309.1) and HliR (AMM72019.1), hydroxymalonate semialdehyde 
  100 
dehydrogenases asm15 (AAM54093.1), FkbI (TAI41666.1), and ZmaE (AAD40109.1), aminomalonate 
semialdehyde dehydrogenase ZmaI (AAR87758.1), and α,β-ACADs SCAD_Me (pdb 1buc), SCAD_Pp 
(NP_744365.1), SCAD_Rn (pdb 1jqi), and SCAD_Hs (pdb 2vig). Green stars denote residues that form the 
active site pocket. 
 
Figure 4-14 Web logo depicting the conservation of amino acids across a multiple sequence alignment 
of all γ,δ-ACADs identified in this work. Larger-sized letters represent higher conservation, while smaller 
letters represent less conserved amino acids. 
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Figure 4-15 Top half of phylogenetic tree and genomic contexts of γ,δ-ACADs identified in this work. 
This figure represents the top portion of the tree and connects to the bottom portion (Figure 4-16). 
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Figure 4-16 Bottom half of phylogenetic tree and genomic contexts of γ,δ-ACADs identified in this 
work. This figure represents the bottom portion of the tree and connects to the top portion (Figure 4-15). 
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Figure 4-17 Sequence alignment of TcsD with homologs, including Nmex-ACAD. Structural elements 
are based on the TcsD structure, and green stars denote residues that line the active site pocket. Proteins 
included in the alignment and their Genbank accession numbers are listed in the description for Figure 4-
13. 
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Figure 4-18 Genomic context of the Nocardia mexicana γ,δ-acyl-CoA dehydrogenase (Nmex-ACAD) and 
predicted gene products for each coding sequence.  
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Figure 4-19 Activity of Nmex-ACAD analyzed by targeted LC-MS/MS. N.mex ACAD = wild type Nmex-
ACAD, (-) = negative control. Chromatograms representing different transitions are color coded (key is 
shown on right side of figure). The chromatograms shown depict assays on the following substrates: A) 2-
heptenoyl-ACP, B) pentanoyl-ACP, or C) butyryl-ACP. For all samples, only the substrate (no product) 
was observed. 
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Table 4-1 Uncharacterized homologs of TcsD that contain characteristic γ,δ-ACAD 
motifs 
Species 
Protein GenBank 
Accession 
DNA GenBank 
Accession 
Gene cluster type 
(Antismash annotation) 
Closest 
homologous 
cluster 
(Antismash) 
Streptomyces 
kanamyceticus ADU56239.1 HM116536.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
tacrolimicus ADU56353.1 HM116538.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
tsukubensis 
VKM Ac-2618D WP_006350839.1 
NZ_SGFG0100000
8.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
sp. KCTC 
11604BP ADU56309.1 HM116537.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
tsukubensis 
NRRL 18488 WP_006350839.1 
NZ_AJSZ01000908
.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
tsukubensis 
F601 WP_077974278.1 
NZ_MVFC0100005
6.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Streptomyces 
sp. MJM7001 WP_006350839.1 HQ696504.1 N/A 
Allylmalonyl-
ACP/FK506 
(T1PKS) 
Haliangium 
ochraceum 
DSM 14365 AMM72019.1 KU523555.1 N/A 
Haliangicin 
(T1PKS) 
Nocardia 
brasiliensis 
ATCC 700358 WP_014984668.1 NC_018681.1 T1PKS 
Akaeolide 
(polyketide) 
(16%) 
Nocardia 
brasiliensis 
HUJEG-1 
isolate P-200 WP_014984668.1 
NZ_LRRM0100000
6.1 T1PKS 
Akaeolide 
(polyketide) 
(16%) 
Saccharomonos
pora saliphila 
YIM 90502 WP_019815635.1 NZ_KB912660.1 PKS-like,T1PKS 
Arsenopolyket
ides (45%) 
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Streptomyces 
sp. ADI96-15 WP_023416081.1 NZ_ML123109.1 PKS-like,T1PKS 
Arsenopolyket
ides (54%) 
Streptomyces 
sp. PVA 94-07 
WP_023416081.1/ESQ0
7377.1 NZ_CM002273.1 PKS-like,T1PKS 
Arsenopolyket
ides (58%) 
Streptomyces 
sp. Root63 WP_023416081.1 
NZ_LMGX010000
18.1 PKS-like,T1PKS 
Arsenopolyket
ides (58%) 
Streptomyces 
sp. Root1295 WP_023416081.1 
NZ_LMEL0100002
1.1 PKS-like,T1PKS 
Arsenopolyket
ides (58%) 
Streptomyces 
sp. GBA 94-10 WP_023416081.1 NZ_CM002271.1 PKS-like,T1PKS 
Arsenopolyket
ides (58%) 
Streptomyces 
sp. CB00072 WP_073868671.1 
NZ_LIPB01000003.
1 PKS-like,T1PKS 
Arsenopolyket
ides (58%) 
Millisia brevis WP_066907456.1 
NZ_BCRN0100000
7.1 NRPS,T1PKS 
Aurantimycin 
(18%) 
Pseudonocardi
a endophytica WP_132431031.1 
NZ_SMFZ0100000
2.1 NRPS,PKS-like,T1PKS 
Butyrolactol A 
(46%) 
Herbidospora 
sp. NEAU-
GS14 WP_137246715.1 
NZ_SZQA0100000
7.1 T1PKS 
Butyrolactol A 
(33%) 
Herbidospora 
yilanensis 
strain NBRC 
106371 WP_062352189.1 
NZ_BBXE0100003
0.1 NRPS,T1PKS 
Butyrolactol A 
(40%) 
Streptomyces 
sp. AmelKG-
E11A WP_099283133.1 
NZ_AQRJ0100007
0.1 T1PKS/NRPS/lassopeptide 
Butyrolactol A 
(40%) 
Streptomyces 
uncialis WP_073788609.1 
NZ_LFBV0100000
1.1 T1PKS/NRPS/lassopeptide 
Butyrolactol A 
(40%) 
Herbidospora 
cretacea strain 
NRRL B-16917 WP_030450088.1 
NZ_JODQ0100000
1.1 NRPS,T1PKS,arylpolyene 
Butyrolactol A 
(46%) 
Herbidospora 
daliensis strain 
NBRC 106372 WP_062432695.1 
NZ_BBXF01000003
.1 NRPS,T1PKS,arylpolyene 
Butyrolactol A 
(46%) 
Herbidospora 
sakaeratensis 
strain NBRC 
102641 WP_062330499.1 
NZ_BBXC0100000
7.1 NRPS,T1PKS,ladderane 
Butyrolactol A 
(46%) 
Herbidospora 
mongoliensis WP_066370148.1 
NZ_BBXD0100001
7.1 NRPS,T1PKS,ladderane 
Butyrolactol A 
(46%) 
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strain NBRC 
105882 
Alloactinosynn
ema album WP_091377637.1  T1PKS/NRPS 
Butyrolactol A 
(46%) 
Nonomuraea 
sp. PA1-10 WP_139634331 
NZ_VDLX0100001
3.1 NRPS,T1PKS 
Butyrolactol A 
(53%) 
Nonomuraea 
coxensis DSM 
45129 WP_020541001.1 NZ_KB903944.1 T1PKS 
Butyrolactol A 
(66%) 
Labedaea 
rhizosphaerae 
DSM 45361 WP_133849167.1 
NZ_SNXZ0100000
2.1 
NRPS,T1PKS,betalactone,t
ransAT-PKS-like 
Butyrolactol A 
(40%) 
Nocardia 
vulneris W9851 WP_052281359.1 
NZ_JNFP00000000
.1 T1PKS 
Chalcomycin 
(9%) 
Nocardia 
vulneris NBRC 
108936 WP_052281359.1 
NZ_BDCI01000001
.1 T1PKS 
Chalcomycin 
(9%) 
Amycolatopsis 
coloradensis WP_076160419.1 
NZ_MQUQ010000
06.1 butyrolactone 
Chlorothricin 
(4%) 
Amycolatopsis 
coloradensis WP_076160419.1 
NZ_MQUQ000000
00 
(NZ_MQUQ01000
006.1) butyrolactone 
Chlorothricin 
(4%) 
Actinocrispum 
wychmicini WP_132116054.1 
NZ_SLWS0100000
3.1 PKS-like,T1PKS 
Chlorothricin 
(48%) 
Nocardia 
suismassiliense 
S-137 WP_107655957.1 NZ_LT985361.1 NRPS,T1PKS,ladderane 
Coelimycin 
(29%) 
Nocardia 
mexicana WP_068019852.1 
NZ_QQAZ010000
01 butyrolactone/ladderane 
Colabomycin 
(4%) 
Nocardia sp. 
BMG51109 WP_024802972.1 
NZ_JAFQ0100000
4.1 T1PKS 
Stambomycin 
(40%) 
Streptomyces 
peucetius 
subsp. caesius 
ATCC 27952 WP_017584471.1 NZ_CP022438.1 T1PKS,T2PKS 
Oligomycin 
(61%) 
Actinosynnema 
mirum ATCC 
29888 WP_015803413.1 NC_013093.1 T1PKS 
Cyclizidine 
(41%) 
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Streptomyces 
puniciscabiei WP_069777509.1 NZ_CP017248.1 T1PKS E-837 (100%) 
Lechevalieria 
aerocolonigene
s WP_051784425.1 
NZ_BBOJ01000031
.1 arylpolyene,butyrolactone 
Enduracidin 
(4%) 
Saccharothrix 
sp. NRRL B-
16348 WP_053716783.1 
NZ_LGED0100012
5.1 NRPS 
Erythrochelin 
(85%) 
Saccharothrix 
carnea WP_106615758.1 
NZ_PYAX0100000
4.1 NRPS 
Erythrochelin 
(85%) 
Saccharothrix 
texasensis WP_123742396.1 
NZ_RJKM0100000
1.1 NRPS 
Erythrochelin 
(85%) 
Streptomyces 
sp. P3 WP_107448820.1 NZ_CP028369.1 
LAP,PKS-
like,T1PKS,T2PKS 
Hedamycin 
(43%) 
Kitasatospora 
griseola WP_043910458.1 
NZ_JXZB01000002
.1 
NRPS,PKS-
like,T1PKS,T2PKS 
Hedamycin 
(31%) 
Kitasatospora 
sp. CB02891 WP_100586111.1 
NZ_NNBO010000
04.1 
NRPS,PKS-
like,T1PKS,T2PKS 
Hedamycin 
(34%) 
Streptomyces 
sp. FBKL.4005 WP_059247715.1 
NZ_NPKF0100000
1.1 
LAP,PKS-
like,T1PKS,T2PKS 
Hedamycin 
(43%) 
Streptomyces 
reticuli WP_059247715.1 NZ_LN997842.1 LAP,PKS-like,T2PKS 
Hedamycin 
(46%) 
Actinocorallia 
populi strain 
A251 WP_106396532.1 
NZ_PVZV0100000
1.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(56%) 
Streptomyces 
sp. t99 WP_030720926.1 
NZ_NTGQ010000
69.1 T1PKS,T2PKS 
Hedamycin 
(59%) 
Streptomyces 
sp. st140 WP_030720926.1 
NZ_NTGS0100003
7.1 T2PKS 
Hedamycin 
(59%) 
Streptomyces 
sp. f51 WP_030720926.1 
NZ_NTHH010000
40.1 T1PKS,T2PKS 
Hedamycin 
(62%) 
Thermomonosp
ora curvata 
ATCC 19995 WP_012853108.1 NC_013510.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(81%) 
Streptomyces 
sp. ms115 WP_097947834.1 
NZ_NTHD010000
48.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
Streptomyces 
sp. b62 WP_030720926.1 
NZ_NTHK010000
12.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
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Streptomyces 
sp. f150 WP_030720926.1 
NZ_NTHG010000
36.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
Streptomyces 
griseus subsp. 
griseus NRRL 
F-5144 WP_030720926.1 
NZ_JOGA0100002
6.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
Streptomyces 
sp. gb14 WP_030720926.1 
NZ_NTHF0100002
1.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
Streptomyces 
sp. SS07 WP_030720926.1 NZ_KZ268499.1 
PKS-
like,T1PKS,T2PKS,terpene 
Hedamycin 
(87%) 
Streptomyces 
rubellomurinus 
subsp. 
indigoferus KJS54098.1 JZKG00000000.1 T1PKS 
Hedamycin 
(9%) 
Streptomyces 
sp. NRRL S-146 WP_031110854.1 
NZ_JOAW0100049
3.1 T2PKS 
Hedamycin 
(9%) 
Streptomyces 
sp. Ag82_G6-1 WP_097222862.1 
NZ_OCNA010000
01.1 PKS-like, T1PKS, T2PKS 
Hedamycin 
(90%) 
Nocardia alba 
DSM 44684 TCJ89880.1 SMFR01000008.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(25%) 
Nocardia alba 
NBRC 108234 WP_067458355.1 
NZ_BDAX0100003
3.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(25%) 
Streptomyces 
sp. NP10 WP_126932507.1 
NZ_PDIQ0100002
4.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(50%) 
Streptomyces 
sp. JS01 WP_030720926.1 
NZ_JPWW0100002
0.1 PKS-like,T1PKS,T2PKS 
Hedamycin 
(87%) 
Streptomyces 
sp. Root264 KRD19112.1 
NZ_LMIZ0100000
1 
LAP,PKS-
like,T1PKS,T2PKS 
Hedamycin 
(43%) 
Actinophytocol
a oryzae DSM 
45499 WP_133905254.1 
NZ_SOCP0100000
9.1 T1PKS 
Incednine 
(17%) 
Streptomyces 
sp. WAC 01529 WP_125514820.1 CP029617.1 T1PKS/NRPS 
Lorneic acid A 
(23%) 
uncultured 
bacterium ASV46999.1 KY560362.1 T1PKS 
Lorneic acid A 
(23%) 
Streptomyces 
oceani WP_070197325.1 
NZ_LJGU0000000
0.1 T1PKS 
Lorneic acid A 
(23%) 
Streptomyces 
puniciscabiei WP_069776466.1 NZ_CP017248.1 T1PKS,terpene 
Lorneic acid A 
(28%) 
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Streptomyces 
sp. DS1-2 WP_120696069.1 
NZ_RBDY0100000
3.1 T1PKS 
Methymycin / 
pikromycin 
(57%) 
Sorangium 
cellulosum KYF78568.1 JEMB01002769.1 T1PKS 
Micromonolac
tam (100%) 
Actinosynnema 
pretiosum 
strain X47 WP_096495686.1 NZ_CP023445.1 T1PKS 
Microtermolid
e A (33%) 
Streptomyces 
sp. CNQ-509 WP_047018908.1 NZ_CP011492.1 NRPS,PKS-like,T1PKS 
Microtermolid
e A (53%) 
Streptomyces 
sp. AZ1-7 WP_120696069.1 
NZ_RBDX0100000
2.1 T1PKS 
Nocardiopsin 
(21%) 
Catenulispora 
acidiphila DSM 
44928 WP_015795553.1 NC_013131.1 T1PKS/NRPS 
Octacosamicin 
(29%) 
Streptomyces 
sp. NRRL S-118 WP_031080613.1 NZ_KL591043.1 T1PKS 
Piericidin A1 
(58%) 
Streptomyces 
griseus subsp. 
griseus NRRL 
F-5144 WP_030723159.1 
NZ_JOGA0100004
0.1 NRPS 
Polyoxypeptin 
(40%) 
Streptomyces 
phaeoluteigrise
us strain DSM 
41896 OJT46852.1 MPOH00000000.2 NRPS,T1PKS,other 
Polyoxypeptin 
(75%) 
Streptomyces 
sp. XY006 WP_094055126.1 
NZ_NOKT010000
17.1 NRPS,other 
Polyoxypeptin 
(40%) 
Streptomyces 
sp. E5N91 s-91 WP_121712942.1 
NZ_RAIE01000715
.1 other 
Polyoxypeptin 
(40%) 
Pseudonocardi
aceae 
bacterium YIM 
PH 21723 WP_120088448.1 
NZ_QZFT0000000
0.1 T1PKS 
Pyrronazol B 
(9%) 
Nocardia 
altamirensis 
NBRC 108246 WP_069164184.1 
NZ_BDAY0100004
6.1 T1PKS 
Stambomycin 
(40%) 
Streptomyces 
sp. NRRL WC-
3742 WP_031071135.1 
NZ_JOCF01000031
.1 NRPS,T1PKS 
Lydicamycin 
(40%) 
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Kitasatospora 
azatica KCTC 
9699 WP_083976688.1 
NZ_JQMO0100000
3.1 PKS-like,T1PKS 
Zincophorin 
(61%) 
Streptomyces 
rubellomurinus 
ATCC 31215 WP_017584471.1 
NZ_JZKH0100009
0.1 N/A N/A 
Streptomyces 
albidoflavus WP_128462586.1 
NZ_QHCQ000000
00.1 
(NZ_SCDQ010000
64.1) N/A N/A 
Streptomyces 
sp. PRh5 WP_051573751.1 
NZ_JABQ0100007
1.1 N/A N/A 
Streptomyces 
sp. FXJ1.172 WP_067044802.1 
NZ_LWRP0100006
8.1 N/A N/A 
Streptomyces 
sp. AVP053U2 WP_062189972.1 
NZ_LMTQ020000
08.1 N/A N/A 
Enhygromyxa 
salina KIG11693.1 JMCC00000000.2 N/A N/A 
Streptomyces 
tricolor NRRL 
B-16925 WP_086702637.1 
NZ_MUMF000000
00.1 N/A N/A 
Streptomyces 
sp. 8K308 WP_132929808.1 
NZ_SMKC0100004
3.1 N/A N/A 
Mycobacteroide
s abscessus 
WP_079869619.1/SHS5
1726.1 
NZ_FSAT0100000
4.1 N/A N/A 
Streptomyces 
atriruber WP_055564739.1 
NZ_LIPN01000084
.1 
(NZ_SMKI0000000
0.1) N/A N/A 
Streptomyces 
hainanensis 
DSM 41900 WP_132818863.1 
NZ_SMKI0100016
2.1 N/A N/A 
Nocardiopsis 
valliformis 
DSM 45023 WP_017584471.1 
NZ_ANAZ010000
58.1 N/A N/A 
Streptomyces 
sp. E2N166 WP_121750360.1 
NZ_RAIF01000032
.1 N/A N/A 
Streptomyces 
sp. NBRC 
110035 WP_042171193.1 
NZ_BBNN0100002
7.1 N/A N/A 
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Plesiocystis 
pacifica SIR-1 
WP_006969759.1/EDM
81215.1 
NZ_ABCS0100000
5.1 transAT-PKS N/A 
Nonomuraea 
sp. SBT364 WP_049575489.1 
NZ_LAVL0100020
5.1 T1PKS N/A 
Chapter 5. References 
1. Julien, B. et al. Isolation and characterization of the epothilone biosynthetic gene 
cluster from Sorangium cellulosum. Gene 249, 153–160 (2000). 
2. Bollag, D. M. et al. Epothilones, a new class of microtubule-stabilizing agents with 
a taxol-like mechanism of action. Cancer Res. 55, 2325–2333 (1995). 
3. Luo, G., Pieper, R., Rosa, A., Khosla, C. & Cane, D. E. Erythromycin biosynthesis: 
exploiting the catalytic versatility of the modular polyketide synthase. Bioorg. Med. 
Chem. 4, 995–999 (1996). 
4. Waldron, C. et al. A cluster of genes for the biosynthesis of spinosyns, novel 
macrolide insect control agents produced by Saccharopolyspora spinosa. Antonie 
Van Leeuwenhoek 78, 385–390 (2000). 
5. Khan, N., Rawlings, B. & Caffrey, P. A labile point in mutant amphotericin 
polyketide synthases. Biotechnol. Lett. 33, 1121–1126 (2011). 
6. Weissman, K. J. & Leadlay, P. F. Combinatorial biosynthesis of reduced 
polyketides. Nat. Rev. Microbiol. 3, 925–936 (2005). 
7. Donadio, S., Staver, M. J., McAlpine, J. B., Swanson, S. J. & Katz, L. Modular 
organization of genes required for complex polyketide biosynthesis. Science 252, 
675–679 (1991). 
8. Keatinge-Clay, A. T. The structures of type I polyketide synthases. Nat Prod Rep 29, 
1050–1073 (2012). 
9. Du, L. & Lou, L. PKS and NRPS release mechanisms. Nat Prod Rep 27, 255–278 
(2010). 
10. Weissman, K. J. The structural basis for docking in modular polyketide 
biosynthesis. Chembiochem 7, 485–494 (2006). 
11. Borgos, S. E. F. et al. Probing the structure-function relationship of polyene 
macrolides: engineered biosynthesis of soluble nystatin analogues. J. Med. Chem. 
49, 2431–2439 (2006). 
12. Horsman, M. E., Hari, T. P. A. & Boddy, C. N. Polyketide synthase and non-
ribosomal peptide synthetase thioesterase selectivity: logic gate or a victim of fate? 
Nat Prod Rep 33, 183–202 (2016). 
13. Cummings, M., Breitling, R. & Takano, E. Steps towards the synthetic biology of 
polyketide biosynthesis. FEMS Microbiol. Lett. 351, 116–125 (2014). 
  114 
14. Poust, S., Hagen, A., Katz, L. & Keasling, J. D. Narrowing the gap between the 
promise and reality of polyketide synthases as a synthetic biology platform. Curr. 
Opin. Biotechnol. 30, 32–39 (2014). 
15. Rodriguez, E., Menzella, H. G. & Gramajo, H. in Complex Enzymes in Microbial 
Natural Product Biosynthesis, Part B: Polyketides, Aminocoumarins and Carbohydrates 
459, 339–365 (Elsevier, 2009). 
16. Yuzawa, S., Kim, W., Katz, L. & Keasling, J. D. Heterologous production of 
polyketides by modular type I polyketide synthases in Escherichia coli. Curr. Opin. 
Biotechnol. 23, 727–735 (2012). 
17. Stevens, D. C., Hari, T. P. A. & Boddy, C. N. The role of transcription in 
heterologous expression of polyketides in bacterial hosts. Nat Prod Rep 30, 1391–
1411 (2013). 
18. Long, P. F. et al. Engineering specificity of starter unit selection by the 
erythromycin-producing polyketide synthase. Mol. Microbiol. 43, 1215–1225 (2002). 
19. Oefner, C., Schulz, H., D’Arcy, A. & Dale, G. E. Mapping the active site of 
Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by protein 
crystallography. Acta Crystallogr. Sect. D, Biol. Crystallogr. 62, 613–618 (2006). 
20. Dutton, C. J. et al. Novel avermectins produced by mutational biosynthesis. J 
Antibiot 44, 357–365 (1991). 
21. Yuzawa, S., Eng, C. H., Katz, L. & Keasling, J. D. Broad substrate specificity of the 
loading didomain of the lipomycin polyketide synthase. Biochemistry 52, 3791–3793 
(2013). 
22. Moss, S. J. et al. Biosynthesis of the angiogenesis inhibitor borrelidin: directed 
biosynthesis of novel analogues. Chem. Commun. 2341–2343 (2006). 
doi:10.1039/b602931k 
23. Hagen, A. et al. In vitro analysis of carboxyacyl substrate tolerance in the loading 
and first extension modules of borrelidin polyketide synthase. Biochemistry 53, 
5975–5977 (2014). 
24. August, P. R. et al. Biosynthesis of the ansamycin antibiotic rifamycin: deductions 
from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis 
mediterranei S699. Chem. Biol. 5, 69–79 (1998). 
25. Schwecke, T. et al. The biosynthetic gene cluster for the polyketide 
immunosuppressant rapamycin. Proc. Natl. Acad. Sci. USA 92, 7839–7843 (1995). 
26. Traitcheva, N., Jenke-Kodama, H., He, J., Dittmann, E. & Hertweck, C. Non-
colinear polyketide biosynthesis in the aureothin and neoaureothin pathways: an 
evolutionary perspective. Chembiochem 8, 1841–1849 (2007). 
27. Trivedi, O. A. et al. Enzymic activation and transfer of fatty acids as acyl-
adenylates in mycobacteria. Nature 428, 441–445 (2004). 
  115 
28. Motamedi, H. & Shafiee, A. The biosynthetic gene cluster for the macrolactone 
ring of the immunosuppressant FK506. Eur. J. Biochem. 256, 528–534 (1998). 
29. Kuhstoss, S., Huber, M., Turner, J. R., Paschal, J. W. & Rao, R. N. Production of a 
novel polyketide through the construction of a hybrid polyketide synthase. Gene 
183, 231–236 (1996). 
30. Marsden, A. F. et al. Engineering broader specificity into an antibiotic-producing 
polyketide synthase. Science 279, 199–202 (1998). 
31. Rowe, C. J., Cortés, J., Gaisser, S., Staunton, J. & Leadlay, P. F. Construction of new 
vectors for high-level expression in actinomycetes. Gene 216, 215–223 (1998). 
32. Brautaset, T., Borgos, S. E. F., Sletta, H., Ellingsen, T. E. & Zotchev, S. B. Site-
specific mutagenesis and domain substitutions in the loading module of the 
nystatin polyketide synthase, and their effects on nystatin biosynthesis in 
Streptomyces noursei. J. Biol. Chem. 278, 14913–14919 (2003). 
33. Park, S. R., Yoo, Y. J., Ban, Y.-H. & Yoon, Y. J. Biosynthesis of rapamycin and its 
regulation: past achievements and recent progress. J Antibiot 63, 434–441 (2010). 
34. Krastel, P. et al. Nannocystin A: an Elongation Factor 1 Inhibitor from 
Myxobacteria with Differential Anti-Cancer Properties. Angew. Chem. Int. Ed. Engl. 
54, 10149–10154 (2015). 
35. Heia, S. et al. Initiation of polyene macrolide biosynthesis: interplay between 
polyketide synthase domains and modules as revealed via domain swapping, 
mutagenesis, and heterologous complementation. Appl. Environ. Microbiol. 77, 
6982–6990 (2011). 
36. Wilkinson, C. J., Frost, E. J., Staunton, J. & Leadlay, P. F. Chain initiation on the 
soraphen-producing modular polyketide synthase from Sorangium cellulosum. 
Chem. Biol. 8, 1197–1208 (2001). 
37. Hunziker, D., Yu, T.-W., Hutchinson, C. R., Floss, H. G. & Khosla, C. Primer unit 
specificity in rifamycin biosynthesis principally resides in the later stages of the 
biosynthetic pathway. J. Am. Chem. Soc. 120, 1092–1093 (1998). 
38. Dunn, B. J., Watts, K. R., Robbins, T., Cane, D. E. & Khosla, C. Comparative 
analysis of the substrate specificity of trans- versus cis-acyltransferases of 
assembly line polyketide synthases. Biochemistry 53, 3796–3806 (2014). 
39. Ruan, X. et al. Acyltransferase domain substitutions in erythromycin polyketide 
synthase yield novel erythromycin derivatives. J. Bacteriol. 179, 6416–6425 (1997). 
40. Dunn, B. J. & Khosla, C. Engineering the acyltransferase substrate specificity of 
assembly line polyketide synthases. J. R. Soc. Interface 10, 20130297 (2013). 
41. Lau, J., Fu, H., Cane, D. E. & Khosla, C. Dissecting the role of acyltransferase 
domains of modular polyketide synthases in the choice and stereochemical fate of 
extender units. Biochemistry 38, 1643–1651 (1999). 
  116 
42. Hans, M., Hornung, A., Dziarnowski, A., Cane, D. E. & Khosla, C. Mechanistic 
analysis of acyl transferase domain exchange in polyketide synthase modules. J. 
Am. Chem. Soc. 125, 5366–5374 (2003). 
43. Koryakina, I. et al. Inversion of extender unit selectivity in the erythromycin 
polyketide synthase by acyltransferase domain engineering. ACS Chem. Biol. 12, 
114–123 (2017). 
44. Musiol-Kroll, E. M. et al. Polyketide bioderivatization using the promiscuous 
acyltransferase kircii. ACS Synth. Biol. 6, 421–427 (2017). 
45. Reeves, C. D. et al. Alteration of the substrate specificity of a modular polyketide 
synthase acyltransferase domain through site-specific mutations. Biochemistry 40, 
15464–15470 (2001). 
46. Chan, Y. A., Podevels, A. M., Kevany, B. M. & Thomas, M. G. Biosynthesis of 
polyketide synthase extender units. Nat Prod Rep 26, 90–114 (2009). 
47. Tang, Y., Chen, A. Y., Kim, C.-Y., Cane, D. E. & Khosla, C. Structural and 
mechanistic analysis of protein interactions in module 3 of the 6-
deoxyerythronolide B synthase. Chem. Biol. 14, 931–943 (2007). 
48. Tang, Y., Kim, C.-Y., Mathews, I. I., Cane, D. E. & Khosla, C. The 2.7-Angstrom 
crystal structure of a 194-kDa homodimeric fragment of the 6-deoxyerythronolide 
B synthase. Proc. Natl. Acad. Sci. USA 103, 11124–11129 (2006). 
49. Haydock, S. F. et al. Divergent sequence motifs correlated with the substrate 
specificity of (methyl)malonyl-CoA:acyl carrier protein transacylase domains in 
modular polyketide synthases. FEBS Lett. 374, 246–248 (1995). 
50. Petković, H. et al. Substrate specificity of the acyl transferase domains of EpoC 
from the epothilone polyketide synthase. Org. Biomol. Chem. 6, 500–506 (2008). 
51. Jiang, H. et al. An acyltransferase domain of FK506 polyketide synthase 
recognizing both an acyl carrier protein and coenzyme A as acyl donors to transfer 
allylmalonyl and ethylmalonyl units. FEBS J. 282, 2527–2539 (2015). 
52. Ray, L. & Moore, B. S. Recent advances in the biosynthesis of unusual polyketide 
synthase substrates. Nat Prod Rep 33, 150–161 (2016). 
53. Sundermann, U. et al. Enzyme-directed mutasynthesis: a combined experimental 
and theoretical approach to substrate recognition of a polyketide synthase. ACS 
Chem. Biol. 8, 443–450 (2013). 
54. Dunn, B. J., Cane, D. E. & Khosla, C. Mechanism and specificity of an 
acyltransferase domain from a modular polyketide synthase. Biochemistry 52, 
1839–1841 (2013). 
55. Reeves, C. D. et al. Alteration of the Substrate Specificity of a Modular Polyketide 
Synthase Acyltransferase Domain through Site-Specific Mutations?. Biochemistry 
40, 15464–15470 (2001). 
  117 
56. Bravo-Rodriguez, K. et al. Substrate flexibility of a mutated acyltransferase domain 
and implications for polyketide biosynthesis. Chem. Biol. 22, 1425–1430 (2015). 
57. Koryakina, I., McArthur, J. B., Draelos, M. M. & Williams, G. J. Promiscuity of a 
modular polyketide synthase towards natural and non-natural extender units. 
Org. Biomol. Chem. 11, 4449–4458 (2013). 
58. Oliynyk, M., Brown, M. J., Cortés, J., Staunton, J. & Leadlay, P. F. A hybrid 
modular polyketide synthase obtained by domain swapping. Chem. Biol. 3, 833–
839 (1996). 
59. Liu, L., Thamchaipenet, A., Fu, H., Betlach, M. & Ashley, G. Biosynthesis of 2-Nor-
6-deoxyerythronolide B by Rationally Designed Domain Substitution. J. Am. Chem. 
Soc. 119, 10553–10554 (1997). 
60. Stassi, D. L. et al. Ethyl-substituted erythromycin derivatives produced by directed 
metabolic engineering. Proc. Natl. Acad. Sci. USA 95, 7305–7309 (1998). 
61. Petkovic, H. et al. A novel erythromycin, 6-desmethyl erythromycin D, made by 
substituting an acyltransferase domain of the erythromycin polyketide synthase. J 
Antibiot 56, 543–551 (2003). 
62. Revill, W. P. et al. Genetically engineered analogs of ascomycin for nerve 
regeneration. J. Pharmacol. Exp. Ther. 302, 1278–1285 (2002). 
63. Kato, Y. et al. Functional expression of genes involved in the biosynthesis of the 
novel polyketide chain extension unit, methoxymalonyl-acyl carrier protein, and 
engineered biosynthesis of 2-desmethyl-2-methoxy-6-deoxyerythronolide B. J. Am. 
Chem. Soc. 124, 5268–5269 (2002). 
64. Yuzawa, S., Kapur, S., Cane, D. E. & Khosla, C. Role of a conserved arginine 
residue in linkers between the ketosynthase and acyltransferase domains of 
multimodular polyketide synthases. Biochemistry 51, 3708–3710 (2012). 
65. Kapur, S., Chen, A. Y., Cane, D. E. & Khosla, C. Molecular recognition between 
ketosynthase and acyl carrier protein domains of the 6-deoxyerythronolide B 
synthase. Proc. Natl. Acad. Sci. USA 107, 22066–22071 (2010). 
66. Yuzawa, S. et al. Comprehensive in Vitro Analysis of Acyltransferase Domain 
Exchanges in Modular Polyketide Synthases and Its Application for Short-Chain 
Ketone Production. ACS Synth. Biol. 6, 139–147 (2017). 
67. Walker, M. C. et al. Expanding the fluorine chemistry of living systems using 
engineered polyketide synthase pathways. Science 341, 1089–1094 (2013). 
68. Ad, O., Thuronyi, B. W. & Chang, M. C. Y. Elucidating the mechanism of 
fluorinated extender unit loading for improved production of fluorine-containing 
polyketides. Proc. Natl. Acad. Sci. USA 114, E660–E668 (2017). 
  118 
69. Wu, K., Chung, L., Revill, W. P., Katz, L. & Reeves, C. D. The FK520 gene cluster of 
Streptomyces hygroscopicus var. ascomyceticus (ATCC 14891) contains genes for 
biosynthesis of unusual polyketide extender units. Gene 251, 81–90 (2000). 
70. Ban, Y. H., Park, S. R. & Yoon, Y. J. The biosynthetic pathway of FK506 and its 
engineering: from past achievements to future prospects. J. Ind. Microbiol. 
Biotechnol. 43, 389–400 (2016). 
71. Chan, Y. A. et al. Hydroxymalonyl-acyl carrier protein (ACP) and aminomalonyl-
ACP are two additional type I polyketide synthase extender units. Proc. Natl. Acad. 
Sci. USA 103, 14349–14354 (2006). 
72. Park, H., Kevany, B. M., Dyer, D. H., Thomas, M. G. & Forest, K. T. A polyketide 
synthase acyltransferase domain structure suggests a recognition mechanism for 
its hydroxymalonyl-acyl carrier protein substrate. PLoS One 9, e110965 (2014). 
73. Valenzano, C. R., Lawson, R. J., Chen, A. Y., Khosla, C. & Cane, D. E. The 
biochemical basis for stereochemical control in polyketide biosynthesis. J. Am. 
Chem. Soc. 131, 18501–18511 (2009). 
74. Zheng, J., Piasecki, S. K. & Keatinge-Clay, A. T. Structural studies of an A2-type 
modular polyketide synthase ketoreductase reveal features controlling α-
substituent stereochemistry. ACS Chem. Biol. 8, 1964–1971 (2013). 
75. Xie, X., Garg, A., Keatinge-Clay, A. T., Khosla, C. & Cane, D. E. Epimerase and 
reductase activities of polyketide synthase ketoreductase domains utilize the same 
conserved tyrosine and serine residues. Biochemistry 55, 1179–1186 (2016). 
76. Zheng, J., Taylor, C. A., Piasecki, S. K. & Keatinge-Clay, A. T. Structural and 
functional analysis of A-type ketoreductases from the amphotericin modular 
polyketide synthase. Structure 18, 913–922 (2010). 
77. Keatinge-Clay, A. T. A tylosin ketoreductase reveals how chirality is determined 
in polyketides. Chem. Biol. 14, 898–908 (2007). 
78. Keatinge-Clay, A. T. & Stroud, R. M. The structure of a ketoreductase determines 
the organization of the beta-carbon processing enzymes of modular polyketide 
synthases. Structure 14, 737–748 (2006). 
79. Zheng, J. & Keatinge-Clay, A. T. Structural and functional analysis of C2-type 
ketoreductases from modular polyketide synthases. J. Mol. Biol. 410, 105–117 
(2011). 
80. Bailey, C. B., Pasman, M. E. & Keatinge-Clay, A. T. Substrate structure-activity 
relationships guide rational engineering of modular polyketide synthase 
ketoreductases. Chem. Commun. 52, 792–795 (2016). 
81. Reid, R. et al. A model of structure and catalysis for ketoreductase domains in 
modular polyketide synthases. Biochemistry 42, 72–79 (2003). 
  119 
82. Bedford, D., Jacobsen, J. R., Luo, G., Cane, D. E. & Khosla, C. A functional chimeric 
modular polyketide synthase generated via domain replacement. Chem. Biol. 3, 
827–831 (1996). 
83. McDaniel, R. et al. Multiple genetic modifications of the erythromycin polyketide 
synthase to produce a library of novel “unnatural” natural products. Proc. Natl. 
Acad. Sci. USA 96, 1846–1851 (1999). 
84. Kao, C. M. et al. Alcohol Stereochemistry in Polyketide Backbones Is Controlled by 
the β-Ketoreductase Domains of Modular Polyketide Synthases. J. Am. Chem. Soc. 
120, 2478–2479 (1998). 
85. McDaniel, R., Kao, C. M., Hwang, S. J. & Khosla, C. Engineered intermodular and 
intramodular polyketide synthase fusions. Chem. Biol. 4, 667–674 (1997). 
86. Annaval, T., Paris, C., Leadlay, P. F., Jacob, C. & Weissman, K. J. Evaluating 
ketoreductase exchanges as a means of rationally altering polyketide 
stereochemistry. Chembiochem 16, 1357–1364 (2015). 
87. Eng, C. H. et al. Alteration of Polyketide Stereochemistry from anti to syn by a 
Ketoreductase Domain Exchange in a Type I Modular Polyketide Synthase 
Subunit. Biochemistry 55, 1677–1680 (2016). 
88. Keatinge-Clay, A. Crystal structure of the erythromycin polyketide synthase 
dehydratase. J. Mol. Biol. 384, 941–953 (2008). 
89. Kandziora, N. et al. Uncovering the origin of Z-configured double bonds in 
polyketides: intermediate E-double bond formation during borrelidin 
biosynthesis. Chem. Sci. 5, 3563 (2014). 
90. Gay, D., You, Y.-O., Keatinge-Clay, A. & Cane, D. E. Structure and stereospecificity 
of the dehydratase domain from the terminal module of the rifamycin polyketide 
synthase. Biochemistry 52, 8916–8928 (2013). 
91. Alhamadsheh, M. M., Palaniappan, N., Daschouduri, S. & Reynolds, K. A. 
Modular polyketide synthases and cis double bond formation: establishment of 
activated cis-3-cyclohexylpropenoic acid as the diketide intermediate in 
phoslactomycin biosynthesis. J. Am. Chem. Soc. 129, 1910–1911 (2007). 
92. Akey, D. L. et al. Crystal structures of dehydratase domains from the curacin 
polyketide biosynthetic pathway. Structure 18, 94–105 (2010). 
93. Keatinge-Clay, A. T. Stereocontrol within polyketide assembly lines. Nat Prod Rep 
33, 141–149 (2016). 
94. Caffrey, P., Lynch, S., Flood, E., Finnan, S. & Oliynyk, M. Amphotericin 
biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide 
synthase and late genes. Chem. Biol. 8, 713–723 (2001). 
  120 
95. Ikeda, H., Nonomiya, T., Usami, M., Ohta, T. & Omura, S. Organization of the 
biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in 
Streptomyces avermitilis. Proc. Natl. Acad. Sci. USA 96, 9509–9514 (1999). 
96. Brautaset, T. et al. Biosynthesis of the polyene antifungal antibiotic nystatin in 
Streptomyces noursei ATCC 11455: analysis of the gene cluster and deduction of 
the biosynthetic pathway. Chem. Biol. 7, 395–403 (2000). 
97. Sun, Y. et al. A complete gene cluster from Streptomyces nanchangensis NS3226 
encoding biosynthesis of the polyether ionophore nanchangmycin. Chem. Biol. 10, 
431–441 (2003). 
98. Zhou, Y. et al. Incomplete beta-ketone processing as a mechanism for polyene 
structural variation in the FR-008/candicidin complex. Chem. Biol. 15, 629–638 
(2008). 
99. Brautaset, T. et al. Improved antifungal polyene macrolides via engineering of the 
nystatin biosynthetic genes in Streptomyces noursei. Chem. Biol. 15, 1198–1206 
(2008). 
100. Yong, J.-H. & Byeon, W.-H. Alternative production of avermectin components in 
Streptomyces avermitilis by gene replacement. J. Microbiol. 43, 277–284 (2005). 
101. Hagen, A. et al. Engineering a polyketide synthase for in vitro production of adipic 
acid. ACS Synth. Biol. 5, 21–27 (2016). 
102. Kwan, D. H. et al. Prediction and manipulation of the stereochemistry of 
enoylreduction in modular polyketide synthases. Chem. Biol. 15, 1231–1240 (2008). 
103. Zheng, J., Gay, D. C., Demeler, B., White, M. A. & Keatinge-Clay, A. T. Divergence 
of multimodular polyketide synthases revealed by a didomain structure. Nat. 
Chem. Biol. 8, 615–621 (2012). 
104. Donadio, S., McAlpine, J. B., Sheldon, P. J., Jackson, M. & Katz, L. An 
erythromycin analog produced by reprogramming of polyketide synthesis. Proc. 
Natl. Acad. Sci. USA 90, 7119–7123 (1993). 
105. Faille, A. et al. Insights into Substrate Modification by Dehydratases from Type I 
Polyketide Synthases. J. Mol. Biol. 429, 1554–1569 (2017). 
106. Kushnir, S. et al. Minimally invasive mutagenesis gives rise to a biosynthetic 
polyketide library. Angew. Chem. Int. Ed. Engl. 51, 10664–10669 (2012). 
107. Kellenberger, L. et al. A polylinker approach to reductive loop swaps in modular 
polyketide synthases. Chembiochem 9, 2740–2749 (2008). 
108. Qi, Z. et al. Directed accumulation of less toxic pimaricin derivatives by improving 
the efficiency of a polyketide synthase dehydratase domain. Appl. Microbiol. 
Biotechnol. 101, 2427–2436 (2017). 
  121 
109. Zhang, X. et al. Construction of ivermectin producer by domain swaps of 
avermectin polyketide synthase in Streptomyces avermitilis. Appl. Microbiol. 
Biotechnol. 72, 986–994 (2006). 
110. Pinto, A., Wang, M., Horsman, M. & Boddy, C. N. 6-Deoxyerythronolide B 
synthase thioesterase-catalyzed macrocyclization is highly stereoselective. Org. 
Lett. 14, 2278–2281 (2012). 
111. Kao, C. M., Luo, G., Katz, L., Cane, D. E. & Khosla, C. Engineered biosynthesis of 
structurally diverse tetraketides by a trimodular polyketide synthase. J. Am. Chem. 
Soc. 118, 9184–9185 (1996). 
112. Kao, C. M. et al. Gain of Function Mutagenesis of the Erythromycin Polyketide 
Synthase. 2. Engineered Biosynthesis of an Eight-Membered Ring Tetraketide 
Lactone. J. Am. Chem. Soc. 119, 11339–11340 (1997). 
113. Sharma, K. K. & Boddy, C. N. The thioesterase domain from the pimaricin and 
erythromycin biosynthetic pathways can catalyze hydrolysis of simple thioester 
substrates. Bioorg. Med. Chem. Lett. 17, 3034–3037 (2007). 
114. Harper, A. D., Bailey, C. B., Edwards, A. D., Detelich, J. F. & Keatinge-Clay, A. T. 
Preparative, in vitro biocatalysis of triketide lactone chiral building blocks. 
Chembiochem 13, 2200–2203 (2012). 
115. Akey, D. L. et al. Structural basis for macrolactonization by the pikromycin 
thioesterase. Nat. Chem. Biol. 2, 537–542 (2006). 
116. Tripathi, A., Choi, S.-S., Sherman, D. H. & Kim, E.-S. Thioesterase domain 
swapping of a linear polyketide tautomycetin with a macrocyclic polyketide 
pikromycin in Streptomyces sp. CK4412. J. Ind. Microbiol. Biotechnol. 43, 1189–1193 
(2016). 
117. Gehret, J. J. et al. Terminal alkene formation by the thioesterase of curacin A 
biosynthesis: structure of a decarboxylating thioesterase. J. Biol. Chem. 286, 14445–
14454 (2011). 
118. Gu, L. et al. Polyketide decarboxylative chain termination preceded by o-
sulfonation in curacin a biosynthesis. J. Am. Chem. Soc. 131, 16033–16035 (2009). 
119. Dong, Y., Matson, J. B. & Edgar, K. J. Olefin Cross-Metathesis in Polymer and 
Polysaccharide Chemistry: A Review. Biomacromolecules 18, 1661–1676 (2017). 
120. Ciardiello, J. J. et al. An expedient strategy for the diversity-oriented synthesis of 
macrocyclic compounds with natural product-like characteristics. Tetrahedron 72, 
3567–3578 (2016). 
121. Kavanagh, K. L., Jörnvall, H., Persson, B. & Oppermann, U. Medium- and short-
chain dehydrogenase/reductase gene and protein families : the SDR superfamily: 
functional and structural diversity within a family of metabolic and regulatory 
enzymes. Cell Mol. Life Sci. 65, 3895–3906 (2008). 
  122 
122. Wyatt, M. A., Mok, M. C. Y., Junop, M. & Magarvey, N. A. Heterologous 
expression and structural characterisation of a pyrazinone natural product 
assembly line. Chembiochem 13, 2408–2415 (2012). 
123. Chhabra, A. et al. Nonprocessive [2 + 2]e- off-loading reductase domains from 
mycobacterial nonribosomal peptide synthetases. Proc. Natl. Acad. Sci. USA 109, 
5681–5686 (2012). 
124. Silakowski, B., Nordsiek, G., Kunze, B., Blöcker, H. & Müller, R. Novel features in 
a combined polyketide synthase/non-ribosomal peptide synthetase: the 
myxalamid biosynthetic gene cluster of the myxobacterium Stigmatella aurantiaca 
Sga1511This article is dedicated to Prof. Dr. E. Leistner on the occasion of his 60th 
birthday. Chem. Biol. 8, 59–69 (2001). 
125. Barajas, J. F. et al. Comprehensive structural and biochemical analysis of the 
terminal myxalamid reductase domain for the engineered production of primary 
alcohols. Chem. Biol. 22, 1018–1029 (2015). 
126. Jin, C., Yao, M., Liu, H., Lee, C. F. & Ji, J. Progress in the production and 
application of n-butanol as a biofuel. Renewable and Sustainable Energy Reviews 15, 
4080–4106 (2011). 
127. Dorival, J. et al. Characterization of Intersubunit Communication in the 
Virginiamycin trans-Acyl Transferase Polyketide Synthase. J. Am. Chem. Soc. 138, 
4155–4167 (2016). 
128. Whicher, J. R. et al. Cyanobacterial polyketide synthase docking domains: a tool for 
engineering natural product biosynthesis. Chem. Biol. 20, 1340–1351 (2013). 
129. Buchholz, T. J. et al. Structural basis for binding specificity between subclasses of 
modular polyketide synthase docking domains. ACS Chem. Biol. 4, 41–52 (2009). 
130. Gokhale, R. S., Tsuji, S. Y., Cane, D. E. & Khosla, C. Dissecting and exploiting 
intermodular communication in polyketide synthases. Science 284, 482–485 (1999). 
131. Wu, N., Cane, D. E. & Khosla, C. Quantitative analysis of the relative contributions 
of donor acyl carrier proteins, acceptor ketosynthases, and linker regions to 
intermodular transfer of intermediates in hybrid polyketide synthases. 
Biochemistry 41, 5056–5066 (2002). 
132. Menzella, H. G. et al. Combinatorial polyketide biosynthesis by de novo design 
and rearrangement of modular polyketide synthase genes. Nat. Biotechnol. 23, 
1171–1176 (2005). 
133. Klaus, M. et al. Protein-Protein Interactions, Not Substrate Recognition, Dominate 
the Turnover of Chimeric Assembly Line Polyketide Synthases. J. Biol. Chem. 291, 
16404–16415 (2016). 
  123 
134. Kennedy, J. Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: 
combining synthetic chemistry and biosynthetic engineering for diversifying 
natural products. Nat Prod Rep 25, 25–34 (2008). 
135. Mehlhorn, H., Jones, H. L., Weatherley, A. J. & Schumacher, B. Doramectin, a new 
avermectin highly efficacious against gastrointestinal nematodes and lungworms 
of cattle and pigs: two studies carried out under field conditions in Germany. 
Parasitol. Res. 79, 603–607 (1993). 
136. Cropp, T. A., Wilson, D. J. & Reynolds, K. A. Identification of a cyclohexylcarbonyl 
CoA biosynthetic gene cluster and application in the production of doramectin. 
Nat. Biotechnol. 18, 980–983 (2000). 
137. Zhao, X. et al. Construction of a doramectin producer mutant from an avermectin-
overproducing industrial strain of Streptomyces avermitilis. Can. J. Microbiol. 55, 
1355–1363 (2009). 
138. Werneburg, M. et al. Exploiting enzymatic promiscuity to engineer a focused 
library of highly selective antifungal and antiproliferative aureothin analogues. J. 
Am. Chem. Soc. 132, 10407–10413 (2010). 
139. Lowden, P. A. S., Böhm, G. A., Metcalfe, S., Staunton, J. & Leadlay, P. F. New 
rapamycin derivatives by precursor-directed biosynthesis. Chembiochem 5, 535–538 
(2004). 
140. Sheehan, L. S. et al. Engineering of the spinosyn PKS: directing starter unit 
incorporation. J. Nat. Prod. 69, 1702–1710 (2006). 
141. Lee, H. Y., Harvey, C. J. B., Cane, D. E. & Khosla, C. Improved precursor-directed 
biosynthesis in E. coli via directed evolution. J Antibiot 64, 59–64 (2011). 
142. Kibwage, I. O. et al. Identification of novel erythromycin derivatives in mother 
liquor concentrates of Streptomyces erythraeus. J Antibiot 40, 1–6 (1987). 
143. Oliynyk, M. et al. Analysis of the biosynthetic gene cluster for the polyether 
antibiotic monensin in Streptomyces cinnamonensis and evidence for the role of 
monB and monC genes in oxidative cyclization. Mol. Microbiol. 49, 1179–1190 
(2003). 
144. Bhatt, A. et al. Accumulation of an E,E,E-triene by the monensin-producing 
polyketide synthase when oxidative cyclization is blocked. Angew. Chem. Int. Ed. 
Engl. 44, 7075–7078 (2005). 
145. Bravo-Rodriguez, K. et al. Predicted incorporation of non-native substrates by a 
polyketide synthase yields bioactive natural product derivatives. Chembiochem 15, 
1991–1997 (2014). 
146. Eustáquio, A. S. et al. Biosynthesis of the salinosporamide A polyketide synthase 
substrate chloroethylmalonyl-coenzyme A from S-adenosyl-L-methionine. Proc. 
Natl. Acad. Sci. USA 106, 12295–12300 (2009). 
  124 
147. Eustáquio, A. S. & Moore, B. S. Mutasynthesis of fluorosalinosporamide, a potent 
and reversible inhibitor of the proteasome. Angew. Chem. Int. Ed. Engl. 47, 3936–
3938 (2008). 
148. Eustáquio, A. S., O’Hagan, D. & Moore, B. S. Engineering fluorometabolite 
production: fluorinase expression in Salinispora tropica Yields 
Fluorosalinosporamide. J. Nat. Prod. 73, 378–382 (2010). 
149. Ye, Z., Musiol, E. M., Weber, T. & Williams, G. J. Reprogramming acyl carrier 
protein interactions of an Acyl-CoA promiscuous trans-acyltransferase. Chem. Biol. 
21, 636–646 (2014). 
150. Koryakina, I. et al. Poly specific trans-acyltransferase machinery revealed via 
engineered acyl-CoA synthetases. ACS Chem. Biol. 8, 200–208 (2013). 
151. Koryakina, I. & Williams, G. J. Mutant malonyl-CoA synthetases with altered 
specificity for polyketide synthase extender unit generation. Chembiochem 12, 2289–
2293 (2011). 
152. Rokem, J. S., Lantz, A. E. & Nielsen, J. Systems biology of antibiotic production by 
microorganisms. Nat Prod Rep 24, 1262–1287 (2007). 
153. Olano, C., Lombó, F., Méndez, C. & Salas, J. A. Improving production of bioactive 
secondary metabolites in actinomycetes by metabolic engineering. Metab. Eng. 10, 
281–292 (2008). 
154. Li, R. & Townsend, C. A. Rational strain improvement for enhanced clavulanic 
acid production by genetic engineering of the glycolytic pathway in Streptomyces 
clavuligerus. Metab. Eng. 8, 240–252 (2006). 
155. Zabala, D., Braña, A. F., Flórez, A. B., Salas, J. A. & Méndez, C. Engineering 
precursor metabolite pools for increasing production of antitumor mithramycins 
in Streptomyces argillaceus. Metab. Eng. 20, 187–197 (2013). 
156. Zhang, H., Boghigian, B. A. & Pfeifer, B. A. Investigating the role of native 
propionyl-CoA and methylmalonyl-CoA metabolism on heterologous polyketide 
production in Escherichia coli. Biotechnol. Bioeng. 105, 567–573 (2010). 
157. Vandova, G. A. et al. Heterologous expression of diverse propionyl-CoA 
carboxylases affects polyketide production in Escherichia coli. J Antibiot 70, 859–
863 (2017). 
158. Arabolaza, A. et al. Crystal structures and mutational analyses of acyl-CoA 
carboxylase beta subunit of Streptomyces coelicolor. Biochemistry 49, 7367–7376 
(2010). 
159. Ray, L. et al. A crotonyl-CoA reductase-carboxylase independent pathway for 
assembly of unusual alkylmalonyl-CoA polyketide synthase extender units. Nat. 
Commun. 7, 13609 (2016). 
  125 
160. Rodriguez, E. et al. Engineered biosynthesis of 16-membered macrolides that 
require methoxymalonyl-ACP precursors in Streptomyces fradiae. Appl. Microbiol. 
Biotechnol. 66, 85–91 (2004). 
161. Lu, C., Zhang, X., Jiang, M. & Bai, L. Enhanced salinomycin production by 
adjusting the supply of polyketide extender units in Streptomyces albus. Metab. 
Eng. 35, 129–137 (2016). 
162. Bunet, R. et al. A single Sfp-type phosphopantetheinyl transferase plays a major 
role in the biosynthesis of PKS and NRPS derived metabolites in Streptomyces 
ambofaciens ATCC23877. PLoS One 9, e87607 (2014). 
163. Chen, X.-H. et al. Structural and functional characterization of three polyketide 
synthase gene clusters in Bacillus amyloliquefaciens FZB 42. J. Bacteriol. 188, 4024–
4036 (2006). 
164. Volokhan, O., Sletta, H., Sekurova, O. N., Ellingsen, T. E. & Zotchev, S. B. An 
unexpected role for the putative 4’-phosphopantetheinyl transferase-encoding 
gene nysF in the regulation of nystatin biosynthesis in Streptomyces noursei 
ATCC 11455. FEMS Microbiol. Lett. 249, 57–64 (2005). 
165. Beld, J., Sonnenschein, E. C., Vickery, C. R., Noel, J. P. & Burkart, M. D. The 
phosphopantetheinyl transferases: catalysis of a post-translational modification 
crucial for life. Nat Prod Rep 31, 61–108 (2014). 
166. Quadri, L. E. et al. Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl 
transferase for peptidyl carrier protein domains in peptide synthetases. 
Biochemistry 37, 1585–1595 (1998). 
167. Peypoux, F., Bonmatin, J. M. & Wallach, J. Recent trends in the biochemistry of 
surfactin. Appl. Microbiol. Biotechnol. 51, 553–563 (1999). 
168. Pfeifer, B. A., Admiraal, S. J., Gramajo, H., Cane, D. E. & Khosla, C. Biosynthesis of 
complex polyketides in a metabolically engineered strain of E. coli. Science 291, 
1790–1792 (2001). 
169. Murli, S., Kennedy, J., Dayem, L. C., Carney, J. R. & Kealey, J. T. Metabolic 
engineering of Escherichia coli for improved 6-deoxyerythronolide B production. 
J. Ind. Microbiol. Biotechnol. 30, 500–509 (2003). 
170. Mutka, S. C., Bondi, S. M., Carney, J. R., Da Silva, N. A. & Kealey, J. T. Metabolic 
pathway engineering for complex polyketide biosynthesis in Saccharomyces 
cerevisiae. FEMS Yeast Res 6, 40–47 (2006). 
171. Kealey, J. T., Liu, L., Santi, D. V., Betlach, M. C. & Barr, P. J. Production of a 
polyketide natural product in nonpolyketide-producing prokaryotic and 
eukaryotic hosts. Proc. Natl. Acad. Sci. USA 95, 505–509 (1998). 
172. Mootz, H. D., SchÃ¶rgendorfer, K. & Marahiel, M. A. Functional characterization 
of 4â€2-phosphopantetheinyl transferase genes of bacterial and fungal origin by 
  126 
complementation ofSaccharomyces cerevisiae lys5. FEMS Microbiol. Lett. 213, 51–57 
(2002). 
173. Zobel, S., Kumpfmüller, J., Süssmuth, R. D. & Schweder, T. Bacillus subtilis as 
heterologous host for the secretory production of the non-ribosomal 
cyclodepsipeptide enniatin. Appl. Microbiol. Biotechnol. 99, 681–691 (2015). 
174. Kumpfmüller, J. et al. Production of the polyketide 6-deoxyerythronolide B in the 
heterologous host Bacillus subtilis. Appl. Microbiol. Biotechnol. 100, 1209–1220 
(2016). 
175. Sánchez, C., Du, L., Edwards, D. J., Toney, M. D. & Shen, B. Cloning and 
characterization of a phosphopantetheinyl transferase from Streptomyces 
verticillus ATCC15003, the producer of the hybrid peptide-polyketide antitumor 
drug bleomycin. Chem. Biol. 8, 725–738 (2001). 
176. Baltz, R. H. Streptomyces and Saccharopolyspora hosts for heterologous 
expression of secondary metabolite gene clusters. J. Ind. Microbiol. Biotechnol. 37, 
759–772 (2010). 
177. Jiang, H. et al. Improvement of natamycin production by engineering of 
phosphopantetheinyl transferases in Streptomyces chattanoogensis L10. Appl. 
Environ. Microbiol. 79, 3346–3354 (2013). 
178. Zhang, B. et al. Activation of natural products biosynthetic pathways via a protein 
modification level regulation. ACS Chem. Biol. 12, 1732–1736 (2017). 
179. Stratigopoulos, G., Gandecha, A. R. & Cundliffe, E. Regulation of tylosin 
production and morphological differentiation in Streptomyces fradiae by TylP, a 
deduced gamma-butyrolactone receptor. Mol. Microbiol. 45, 735–744 (2002). 
180. Stratigopoulos, G., Bate, N. & Cundliffe, E. Positive control of tylosin biosynthesis: 
pivotal role of TylR. Mol. Microbiol. 54, 1326–1334 (2004). 
181. Garcia-Bernardo, J., Braña, A. F., Méndez, C. & Salas, J. A. Insertional inactivation 
of mtrX and mtrY genes from the mithramycin gene cluster affects production and 
growth of the producer organism Streptomyces argillaceus. FEMS Microbiol. Lett. 
186, 61–65 (2000). 
182. Lombó, F., Braña, A. F., Méndez, C. & Salas, J. A. The mithramycin gene cluster of 
Streptomyces argillaceus contains a positive regulatory gene and two repeated 
DNA sequences that are located at both ends of the cluster. J. Bacteriol. 181, 642–
647 (1999). 
183. Song, K. et al. Engineering of the LysR family transcriptional regulator FkbR1 and 
its target gene to improve ascomycin production. Appl. Microbiol. Biotechnol. 101, 
4581–4592 (2017). 
184. Stratigopoulos, G. & Cundliffe, E. Expression analysis of the tylosin-biosynthetic 
gene cluster: pivotal regulatory role of the tylQ product. Chem. Biol. 9, 71–78 (2002). 
  127 
185. Shao, Z. et al. Refactoring the silent spectinabilin gene cluster using a plug-and-
play scaffold. ACS Synth. Biol. 2, 662–669 (2013). 
186. Basitta, P. et al. AGOS: A Plug-and-Play Method for the Assembly of Artificial 
Gene Operons into Functional Biosynthetic Gene Clusters. ACS Synth. Biol. 6, 817–
825 (2017). 
187. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome 
engineering with CRISPR-Cas9. Science 346, 1258096 (2014). 
188. Zhang, M. M., Wang, Y., Ang, E. L. & Zhao, H. Engineering microbial hosts for 
production of bacterial natural products. Nat Prod Rep 33, 963–987 (2016). 
189. Huang, H., Zheng, G., Jiang, W., Hu, H. & Lu, Y. One-step high-efficiency 
CRISPR/Cas9-mediated genome editing in Streptomyces. Acta Biochim. Biophys. 
Sin. (Shanghai) 47, 231–243 (2015). 
190. Cobb, R. E., Wang, Y. & Zhao, H. High-efficiency multiplex genome editing of 
Streptomyces species using an engineered CRISPR/Cas system. ACS Synth. Biol. 4, 
723–728 (2015). 
191. Zhang, M. M. et al. CRISPR-Cas9 strategy for activation of silent Streptomyces 
biosynthetic gene clusters. Nat. Chem. Biol. (2017). doi:10.1038/nchembio.2341 
192. Khosla, C., Tang, Y., Chen, A. Y., Schnarr, N. A. & Cane, D. E. Structure and 
mechanism of the 6-deoxyerythronolide B synthase. Annu. Rev. Biochem. 76, 195–
221 (2007). 
193. Yan, J., Hazzard, C., Bonnett, S. A. & Reynolds, K. A. Functional modular 
dissection of DEBS1-TE changes triketide lactone ratios and provides insight into 
Acyl group loading, hydrolysis, and ACP transfer. Biochemistry 51, 9333–9341 
(2012). 
194. Kao, C. M., Katz, L. & Khosla, C. Engineered biosynthesis of a complete 
macrolactone in a heterologous host. Science 265, 509–512 (1994). 
195. Hertweck, C. Decoding and reprogramming complex polyketide assembly lines: 
prospects for synthetic biology. Trends Biochem. Sci. 40, 189–199 (2015). 
196. Licona-Cassani, C. et al. Systems biology approaches to understand natural 
products biosynthesis. Front. Bioeng. Biotechnol. 3, 199 (2015). 
197. Pérez-Victoria, I., Martín, J. & Reyes, F. Combined LC/UV/MS and NMR strategies 
for the dereplication of marine natural products. Planta Med. 82, 857–871 (2016). 
198. Covington, B. C., McLean, J. A. & Bachmann, B. O. Comparative mass 
spectrometry-based metabolomics strategies for the investigation of microbial 
secondary metabolites. Nat Prod Rep 34, 6–24 (2017). 
199. Hoffmann, T., Krug, D., Hüttel, S. & Müller, R. Improving natural products 
identification through targeted LC-MS/MS in an untargeted secondary 
metabolomics workflow. Anal. Chem. 86, 10780–10788 (2014). 
  128 
200. Rogers, J. K. et al. Synthetic biosensors for precise gene control and real-time 
monitoring of metabolites. Nucleic Acids Res. 43, 7648–7660 (2015). 
201. Tremblay, N., Hill, P., Conway, K. R. & Boddy, C. N. The use of clustermine360 for 
the analysis of polyketide and nonribosomal peptide biosynthetic pathways. 
Methods Mol. Biol. 1401, 233–252 (2016). 
202. Khater, S. et al. SBSPKSv2: structure-based sequence analysis of polyketide 
synthases and non-ribosomal peptide synthetases. Nucleic Acids Res. 45, W72–W79 
(2017). 
203. Ichikawa, N. et al. DoBISCUIT: a database of secondary metabolite biosynthetic 
gene clusters. Nucleic Acids Res. 41, D408–14 (2013). 
204. Blin, K. et al. antiSMASH 4.0-improvements in chemistry prediction and gene 
cluster boundary identification. Nucleic Acids Res. 45, W36–W41 (2017). 
205. Conway, K. R. & Boddy, C. N. ClusterMine360: a database of microbial PKS/NRPS 
biosynthesis. Nucleic Acids Res. 41, D402–7 (2013). 
206. Medema, M. H. et al. Minimum Information about a Biosynthetic Gene cluster. 
Nat. Chem. Biol. 11, 625–631 (2015). 
207. Newman, D. J. & Cragg, G. M. Natural Products as Sources of New Drugs from 
1981 to 2014. J. Nat. Prod. 79, 629–661 (2016). 
208. Dias, D. A., Urban, S. & Roessner, U. A historical overview of natural products in 
drug discovery. Metabolites 2, 303–336 (2012). 
209. Scott, T. A. & Piel, J. The hidden enzymology of bacterial natural product 
biosynthesis. Nat. Rev. Chem. (2019). doi:10.1038/s41570-019-0107-1 
210. Minowa, Y., Araki, M. & Kanehisa, M. Comprehensive analysis of distinctive 
polyketide and nonribosomal peptide structural motifs encoded in microbial 
genomes. J. Mol. Biol. 368, 1500–1517 (2007). 
211. Waldron, C. et al. Cloning and analysis of the spinosad biosynthetic gene cluster of 
Saccharopolyspora spinosa. Chem. Biol. 8, 487–499 (2001). 
212. Copéret, C., Adolfsson, H. & Barry Sharpless, K. A simple and efficient method for 
epoxidation of terminal alkenes. Chem. Commun. 1565–1566 (1997). 
doi:10.1039/a703542j 
213. Mlynarski, S. N., Schuster, C. H. & Morken, J. P. Asymmetric synthesis from 
terminal alkenes by cascades of diboration and cross-coupling. Nature 505, 386–390 
(2014). 
214. Becker, H. & Sharpless, K. B. A new ligand class for the asymmetric 
dihydroxylation of olefins. Angew. Chem. Int. Ed. Engl. 35, 448–451 (1996). 
215. Xu, J. et al. Copper-catalyzed trifluoromethylation of terminal alkenes through 
allylic C-H bond activation. J. Am. Chem. Soc. 133, 15300–15303 (2011). 
  129 
216. Breit, B. & Seiche, W. Hydrogen bonding as a construction element for bidentate 
donor ligands in homogeneous catalysis: regioselective hydroformylation of 
terminal alkenes. J. Am. Chem. Soc. 125, 6608–6609 (2003). 
217. Urkalan, K. B. & Sigman, M. S. Palladium-catalyzed oxidative intermolecular 
difunctionalization of terminal alkenes with organostannanes and molecular 
oxygen. Angew. Chem. Int. Ed. Engl. 48, 3146–3149 (2009). 
218. Rucker, R. P., Whittaker, A. M., Dang, H. & Lalic, G. Synthesis of tertiary alkyl 
amines from terminal alkenes: copper-catalyzed amination of alkyl boranes. J. Am. 
Chem. Soc. 134, 6571–6574 (2012). 
219. Coombs, J. R. & Morken, J. P. Catalytic enantioselective functionalization of 
unactivated terminal alkenes. Angew. Chem. Int. Ed. Engl. 55, 2636–2649 (2016). 
220. Nishimura, T., Kakiuchi, N., Onoue, T., Ohe, K. & Uemura, S. Palladium(II)-
catalyzed oxidation of terminal alkenes to methyl ketones using molecular oxygen. 
J. Chem. Soc., Perkin Trans. 1 1915–1918 (2000). doi:10.1039/b001854f 
221. Jensen, C. M. & Trogler, W. C. Catalytic hydration of terminal alkenes to primary 
alcohols. Science 233, 1069–1071 (1986). 
222. Du, X. & Huang, Z. Advances in Base-Metal-Catalyzed Alkene Hydrosilylation. 
ACS Catal. 7, 1227–1243 (2017). 
223. Fürstner, A. Olefin metathesis and beyond. Angew. Chem. Int. Ed. 39, 3012–3043 
(2000). 
224. Buslov, I., Becouse, J., Mazza, S., Montandon-Clerc, M. & Hu, X. Chemoselective 
alkene hydrosilylation catalyzed by nickel pincer complexes. Angew. Chem. Int. Ed. 
Engl. 54, 14523–14526 (2015). 
225. Cannon, J. S. & Grubbs, R. H. Alkene chemoselectivity in ruthenium-catalyzed Z-
selective olefin metathesis. Angew. Chem. Int. Ed. Engl. 52, 9001–9004 (2013). 
226. Cristina Silva Costa, D. Additions to non-activated alkenes: Recent advances. 
Arabian Journal of Chemistry (2017). doi:10.1016/j.arabjc.2017.07.017 
227. Chatterjee, A. K., Choi, T.-L., Sanders, D. P. & Grubbs, R. H. A general model for 
selectivity in olefin cross metathesis. J. Am. Chem. Soc. 125, 11360–11370 (2003). 
228. O’Leary, D. J., Blackwell, H. E., Washenfelder, R. A. & Grubbs, R. H. A new 
method for cross-metathesis of terminal olefins. Tetrahedron Lett. 39, 7427–7430 
(1998). 
229. Andrus, M. B., Lepore, S. D. & Sclafani, J. A. Selective dihydroxylation of non-
conjugated dienes in favor of the terminal olefin. Tetrahedron Lett. 38, 4043–4046 
(1997). 
230. Campbell, A. N., White, P. B., Guzei, I. A. & Stahl, S. S. Allylic C-H acetoxylation 
with a 4,5-diazafluorenone-ligated palladium catalyst: a ligand-based strategy to 
achieve aerobic catalytic turnover. J. Am. Chem. Soc. 132, 15116–15119 (2010). 
  130 
231. Bigi, M. A. & White, M. C. Terminal olefins to linear α,β-unsaturated ketones: 
Pd(II)/hypervalent iodine co-catalyzed Wacker oxidation-dehydrogenation. J. Am. 
Chem. Soc. 135, 7831–7834 (2013). 
232. Dong, G., Teo, P., Wickens, Z. K. & Grubbs, R. H. Primary alcohols from terminal 
olefins: formal anti-Markovnikov hydration via triple relay catalysis. Science 333, 
1609–1612 (2011). 
233. Klar, U. et al. Total synthesis and antitumor activity of ZK-EPO: the first fully 
synthetic epothilone in clinical development. Angew. Chem. Int. Ed. Engl. 45, 7942–
7948 (2006). 
234. Klar, U., Hoffmann, J. & Giurescu, M. Sagopilone (ZK-EPO): from a natural 
product to a fully synthetic clinical development candidate. Expert Opin. Investig. 
Drugs 17, 1735–1748 (2008). 
235. Kino, T. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. 
Fermentation, isolation, and physico-chemical and biological characteristics. J 
Antibiot 40, 1249–1255 (1987). 
236. Mitsuhashi, S. et al. Tautomycetin is a novel and specific inhibitor of 
serine/threonine protein phosphatase type 1, PP1. Biochem. Biophys. Res. Commun. 
287, 328–331 (2001). 
237. Fudou, R., Iizuka, T. & Yamanaka, S. Haliangicin, a novel antifungal metabolite 
produced by a marine myxobacterium. 1. Fermentation and biological 
characteristics. J Antibiot 54, 149–152 (2001). 
238. Scaglione, J. B. et al. Biochemical and structural characterization of the 
tautomycetin thioesterase: analysis of a stereoselective polyketide hydrolase. 
Angew. Chem. Int. Ed. Engl. 49, 5726–5730 (2010). 
239. Li, W. et al. Characterization of the tautomycetin biosynthetic gene cluster from 
Streptomyces griseochromogenes provides new insight into dialkylmaleic 
anhydride biosynthesis. J. Nat. Prod. 72, 450–459 (2009). 
240. Sun, Y. et al. Heterologous production of the marine myxobacterial antibiotic 
haliangicin and its unnatural analogues generated by engineering of the 
biochemical pathway. Sci. Rep. 6, 22091 (2016). 
241. Mo, S. et al. Biosynthesis of the allylmalonyl-CoA extender unit for the FK506 
polyketide synthase proceeds through a dedicated polyketide synthase and 
facilitates the mutasynthesis of analogues. J. Am. Chem. Soc. 133, 976–985 (2011). 
242. Ghisla, S. & Thorpe, C. Acyl-CoA dehydrogenases. A mechanistic overview. Eur. J. 
Biochem. 271, 494–508 (2004). 
243. Fendrich, G. & Abeles, R. H. Mechanism of action of butyryl-CoA dehydrogenase: 
reactions with acetylenic, olefinic, and fluorinated substrate analogues. 
Biochemistry 21, 6685–6695 (1982). 
  131 
244. Powell, P. J. & Thorpe, C. 2-octynoyl coenzyme A is a mechanism-based inhibitor 
of pig kidney medium-chain acyl coenzyme A dehydrogenase: isolation of the 
target peptide. Biochemistry 27, 8022–8028 (1988). 
245. Kim, J. J., Wang, M. & Paschke, R. Crystal structures of medium-chain acyl-CoA 
dehydrogenase from pig liver mitochondria with and without substrate. Proc. Natl. 
Acad. Sci. USA 90, 7523–7527 (1993). 
246. Ghisla, S., Thorpe, C. & Massey, V. Mechanistic studies with general acyl-CoA 
dehydrogenase and butyryl-CoA dehydrogenase: evidence for the transfer of the 
beta-hydrogen to the flavin N(5)-position as a hydride. Biochemistry 23, 3154–3161 
(1984). 
247. Trievel, R. C., Wang, R., Anderson, V. E. & Thorpe, C. Role of the carbonyl group 
in thioester chain length recognition by the medium chain acyl-CoA 
dehydrogenase. Biochemistry 34, 8597–8605 (1995). 
248. Mancini-Samuelson, G. J., Kieweg, V., Sabaj, K. M., Ghisla, S. & Stankovich, M. T. 
Redox properties of human medium-chain acyl-CoA dehydrogenase, modulation 
by charged active-site amino acid residues. Biochemistry 37, 14605–14612 (1998). 
249. Becker, D. F., Fuchs, J. A. & Stankovich, M. T. Product binding modulates the 
thermodynamic properties of a Megasphaera elsdenii short-chain acyl-CoA 
dehydrogenase active-site mutant. Biochemistry 33, 7082–7087 (1994). 
250. Vock, P., Engst, S., Eder, M. & Ghisla, S. Substrate activation by acyl-CoA 
dehydrogenases: transition-state stabilization and pKs of involved functional 
groups. Biochemistry 37, 1848–1860 (1998). 
251. Engst, S., Vock, P., Wang, M., Kim, J. J. & Ghisla, S. Mechanism of activation of 
acyl-CoA substrates by medium chain acyl-CoA dehydrogenase: interaction of the 
thioester carbonyl with the flavin adenine dinucleotide ribityl side chain. 
Biochemistry 38, 257–267 (1999). 
252. Lau, S. M., Brantley, R. K. & Thorpe, C. The reductive half-reaction in Acyl-CoA 
dehydrogenase from pig kidney: studies with thiaoctanoyl-CoA and oxaoctanoyl-
CoA analogues. Biochemistry 27, 5089–5095 (1988). 
253. Stankovich, M. T., Sabaj, K. M. & Tonge, P. J. Structure/function of medium chain 
acyl-CoA dehydrogenase: the importance of substrate polarization. Arch. Biochem. 
Biophys. 370, 16–21 (1999). 
254. Lehman, T. C., Hale, D. E., Bhala, A. & Thorpe, C. An acyl-coenzyme a 
dehydrogenase assay utilizing the ferricenium ion. Anal. Biochem. 186, 280–284 
(1990). 
255. Dorrestein, P. C. et al. Facile detection of acyl and peptidyl intermediates on 
thiotemplate carrier domains via phosphopantetheinyl elimination reactions 
during tandem mass spectrometry. Biochemistry 45, 12756–12766 (2006). 
  132 
256. Cummings, J. G. & Thorpe, C. 3-Methyleneoctanoyl-CoA and 3-methyl-trans-2-
octenoyl-CoA: two new mechanism-based inhibitors of medium chain acyl-CoA 
dehydrogenase from pig kidney. Biochemistry 33, 788–797 (1994). 
257. Satoh, A. et al. Structure of the transition state analog of medium-chain acyl-CoA 
dehydrogenase. Crystallographic and molecular orbital studies on the charge-
transfer complex of medium-chain acyl-CoA dehydrogenase with 3-thiaoctanoyl-
CoA. J. Biochem. 134, 297–304 (2003). 
258. Battaile, K. P. et al. Crystal structure of rat short chain acyl-CoA dehydrogenase 
complexed with acetoacetyl-CoA: comparison with other acyl-CoA 
dehydrogenases. J. Biol. Chem. 277, 12200–12207 (2002). 
259. Djordjevic, S., Pace, C. P., Stankovich, M. T. & Kim, J. J. Three-dimensional 
structure of butyryl-CoA dehydrogenase from Megasphaera elsdenii. Biochemistry 
34, 2163–2171 (1995). 
260. Watanabe, K., Khosla, C., Stroud, R. M. & Tsai, S. C. Crystal structure of an Acyl-
ACP dehydrogenase from the FK520 polyketide biosynthetic pathway: insights 
into extender unit biosynthesis. J. Mol. Biol. 334, 435–444 (2003). 
261. McMahon, B., Gallagher, M. E. & Mayhew, S. G. The protein coded by the PP2216 
gene of Pseudomonas putida KT2440 is an acyl-CoA dehydrogenase that oxidises 
only short-chain aliphatic substrates. FEMS Microbiol. Lett. 250, 121–127 (2005). 
262. Cruz-Morales, P. et al. Actinobacteria phylogenomics, selective isolation from an 
iron oligotrophic environment and siderophore functional characterization, unveil 
new desferrioxamine traits. FEMS Microbiol. Ecol. 93, (2017). 
263. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local 
alignment search tool. J. Mol. Biol. 215, 403–410 (1990). 
264. Finn, R. D., Clements, J. & Eddy, S. R. HMMER web server: interactive sequence 
similarity searching. Nucleic Acids Res. 39, W29–37 (2011). 
265. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred 
kilobases. Nat. Methods 6, 343–345 (2009). 
266. Engler, C., Gruetzner, R., Kandzia, R. & Marillonnet, S. Golden gate shuffling: a 
one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS One 4, 
e5553 (2009). 
267. Oberortner, E., Cheng, J.-F., Hillson, N. J. & Deutsch, S. Streamlining the Design-
to-Build Transition with Build-Optimization Software Tools. ACS Synth. Biol. 6, 
485–496 (2017). 
268. Jancarik, J. & Kim, S. H. Sparse matrix sampling: a screening method for 
crystallization of proteins. J Appl Crystallogr 24, 409–411 (1991). 
269. McCoy, A. J. et al. Phaser crystallographic software. J Appl Crystallogr 40, 658–674 
(2007). 
  133 
270. Afonine, P. V. et al. Towards automated crystallographic structure refinement with 
phenix.refine. Acta Crystallogr. Sect. D, Biol. Crystallogr. 68, 352–367 (2012). 
271. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta 
Crystallogr. Sect. D, Biol. Crystallogr. 60, 2126–2132 (2004). 
272. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for 
macromolecular structure solution. Acta Crystallogr. Sect. D, Biol. Crystallogr. 66, 
213–221 (2010). 
273. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for 
proteins and nucleic acids. Nucleic Acids Res. 35, W375–83 (2007). 
274. The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.' '           . at 
<https://pymol.org/2/> 
275. Mishra, P. K. & Drueckhammer, D. G. Coenzyme A Analogues and Derivatives: 
Synthesis and Applications as Mechanistic Probes of Coenzyme A Ester-Utilizing 
Enzymes. Chem. Rev. 100, 3283–3310 (2000). 
276. Wessel, D. & Flügge, U. I. A method for the quantitative recovery of protein in 
dilute solution in the presence of detergents and lipids. Anal. Biochem. 138, 141–143 
(1984). 
277. MacLean, B. et al. Skyline: an open source document editor for creating and 
analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010). 
278. Sharma, V. et al. Panorama public: A public repository for quantitative data sets 
processed in skyline. Mol. Cell Proteomics 17, 1239–1244 (2018). 
279. Baidoo, E. E. K., Wang, G., Joshua, C. J., Benites, V. T. & Keasling, J. D. Liquid 
Chromatography and Mass Spectrometry Analysis of Isoprenoid Intermediates in 
Escherichia coli. Methods Mol. Biol. 1859, 209–224 (2019). 
280. Medema, M. H. et al. antiSMASH: rapid identification, annotation and analysis of 
secondary metabolite biosynthesis gene clusters in bacterial and fungal genome 
sequences. Nucleic Acids Res. 39, W339–46 (2011). 
281. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence 
alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011). 
282. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new 
ENDscript server. Nucleic Acids Res. 42, W320–4 (2014). 
283. Katoh, K., Kuma, K., Toh, H. & Miyata, T. MAFFT version 5: improvement in 
accuracy of multiple sequence alignment. Nucleic Acids Res. 33, 511–518 (2005). 
284. Okonechnikov, K., Golosova, O., Fursov, M. & UGENE team. Unipro UGENE: a 
unified bioinformatics toolkit. Bioinformatics 28, 1166–1167 (2012). 
285. Bakan, A., Meireles, L. M. & Bahar, I. ProDy: protein dynamics inferred from 
theory and experiments. Bioinformatics 27, 1575–1577 (2011). 
  134 
286. Bakan, A. et al. Evol and ProDy for bridging protein sequence evolution and 
structural dynamics. Bioinformatics 30, 2681–2683 (2014). 
287. Terwilliger, T. C., Klei, H., Adams, P. D., Moriarty, N. W. & Cohn, J. D. Automated 
ligand fitting by core-fragment fitting and extension into density. Acta Crystallogr. 
Sect. D, Biol. Crystallogr. 62, 915–922 (2006). 
288. Terwilliger, T. C., Adams, P. D., Moriarty, N. W. & Cohn, J. D. Ligand 
identification using electron-density map correlations. Acta Crystallogr. Sect. D, 
Biol. Crystallogr. 63, 101–107 (2007). 
289. Lee, T.S., Krupa, R.A., Zhang, F., Hajimorad, M., Holtz, W.J., Prasad, N., Lee, S.K., 
Keasling, J.D., BglBrick vectors and datasheets: A synthetic biology platform for 
gene expression. J Biol Eng 5, 12 (2011). 
 
